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Abstract	
	Cardiovascular	 disease	 (CVD)	 affects	 one	 in	 six	 Australians,	 with	 healthcare	expenditure	that	exceeds	that	for	any	other	disease.	Recently,	there	has	been	an	increased	 interest	 in	 studying	 the	 regulation	 of	 and	 by	 RNAs	 to	 find	 novel	targets	for	the	treatment	of	CVD.	microRNAs	(miRNAs)	in	particular,	have	been	implicated	 in	 the	 pathogenesis	 of	 CVD,	 and	 thus	 have	 emerged	 as	 promising	candidates	 for	 therapeutic	 interventions.	 In	 addition	 to	 differential	 miRNA	expression,	 miRNA-mediated	 control	 is	 also	 affected	 by	 variable	 miRNA	processing	and	alternative	3’-end	cleavage	and	polyadenylation	(APA)	of	 their	mRNA	targets.	To	what	extent	these	phenomena	play	a	role	in	the	heart	remains	unclear.	Thus,	 the	 major	 aim	 of	 this	 thesis	 is	 to	 uncover	 the	 expression	 and	processing	variations	of	miRNAs	and	mRNA	3’-ends,	and	evaluate	their	changes	during	cardiac	hypertrophy.		Thoracic	 aortic	 constriction	 (TAC)	 was	 performed	 to	 induce	 hypertrophy	 in	C57BL/6J	 mice.	 RNA	 extracted	 from	 cardiomyocytes	 of	 sham-treated,	 pre-hypertrophic	(2	days	post-TAC),	and	hypertrophic	(7	days	post-TAC)	mice	was	subjected	 to	 small	 RNA-	 and	 poly(A)-test	 sequencing	 (PAT-Seq).	 The	sequencing	 datasets	 were	 mined	 for	 expressions	 of	 non-coding	 and	 protein-coding	transcripts	and	their	variants.		The	 analyses	 of	 differential	 expression	 of	 miRNA	 and	 mRNA	 during	 cardiac	hypertrophy	matched	 expectations,	 although	we	 identified	 ~400	mRNAs	 and	hundreds	of	noncoding	RNA	loci	as	altered	with	hypertrophy	for	the	first	time.	There	 is	 a	 widespread	 occurrence	 of	 miRNA	 processing	 variations	 in	 the	cardiomyocyte,	however	their	relative	proportions	remained	largely	unchanged	during	hypertrophy.	Our	mRNA	3’end-sequencing	data	identified	novel	3’UTRs	for	7,348	genes.	Notably,	there	was	a	significant	net	shift	towards	shorter	3’UTR	variants	 as	 hypertrophy	 develops.	 We	 independently	 validated	 several	examples	 of	 3’UTR	 proportion	 change,	 and	 showed	 that	 alternative	 3’UTRs	associate	with	differences	 in	mRNA	 translation.	We	 combined	 the	 small	RNA-	
	 VII	
and	 PAT-sequencing	 datasets	 for	 a	 cardiac-specific	 miRNA	 target	 predictions	analysis.	 Differential	 analyses	 of	 these	 interactions	 during	 hypertrophy	suggested	 that	 the	 connectivity	 between	 miRNA	 and	 their	 3’UTR	 targets	 are	modulated,	 with	 an	 overall	 decrease	 in	 miRNA	 repression	 strength	 during	cardiac	 hypertrophy.	 The	 findings	 presented	 in	 this	 thesis	 suggest	 that	 APA	contributes	to	altered	gene	expression	with	the	development	of	cardiomyocyte	hypertrophy.	 This	 thesis	 provides	 a	 rich	 resource	 for	 a	 systems-level	understanding	of	miRNA-mediated	regulation	in	physiological	and	pathological	states	of	the	heart.		 	
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Chapter	1.	Introduction	
Cardiovascular	 disease	 (CVD)	 is	 the	 number	 one	 cause	 of	 morbidity	 and	mortality	 worldwide	 (2016).	 In	 addition	 to	 the	 devastating	 personal	consequences,	 cardiovascular	 conditions	 pose	 a	 significant	 burden	 to	 the	Australian	society	in	terms	of	health	care	expenditure	and	loss	of	productivity.	Current	 therapy	 for	 CVD,	 such	 as	 β-blockers,	 diuretics,	 and	 angiotensin	converting	enzyme	inhibitors	(ACEi),	is	based	on	relief	of	symptoms	rather	than	reversal	of	the	underlying	process	(Tijsen	et	al.,	2016).	The	prevalence	of	heart	disease	continues	to	increase,	highlighting	the	need	for	new,	better	strategies	in	the	prevention	and	treatment	of	this	disease.	These	efforts	hinge	on	deepening	our	 understanding	 of	 the	 processes	 that	 govern	 cardiac	 homeostasis	 and	disease	progression.		Many	 aspects	 of	 cardiac	 functions	 are	 dependent	 on	 a	 carefully	 orchestrated	expression	 of	 the	 genome.	 Perturbation	 of	 these	 controls	 is	 intrinsic	 to	 heart	disease,	 and	 thus	 regulation	 of	 gene	 expression	 has	 been	 a	 major	 focus	 of	research	to	better	understand,	diagnose	and	ultimately	prevent	or	cure	cardiac	pathologies.	The	 field	has	 seen	 a	 surge	of	 interest	 in	 the	 regulation	of	 and	by	RNAs.	This	thesis	aims	to	uncover	the	expression	and	processing	variations	of	various	 RNA	 subtypes	 in	 the	 cardiomyocyte,	 and	 investigate	 their	 changes	during	cardiac	hypertrophy.				
1.1.	Cardiac	hypertrophy	A	 variety	 of	 pathological	 conditions	 of	 the	 cardiovascular	 system,	 such	 as	hypertension,	aortic	valve	stenosis,	and	myocardial	 infarction,	can	provoke	an	increase	in	hemodynamic	load	(Frey	and	Olson,	2003).	To	compensate	for	this	pressure	 overload,	 the	 heart	 undergoes	 a	 hypertrophic	 enlargement,	characterized	 by	 an	 increase	 in	 the	 size	 of	 individual	 cardiomyocytes.	 This	adaptive	response	serves	to	normalize	the	stress	on	the	heart	walls,	and	allows	the	heart	 to	maintain	 sufficient	perfusion	of	 the	 tissue	without	operating	 at	 a	
		 3	
high	end	diastolic	volume	(EDV)	that	results	from	an	increased	load	(Frey	and	Olson,	 2003).	 However,	 while	 initially	 advantageous,	 this	 hypertrophic	remodeling	results	in	an	inefficient	system	that	overtime	actually	intensifies	the	cardiac	 dysfunction.	 Prolonged	 cardiac	 hypertrophy	 eventually	 leads	 to	myocardial	 deterioration,	 and	 is	 considered	 to	 be	 one	 of	 the	 strongest	 risk	factor	 for	 arrhythmia,	 congestive	 heart	 failure,	 and	 sudden	 cardiac	 death	(Kahan	et	al).		At	 the	 cellular	 level,	 cardiac	hypertrophy	develops	when	various	extracellular	stimuli	 interact	 with	 cell	 surface	 receptors	 and	 induce	 signal	 transduction	pathways	within	the	cell	(Heineke	and	Molkentin,	2006,	Rohini	et	al.,	2010).	The	pathways	 identified	 thus	 far	are	calcineurin/nuclear	 factor	of	T	cells	 (NFATc),	cyclic	 guanosine	 monophosphate	 (cGMP)/protein	 kinase	 G-1	 (PKG-1),	phosphoinositide	 3-kinase	 (PI3K)/Akt,	 G	 protein-coupled	 receptor	 (GPCR),	mitogen	 activated	protein	 kinases	 (MAPK),	 interleukin-6	 (IL-6)	 cytokine,	 JAK-STAT	and	the	renin	angiotensin	system	(RAS).	These	signaling	pathways	end	in	the	nucleus,	where	they	activate	immediate	early	response	genes	such	as	c-fos,	c-myc,	 and	 c-jun.	 These	 then	 regulate	 various	 other	 gene	 expression	 changes,	including	the	re-expression	of	genes	normally	expressed	only	in	the	fetal	heart,	such	 as	 ANP,	 BNP,	 β-MHC,	 and	 α-SKA,	 which	 are	 used	 as markers	 of	 the	hypertrophic	 phenotype.	 These	 hypertrophic	 gene	 expression	 changes	subsequently	results	in	the	accumulation	of	cytoskeletal	proteins,	leading	to	the	structural	 enlargement	 of	 the	 cardiomyocyte	 (Sequeira	 et	 al.,	 2014).	 The	regulation	 of	 cardiac	 gene	 expression	 is	 complex	 and	 is	 still	 not	 completely	understood.	 Increases	 in	 protein	 translation	 and	 signature	 patterns	 of	 long	noncoding	 RNA	 (lncRNA)	 and	microRNA	 (miRNA)	 expression	 have	 also	 been	shown	 to	 correlate	with	 cardiac	hypertrophy,	 increasing	 this	 complexity	 even	further	 by	 adding	 layers	 of	 regulation	 at	 the	 post-transcriptional	 level	(Condorelli	et	al.,	2010).			 	
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1.2.	Regulation	of	gene	expression	by	non-coding	RNAs	Although	the	majority	of	the	genome	is	extensively	transcribed,	only	<3%	codes	for	proteins	 (Djebali	 et	 al.,	 2012).	More	 recent	 studies	have	 shown	 that	while	the	 remaining	 non-coding	 RNAs	 do	 not	 generate	 protein,	 they	 are	 important	regulators	of	cellular	processes	(Mercer	et	al.,	2009,	Taft	et	al.,	2010).	LncRNAs	and	miRNAs	in	particular	are	increasingly	recognized	to	play	important	roles	in	cardiac	 diseases	 (Schonrock	 et	 al.,	 2012,	 Thum	 and	 Condorelli,	 2015,	 Uchida	and	Dimmeler,	2015).				
1.2.1.	lncRNAs	in	cardiac	hypertrophy	LncRNAs	are defined as non-coding transcripts that are longer than 200nt in 
size (Reviewed in (Schonrock et al., 2012, Thum and Condorelli, 2015, 
Uchida and Dimmeler, 2015). Similar	 to	mRNAs,	 lncRNAs	are	 transcribed	by	RNA	polymerase	 II	 (RNA	Pol	 II),	 5’-capped,	 and	polyadenylated	 at	 the	 3’-end.	lncRNAs	 are	 broadly	 categorized	 into	 6	 subgroups	 based	 on	 the	 genomic	locations	 from	 which	 the	 lncRNA	 are	 transcribed	 from:	 intergenic	 lncRNA	(transcribed	 from	 regions	 located	 between	 genes,	 previously	 referred	 to	 as	“junk	DNA”);	 intronic	 lncRNA	 (transcribed	 from	 the	 introns	 of	 protein	 coding	genes);	 enhancer	 RNA	 (transcribed	 from	 enhancer	 regions);	 sense	 lncRNA	(transcribed	from	the	sense	strand	of	protein-coding	genes,	and	overlap	one	or	several	 introns/exons);	 anti-sense	 (transcribed	 from	 locations	 anti-sense	 to	protein	 coding	 genes	 and	 overlap	 one	 or	 several	 introns/exons);	 and	bidirectional	 lncRNAs	 (located	 within	 1kb	 of	 promoters	 in	 the	 opposite	direction	from	the	protein	coding	gene).		Regulation	 of	 gene	 expression	 by	 lncRNAs	 is	 mediated	 through	 several	mechanisms	 (Mercer	 et	 al.,	 2009).	 LncRNAs	 can	 act	 as	 structural	 scaffolds	 by	interacting	 with	 transcription	 factors	 and	 chromatin	 modifying	 complexes	(“Scaffold	 lncRNAs”),	 and	 have	 been	 reported	 to	 be	 involved	 in	 intracellular	signaling	 by	 responding	 to	 various	 stimuli	 and	 regulating	 transcription	 at	specific	spatial	and	temporal	points	(“Signalling	lncRNAs”).	They	have	also	been	
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shown	to	form	complexes	with	proteins	and	guide	their	localization	to	specific	target	 genes,	 which	 could	 activate	 or	 repress	 the	 expression	 of	 the	 gene	depending	 on	 the	 protein	 that	 it	 interacted	 with	 (“Guide	 lncRNAs”).	 Some	lncRNAs	 could	 also	 sequester	 regulatory	 factors	 (“Decoy	 lncRNAs”).	 Most	notably,	some	decoy	lncRNAs	transcribed	from	pseudogenes	have	been	shown	to	act	as	sponges	 for	miRNAs,	and	relieve	the	translational	repression	of	 their	mRNA	targets	(Salmena	et	al.,	2011).			
Table	1.1.	Documented	lncRNA	changes	during	CVD	(Archer	et	al.,	2015).	
CVD	 Dysregulated	lncRNA	 Direction	of	change	Cardiac	hypertrophy	 MHRT	CHRF	 Down-regulated	Up-regulated	Heart	failure	 LIPCAR	 Unknown	Cardiac	ischemia	 UAC1	 UAC1	Myocardial	infarction	 APF	MIRT1	MIRT2	MIAT	ANRIL	
Up-regulated	Up-regulated	Up-regulated	Unknown	Unknown	Atherosclerosis	 CDKNA/B	DYN-LRB2-2	RP5-833A20.1	
Up-regulated	Up-regulated	Up-regulated	Coronary	artery	disease	 ANRIL	 Unknown		A	number	of	studies	have	now	shown	that	lncRNAs	are	dynamically	expressed	in	 cardiovascular	 development	 and	 disease	 (Table	 1.1).	 For	 example,	 the	cardiac-specific	lncRNA	myosin	heavy	chain-associated	RNA	transcripts	(Mhrt),	are	down-regulated	during	cardiac	hypertrophy	(Han	et	al.,	2014).	Mhrt	binds	to	 and	 suppresses	 Brg1,	 a	 chromatin	 remodeling	 factor	 involved	 in	 the	
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induction	 of	 the	 hypertrophic	 marker	 β-MHC.	 Thus,	 its	 down-regulation	 is	associated	 with	 exacerbation	 of	 cardiac	 hypertrophy.	 Conversely,	 transgenic	restoration	of	Mhrt	in	mice	prevented	hypertrophic	growth	and	progression	to	heart	failure	(Han	et	al.,	2014).	While	much	advancement	in	studying	lncRNAs	have	been	made,	 the	 field	 is	still	 in	 its	early	stages	of	discovery,	and	 their	 full	expression	 and	 functionalities	 in	 the	 heart	 and	 during	 cardiac	 hypertrophy	remain	to	be	characterized.			
1.2.2.	miRNAs	in	cardiac	hypertrophy	miRNA	 is	 a	 class	 of	 evolutionarily	 conserved,	 ~22	 nt	 long,	 small	 non-coding	RNAs	(Esteller,	2011,	Liu	and	Olson,	2010,	Pasquinelli,	2012).	miRNAs	bind	to	complementary	 sequences	 on	 the	 3’	 untranslated	 region	 (3’UTR)	 of	 mRNAs,	which	 inhibits	 the	 expression	 of	 the	 mRNA	 by	 inducing	 mRNA	 degradation	and/or	 suppressing	 its	 translation	 (Bartel,	 2009,	 Beilharz	 et	 al.,	 2009,	Humphreys	et	al.,	2005).	Each	miRNA	is	capable	of	influencing	the	expression	of	broad	networks	of	genes,	thereby	affecting	various	biological	pathways.	When	a	miRNA	is	dysregulated,	the	pathways	fine-tuned	by	this	specific	miRNA	become	disrupted,	upsetting	the	delicate	balance	required	for	normal	cell	function.		The	dysregulation	of	miRNAs	has	been	implicated	in	the	pathogenesis	of	cardiac	hypertrophy	 (Bader,	 Carè	 et	 al.,	 2007,	 Condorelli	 et	 al.,	 2010,	 Liu	 and	 Olson,	2010,	Thum	et	al.,	2007).	The	expression	profiles	of	specific	miRNAs	are	altered	during	 the	 disease	 (Table	 1.2)	 (Gladka	 et	 al.,	 2012).	 Furthermore,	 functional	studies	 in	 mice	 using	 overexpression	 and	 knockdown	 approaches	 have	indicated	 that	dysregulation	of	 certain	miRNAs	 is	necessary	 and	 sufficient	 for	inducing	 this	 disease,	 indicating	 a	 causal	 link	 between	 miRNA	 dysregulation	and	cardiac	hypertrophy	 (Callis	et	al.,	2009,	Davis-Dusenbery	and	Hata,	2010,	Poller	 et	 al.,	 2010,	 van	Rooij	 et	 al.,	 2006).	 For	 example,	miR-133a,	 one	 of	 the	most	 abundantly	 expressed	 miRNAs	 in	 the	 heart	 (Ohanian	 et	 al.,	 2013),	 is	down-regulated	during	cardiac	hypertrophy	(Carè	et	al.,	2007).	Experimentally	inhibiting	 this	 miRNA	 in	 vivo	 is	 sufficient	 to	 induce	 hypertrophy,	 whilst	 its	complete	deletion	in	knockout	mice	results	in	death	shortly	after	birth	(Liu	and	
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Olson,	2010).	Conversely,	enforced	increased	or	decreased	expression	of	other	miRNAs	could	protect	the	heart	from	the	disease	(Thum	and	Condorelli,	2015).	For	example,	miR-208a	has	been	shown	to	be	up-regulated	during	hypertrophy	and	 heart	 failure,	 and	 miR-208a-null	 mice	 were	 protected	 from	 cardiac	hypertrophy	in	response	to	various	cardiac	stress	(van	Rooij	et	al.,	2007,	Callis	et	 al.,	 2009).	 Moreover,	 therapeutic	 inhibition	 of	 miR-208a	 by	 antisense	oligonucleotides	 during	 hypertension-induced	 heart	 failure	 in	 rats	 prevented	cardiac	hypertrophy	and	improved	overall	survival	(Montgomery	et	al.,	2011).	Examples	such	as	these	have	led	to	increased	interest	for	the	use	of	miRNAs	in	the	 treatment	 or	 prevention	of	 CVD.	However,	 the	development	 of	 a	 safe	 and	effective	 miRNA-based	 therapy	 remains	 severely	 limited	 by	 a	 poor	understanding	of	 the	biology	behind	 these	regulatory	molecules,	 such	as	 their	processing	variations,	and	 the	presence	of	 their	3’-UTR	 targets	during	cardiac	hypertrophy.		
Table	1.2.	miRNAs	implicated	in	the	development	of	cardiac	hypertrophy	
(Gladka	et	al.,	2012).			 Hypertrophic	processes:		 Intercellular	
communication	
Signalling	
cascades	
Sarcomere	
Organization	
Pro-
hypertrophic	
miRNAs^	
miR-21	 miR-18b	miR-195	miR-199b	miR-23		miR-208a	
miR-208a	miR-499	
Anti-
hypertrophic	
miRNAs^	
miR-29	 miR-	133	miR-1	miR-9	miR-98	miR-211	
miR-133	miR-1	
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Variations	in	miRNA	processing	miRNAs	are	transcribed	by	RNA	Pol	 II	either	 from	independent	genes	or	 from	the	introns	of	protein-coding	genes	(Figure	1.1,	Reviewed	in	(Barry	et	al.,	2008,	Davis-Dusenbery	 and	Hata,	 2010,	 Krol	 et	 al.,	 2010)).	 The	 resulting	 transcript,	known	 as	 primary	 miRNA	 (pri-miRNA),	 fold	 into	 hairpin	 structures	accompanied	 with	 signals	 for	 nuclease	 cleavage.	 The	 RNase	 III	 Drosha	 first	cleaves	 this	 pri-miRNA	 approximately	 11bp	 from	 the	 base	 of	 the	 hairpin,	releasing	 a	 60-70nt	 long	 hairpin	 precursor	 miRNA	 (pre-miRNA).	 The	 pre-miRNA	is	then	transported	into	the	cytoplasm	via	the	nuclear	export	receptor,	Exportin	 5.	 Once	 in	 the	 cytoplasm,	 another	 member	 of	 the	 RNase	 III	superfamily,	Dicer,	cleaves	the	pre-miRNA	approximately	19bp	from	the	Drosha	cut	 site,	 removing	 the	hairpin	 region.	One	 strand	of	 the	double	 stranded	RNA	generated	from	this	cleavage	then	associates	with	an	Argonaute	(AGO)	protein,	a	core	component	of	the	RNA-induced	silencing	complex	(RISC).	This	strand	will	then	 become	 the	 “mature”	 miRNA	 and	 guide	 the	 RISC	 to	 its	 mRNA	 target	through	 complementary	 base-pairing	 of	 the	 miRNA	 “seed”	 sequence	(nucleotides	 2-8)	 to	 the	 3’	 UTR	 of	 the	 mRNA.	 The	 other	 strand,	 called	 the	“passenger”	 strand	 (miRNA*),	 is	 generally	 considered	 non-functional	 and	 is	commonly	thought	to	be	decayed.		 	
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Figure	1.1.	The	biogenesis	of	miRNA	in	mammalian	cells.	(1)	A	~1-3	kb	pri-miRNA	is	transcribed	from	the	miRNA	locus	in	the	genome.	(2)	In	the	nucleus,	the	 “microprocessor	 complex”	 consisting	 of	 Drosha,	 a	 RNAse	 III	 enzyme,	 and	DGCR8,	 a	 cofactor	which	assists	 the	binding	of	Drosha	 to	 the	pri-miRNA,	 cuts	~11	bp	from	the	base	of	the	pri-miRNA	hairpin.	This	produces	a	shorter	~60-70nt	 hairpin	 called	 the	 pre-miRNA.	 (3)	 The	 pre-miRNA	 is	 transported	 to	 the	cytoplasm	by	 exportin-5.	 (4)	Dicer	 then	 removes	 the	 loop	portion	of	 the	pre-miRNA,	 forming	 a	 double	 stranded	 miRNA.	 (5)	 The	 two	 strands	 of	 miRNA	separate.	(6)	The	mature	strand	is	incorporated	onto	an	AGO	protein	to	form	an	active	 RISC,	 while	 the	 miR*	 is	 thought	 to	 be	 degraded.	 (7)	 The	 RISC	 is	 then	guided	to	the	target	mRNA	via	complementary	binding	between	the	miRNA	to	the	 mRNA	 sequence.	 (8)	 This	 induces	 translational	 repression	 and	 mRNA	decay,	thus	inhibiting	expression	of	the	target	mRNA.			
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Contrary	 to	 the	 prevailing	 notion	 that	 one	 pre-miRNA	 hairpin	 gives	 rise	 to	 a	single	 mature	 miRNA,	 recent	 findings	 suggest	 that	 several	 functional	 miRNA	variants	can	be	formed	(Figure	1.2)	(Hynes	et	al.,	2012):	1. Either	 or	 both	 the	 mature	 and	 miRNA*	 strands	 may	 be	 utilized.	 It	 had	previously	 been	 assumed	 that	 only	 the	 mature	 strand	 of	 the	 pre-miRNA	hairpin	 is	 incorporated	 into	 RISC	 complexes,	 while	 the	 miRNA*	 strand	 is	non-functional.	However,	this	view	has	been	challenged	by	more	recent	data.	It	 is	 now	 emerging	 that	 there	 are	 variations	 in	 strand	 usage	 between	different	 tissue	 types	 (Ro	 et	 al.,	 2007)	 and	 cellular	 states	 (Biasiolo	 et	 al.,	2011).	 The	 profound	 role	 of	miRNA*s	 is	 highlighted	 by	 its	 involvement	 in	diseases	 (e.g.	 miRNA-146a*	 in	 thyroid	 cancer	 (Jazdzewski	 et	 al.,	 2009);	miRNA-199a*	in	hepatocellular	carcinoma	(Hou	et	al.,	2011)).	Since	the	two	arms	of	 the	hairpin	 (termed	 -5p	 and	 -3p)	have	unique	 sequences,	 they	 are	predicted	 to	 have	 distinct	 target	 spectra,	 thus	 expanding	 the	 regulatory	capacity	of	each	miRNA	locus.		2. There	 may	 be	 variations	 in	 the	 5’	 start	 and	 3’	 end	 sites	 of	 the	 miRNA.	Differential	 Drosha	 and	 Dicer	 cleavage	 sites	 can	 generate	 miRNAs	 with	sequences	that	is	shifted	relative	to	the	canonical	miRNA	(Chiang	et	al.,	2010,	Fernandez-Valverde	 et	 al.,	 2010).	 These	 variants,	 known	 as	 isomiRs,	 have	been	 detected	 in	 RISC	 complexes,	 indicating	 their	 capacity	 to	 target	 and	repress	mRNAs	(Burroughs	et	al.,	2011).	Since	most	of	the	pairing	specificity	between	 a	miRNA	 and	 its	 target	 is	 provided	 by	 the	 5’	 “seed”	 region	 of	 the	miRNA,	isomiRs	with	5’	alternative	start	sites	(5’	isomiRs)	may	have	different	targeting	 properties.	 The	 functions	 of	 3’	 end	 variants	 (3’	 isomiRs)	 are	 less	obvious,	as	3’	isomiRs	share	a	common	seed	sequence.	However,	it	has	been	shown	 that	 3’	 isomiRs	 are	 dynamically	 regulated	 during	 development	(Fernandez-valverde	 et	 al.,	 2010),	 and	 therefore	 are	 likely	 to	 also	 have	biologically	important	roles.	It	has	been	suggested	that	these	3’	end	variants,	which	 could	 also	 be	 generated	 through	 non-templated	 additions	 (NTA)	(Chiang	 et	 al.,	 2010,	 Fernandez-Valverde	 et	 al.,	 2010),	 can	 alter	 miRNA	
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turnover,	 and	 preferentially	 associate	 with	 different	 AGO	 proteins	(Burroughs	et	al.,	2011).		
	
	
Figure	 1.2.	miRNA	 processing	 variants.	 (A)	The	 traditional	 view	 of	miRNA	processing:	 only	 one	 strand	 of	 the	 pre-miRNA	 hairpin	 becomes	 the	 mature	miRNA,	while	the	other	strand	is	always	degraded.	(B)	It	is	now	emerging	that	one	pre-miRNA	hairpin	 can	 give	 rise	 to	 an	 assortment	of	 processing	 variants.	This	 variety	 can	 be	 achieved	 through	 the	 use	 of	 both	 arms	 of	 the	 hairpin	(variable	 arm	 bias),	 internal	 base	 editing,	 alternative	 Dicer/Drosha	 cleavage	sites	resulting	in	5’-	and	3’-	isomiRs,	and	non-templated	3’-end	additions	(NTA).	
(C)	As	each	variant	may	have	unique	mRNA	targets,	the	pool	of	potential	targets	may	be	much	larger	than	originally	predicted	for	the	canonical	mature	miRNA.	
Image	adapted	from	(Hynes	et	al.,	2012).	
	 	3. miRNAs	 may	 undergo	 internal	 editing.	 The	 most	 common	 RNA	 editing	converts	adenosine	to	inosine	in	double	stranded	RNAs,	a	process	catalysed	
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by	adenosine	deaminases	acting	on	RNA	(ADAR)	enzymes	(Hogg	et	al.,	2011,	Kawahara	 et	 al.,	 2008,	 Nishikura,	 2010).	 Very	 little	 studies	 have	 been	conducted	 in	 the	 heart,	 although	 it	 has	 been	 found	 that	 ~20%	 of	 the	 pri-miRNAs	in	the	human	brain	are	subject	to	this	type	of	editing	(Kawahara	et	al.,	 2008).	 Moreover,	 it	 has	 been	 demonstrated	 that	 pri-miRNA	 editing	results	 in	 the	 expression	 of	 edited	 mature	 miRNA	 strands	 that	 targets	different	genes	compared	to	the	unedited	variant	(Kawahara	et	al.,	2007).				Next	generation	sequencing	data	recently	generated	in	the	lab	has	revealed	that	many	miRNAs	 in	 the	murine	HL-1	 cardiomyocyte	 cell	 line	 exist	 as	 processing	variants	 (Humphreys	 et	 al.,	 2012a).	 This	 observation	 have	 been	 shown	 to	 be	consistent	with	data	obtained	from	the	murine	left	ventricle	(Humphreys	et	al.,	2012)	and	right	atrium	(Ohanian	et	al.,	2013),	as	well	as	from	clinical	samples	of	the	human	atrial	tissue.	Comparison	of	the	microRNAs	in	HL-1	cardiomyocytes	to	those	from	other	murine	tissues	(brain,	ovary	and	testes)	found	that	many	of	the	 processing	 variation	 observed	 in	 the	 HL-1	 cardiomyocyte	 was	 either	 not	present	 in	non-cardiac	tissues,	or	was	present	at	much	less	pronounced	levels	(Humphreys	 et	 al.,	 2012),	 suggesting	 a	 cardiac-specific	 purpose	 for	 these	miRNAs	 variants.	 The	 changes	 in	 miRNA	 processing	 variants	 during	 cardiac	hypertrophy	have	not	been	previously	reported.		
1.3.	mRNA	3’-end	processing	Adding	to	the	layers	of	complexity	in	the	regulation	of	gene	expression,	mRNA	transcripts	 from	 the	same	genomic	 region	could	be	diversified	by	a	variety	of	processing	 mechanisms,	 such	 as	 5’-capping,	 intron	 splicing,	 and	 3’-end	processing.	Following	these	steps,	the	mature	mRNA	consists	of	three	structural	segments:	the	5’UTR,	the	coding	sequence	(CDS),	and	the	3’UTR.	Understanding	regulation	 of	 3’-end	 formation	 in	 the	 heart	 is	 particularly	 important	 for	 the	advancement	of	miRNA	 therapy	research,	as	miRNA-mediated	control	of	gene	expression	 is	 equally	 dependent	 on	 the	 presence	 of	 its	 complementary	 target	
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sites	within	the	3’UTR	of	mRNAs.	This	end-region	of	mRNAs	harbors	many	cis-acting	 elements	 that	 serve	 as	 a	 docking	 platform	 for	 trans-acting	 factors,	including	miRNAs	and	many	RNA	binding	proteins,	and	are	crucial	in	regulating	the	stability,	translation,	and	localization	of	the	mRNA	(Elkon	et	al.,	2013,	Tian	and	Manley,	2013,	Shi,	2012).			
1.3.1.	Molecular	mechanisms	of	3’-end	processing		3’-end	processing	 is	a	 two-step	process	 that	 first	 involves	 the	endonucleolytic	cleavage	of	 the	RNA,	 followed	by	 the	addition	of	 the	poly(A)	 tail	 (Elkon	et	al.,	2013).	 	 Almost	 all	 eukaryotic	 mRNAs	 (except	 replication-dependent	 histone	mRNAs),	 as	 well	 as	 several	 non-coding	 transcripts	 such	 as	 pri-miRNAs	 and	lncRNAs,	are	polyadenylated	at	their	3’-end.	This	process	is	crucial	for	nuclear	export	and	stability	of	the	transcripts.		The	 core	machinery	 responsible	 for	mammalian	3’-end	processing	 consists	 of	over	85	proteins	organized	into	four	multi-subunit	protein	complexes:	cleavage	and	 polyadenylation	 specificity	 factor	 (CPSF),	 cleavage	 stimulation	 factor	(CstF),	 cleavage	 factor	 I	 (CFm)	 and	 cleavage	 factor	 II	 (CFIIm),	 as	 well	 as	 the	single-subunit	poly(A)	polymerase	(PAP),	the	C-terminal	domain	of	RNA	Pol	II,	and	 other	 additional	 accessory	 factors	 (Figure	 1.3,	 Reviewed	 in	 (Elkon	 et	 al.,	2013,	Gruber	et	al.,	2014)).	The	specificity	and	efficiency	of	3’-end	processing	is	determined	by	the	binding	of	this	complex	to	specific	sequences	within	the	pre-mRNA.	CPSF,	composed	of	160kDa	(CPSF1),	100	kDa	(CPSF2),	73	kDa	(CPSF3),	and	 30	 kDa(CPSF4)	 subunits,	 first	 recognizes	 and	 binds	 to	 the	 poly(A)	 signal	motif	 (PAS)	 approximately	 10-35nt	 upstream	 of	 the	 site	 of	cleavage(Danckwardt	et	al.,	2008).	The	most	conserved	PAS	among	eukaryotic	mRNA	is	AAUAAA,	followed	by	its	main	variant	AUUAAA,	detected	in	~60%	and	15%	of	poly(A)	sites,	respectively	(Elkon	et	al.,	2013).	AUUAAA	has	~80%	of	the	processing	 efficiency	 of	 AAUAAA	 (Wilusz	 et	 al.,	 1989).	 Nine	 other	 variants	 of	PAS	 has	 been	 identified,	 each	 with	 considerably	 lower	 processing	 efficiency	than	the	canonical	PAS	(Sheets	et	al.,	1990).	The	CSTF	complex	is	composed	of	a	
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50	kDa	(CSTF1),	64	kDa	(CSTF2),	and	77	kDa	(CSTF3)	subunits,	and	recognizes	U-	 /GU-	 rich	 sequences	 located	within	 30nt	 downstream	 of	 the	 cleavage	 site.	CSTF2	binds	directly	to	this	U-/GU-	downstream	sequence	element	(DSE),	while	CSTF1	 and	 CSTF3	 interact	 with	 the	 C-terminal	 domain	 of	 RNA	 Pol	 II,	 which	facilitate	the	activation	of	3’UTR	processing	proteins	(Cevher	et	al.,	2010).	CFIm	and	 CFIIm	 bind	 to	 the	 UGUA	 motif,	 which	 could	 be	 present	 in	 one	 or	 more	copies	at	a	variable	distance	upstream	of	the	cleavage	site.	In	the	absence	of	PAS	(~10%	of	poly(A)	sites),	 this	 interaction	between	CFIm	and	CFIIm	with	UGUA	motif	 is	 paramount	 in	 determining	 the	 specificity	 of	 the	 3’-end	 cleavage.	Additional	 sequences	 upstream	 of	 the	 cleavage	 site	 (USE)	 serve	 as	 additional	anchor	sites	for	auxiliary	factors	of	the	3’end	machinery.	After	assembly	of	the	3’-end-processing	 machinery	 on	 the	 pre-mRNA,	 CPSF3	 catalyzes	 the	endonucleolytic	 cleavage	 (Mandel	 et	 al.,	 2006,	 Ryan	 et	 al.,	 2004).	 PAP	subsequently	adds	A-nucleotides	to	the	3’-end.	The	length	of	the	poly(A)	tail	is	determined	 by	 an	 interaction	 between	 CPSF,	 PAP,	 and	 the	 nuclear	 poly(A)-binding	protein	(PABPN1)(Kuhn	and	Wahle,	2004),	and	averages	between	150-250nt	in	mammals	(Tian	et	al.,	2005).			
	
Figure	 1.3.	 Sequence	 elements	 and	 protein	 factors	 involved	 in	 3’-end	
processing.	Cleavage	and	polyadenylation	site	is	determined	by	cis-elements	in	the	 3’-UTR.	 Elements	 upstream	 of	 the	 cleavage	 site	 include	 the	 PAS	hexanucleotide	motif,	 and	 the	UGUA	motif.	Downstream	elements	 include	GU-rich	sequences.	The	“strength”	of	the	PAS	is	defined	by	a	combination	of	these	
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sequence	 elements.	 Different	 colors	 represent	 individual	 protein	 sub-complexes.	 CPSF	 (orange)	 recognizes	 and	 binds	 to	 the	 PAS	 motif.	 The	 CSTF	complex	(green)	interacts	with	DSE,	while	CFIm	and	CFIIm	(light	blue)	bind	to	USE	 such	 as	 UGUA,	 providing	 an	 additional	 anchor	 for	 the	 APA	 complex.	Following	cleavage,	the	mRNA	is	polyadenylated	by	PAP	(red),	and	the	poly(A)	tail	bound	by	PAB	(dark	blue).	Image	taken	from	(Elkon	et	al.,	2013).		
1.3.2.	Alternative	3’-end	processing	Although	 there	 is	 generally	 one	 strong,	 canonical	 PAS	 used	 by	 the	 3’-end	processing	 complex,	 over	 half	 of	 the	 genes	 in	 the	 human	 genome	 contain	multiple	functional	PAS	in	its	3’	UTR	(Tian	et	al.,	2005,	Ji	et	al.,	2009).	Through	alternative	 cleavage	 and	 polyadenylation	 (APA),	 a	 number	 of	mRNA	 isoforms	with	 differing	 3’UTR	 lengths	 can	 potentially	 be	 generated	 from	 a	 single	 gene	(Figure	1.4).	It	has	been	reported	that	3’-UTRs	cleaved	at	the	3’	most	distal	site	are		~90%	longer	than	UTRs	cleaved	at	the	most	proximal	site	(Ji	et	al.,	2009).	Given	 the	 role	 of	 the	 3′UTR	 in	 mRNA	 stability,	 translation,	 and	 cellular	localizations,	APA	may	have	a	profound	impact	on	the	overall	expression	of	the	gene.	 For	 example,	 it	 has	 been	 reported	 that	 ~52%	 of	 human	miRNA	 target	sites	are	present	downstream	of	the	most	proximal	poly(A)	site	(Legendre	et	al.,	2006),	 and	 shorter	 mRNA	 isoforms	 of	 specific	 genes	 could	 produce	 10-fold	more	 protein	 than	 the	 longer	 variant	 (Mayr	 and	 Bartel,	 2009b).	 Previous	published	work	 in	 the	 lab	 has	 shown	 that	 the	miRNA	 let-7	 imposes	 stronger	translational	repression	on	targets	with	 longer	3’	UTR	regions,	which	strongly	implies	 that	 changes	 to	 the	 3’UTR	 lengths	 through	 APA	 result	 in	 the	 loss	 of	miRNA	binding	sites	(Clancy	et	al.,	2011).			
 
		 16	
	
Figure	 1.4.	 mRNA	 APA	 and	 the	 consequences	 on	 miRNA	 targeting.	 The	3’UTR	 of	 mRNAs	 contain	 binding	 sites	 for	 many	 regulatory	 factors,	 such	 as	miRNAs	and	RBPs	(not	shown).	One	gene	could	have	multiple	polyadenylation	sites	 along	 its	 3’UTR.	 Cleavage	 at	 alternative	 sites	 generates	 mRNAs	 with	different	3’UTR	lengths,	which	could	expose	or	withdraw	miRNA	binding	sites.	Grey	 bars:	 UTR;	 White	 bars:	 CDS;	 Upright	 colored	 bars:	 miRNA	 target	 sites.	
Image	taken	from	(Hynes	et	al.,	2012).		
1.3.3.	Biological	implications	of	APA	regulation	Expressed	sequence	tag	(EST)	data	have	shown	that	APA	patterns	are	specific	to	 tissue-types	 (e.g.	mRNAs	 in	 the	brain	 typically	 have	 long	3’-UTRs,	whereas	those	 in	 the	 testes	have	shorter	3’	UTRs	(Liu	et	al.,	2007,	Zhang	et	al.,	2005)),	and	are	dynamically	regulated	during	development	and	disease	(Ji	et	al.,	2009,	Ji	and	 Tian,	 2009,	 Ulitsky	 et	 al.,	 2012).	 In	 general,	 3’UTRs	 shorten	 during	proliferative	 stages,	 such	 as	 T-cell	 expansion	 and	 oncogenesis,	 and	progressively	 lengthen	 during	 differentiation	 and	 development	 (Elkon	 et	 al.,	2013,	 Ji	 et	 al.,	 2009,	 Ji	 and	 Tian,	 2009).	 For	 example,	 many	 studies	 have	
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reported	a	global	 shift	 towards	proximal	poly(A)	 site	usage	 in	 tumor	 samples	derived	from	different	organs,	including	breast,	colon,	kidney,	liver,	and	lung.	It	is	 hypothesized	 that	 this	 shortening	 results	 in	 the	 stabilization	 and/or	translational	 activation	 of	 mRNAs	 encoding	 oncogenes,	 and	 is	 thus	advantageous	 for	 the	growth	of	 the	 tumor	 (Mayr	and	Bartel,	2009a,	Lin	et	al.,	2012).	 However,	 this	 hypothesis	 has	 been	 challenged	 by	 other	 studies	examining	changes	in	3’UTR	preference	of	specific	genes.	For	example,	primary	cancer	 samples	 derived	 from	 patients	 with	 mantle	 cell	 lymphoma	 (MCL)	exhibited	a	3’-end	shortening	of	 the	oncogene	gene	Cyclin	D1	(CCND1).	 It	was	shown	that	the	shorter	variant	of	CCND1	is	more	stable	than	the	longer	variant.	This	 led	 to	 increased	 CCND1	 protein	 expression,	 and	 correlates	 with	 overall	survival	 of	 patients	 (Rosenwald	 et	 al.,	 2003,	Hollerer	 et	 al.,	 2014a).	 Thus,	 the	biological	 importance	 of	 3’UTR	 changes	 in	 disease	 aetiology	 is	 still	 largely	unknown.	 Furthermore,	 the	 phenomenon	 of	 APA	 has	 not	 been	 extensively	studied	in	normal	and	diseased	states	of	the	heart.			
1.4.	Aims	Despite	recent	advances	in	studying	post-transcriptional	regulation	in	the	heart,	the	 field	 is	 still	 in	 its	 infancy.	 We	 sought	 to	 uncover	 the	 expression	 of	 non-coding	 and	 protein	 coding	 transcripts	 in	 the	 cardiomyocyte.	 Given	 the	therapeutic	 interest	 in	 miRNA-mediated	 regulation	 for	 CVD,	 the	 bulk	 of	 this	thesis	 largely	 focused	 on	 the	 interactions	 of	 miRNA	 and	 mRNA	 3’UTR	processing	variants	in	the	healthy	and	diseased	hearts.	The	findings	reported	in	this	thesis	enrich	our	understanding	of	miRNA-mediated	regulation,	which	may	contribute	to	the	future	development	of	a	more	efficient	therapy	for	CVD.	
Specific	aims:	Aim	 1:	 To	 establish	 a	 murine	 model	 of	 cardiac	 hypertrophy,	 and	 generate	sequencing	datasets	for	small	RNAs	and	polyadenylated	RNAs		(Chapter	3)	Aim	 2:	 	 To	 document	 the	 expression	 of	 non-coding	 RNAs	 in	 the	 heart,	 and	
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analyse	their	changes	during	cardiac	hypertrophy	(Chapter	4)	Aim	2:	To	investigate	the	expression	of	mRNA	3’UTR	variants	 in	he	heart,	and	evaluate	their	changes	during	cardiac	hypertrophy	(Chapter	5)	Aim	 4:	 To	 explore	 possible	 consequences	 of,	 and	 mechanisms	 behind,	 any	changes	in	mRNA	3’-end	variations	during	cardiac	hypertrophy		
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Chapter	2.	
	
Materials	and	Methods	
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2.1.	Materials	
2.1.1.	Chemicals	and	reagents	The	list	of	chemicals	and	reagents	are	shown	in	Table	2.1	below.		
	
Table	2.1.	List	of	chemicals	and	reagents	(organised	by	manufacturers)	
Manufacturer	 Chemical	Amresco	(Solon	OH,	USA)	 RNA	EZ-Vision®	dye	Coles	 (Hawthorn	 East,	 VIC,	Australia)	 Skim	milk	powder	Corning	 (Tewksbury,	 MA,	USA)	 T-75	 flasks,	 15	 cm	 plates,	 0.22	 μm	 Vacuum	 filter,	Axygen®	8-strip	thin	wall	PCR	tube	strips	and	caps	Fisher	Biotec	(Wembley,	WA,	Australia)	 Sets	of	dNTPs	(100	mM	each)	GE	Healthcare	(Little	Chalfort,	UK)	 Amersham	Hybond™-P	PVDF	transfer	membrane	Life	Technologies	 	 (Carlsbad,	CA,	USA)	 	 DMSO,	 BigDye®	 Terminator	 v1.1	 Ready	 Reaction	 Mix,	Glycogen	 (5	mg/mL),	 Ampicillin,	 AmpliTaq	 Gold®	 360	Master	Mix,	Glycogen,	ATP,	Lipofectamine™	2000,	Opti-MEM®	 Reduced	 Serum	 Media,	 TRIzol®	 Reagent,	Phenol,	 UltraPure™	DNase/RNase-Free	 Distilled	Water,	NaAc,	 DMEM,	 fetal	 bovine	 serum	 (FBS),	 Fast	 SYBR®	Green	Master	Mix.	Enzymes:	Type	II	Collagenase,	Turbo	DNase,	 RNaseOUT™	 Recombinant	 Ribonuclease	Inhibitor,	 TURBO™	 DNase,	 Superscript®	 III	 Reverse	Transcriptase	
	
Table	2.1.	cont.	List	of	chemicals	and	reagents	
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Manufacturer	 Chemical	Merck	 (Darmstadt,	 Hesse,	Germany)	 	 Ethanol,	isopropanol,	Na2HPO4,	
New	 England	 Biolabs	(Ipswich,	MA,	USA)	 Bovine	 serum	albumin	 (BSA),	Random	primer	mix,	 10	x,	NEB	Next®	Small	RNA	Library	Prep	Set	 for	SOLiD™,	dNTPs,	Streptavidin	magnetic	beads	
Promega	(Madison,	WI,	USA)	 X-gal,	PureYield™	plasmid	miniprep	system	
Qiagen	 	(Hilden,	Germany)	 QIAquick	gel	extraction	kit	Roche	 Applied	 Science	(Indianapolis,	IN,	USA)	 LightCycler®	 489	 SYBR	 Green	 I	 Master,	 Complete	protease	 inhibitor	 cocktail	 tablets	 (EDTA-free),	Enzymes:	RNase	T1,	Fast	Start	Taq	DNA	polymerase	
Sigma	(St.	Louis,	MO,	USA)	 Agarose,	Claycomb	media,	Penicillin-streptomycin	(Pen-Strep),	 noradrenaline,	 L-glutamine,	 Trypsin-EDTA,	fibronectin,	 gelatin	 from	 bovine	 skin,	 TEMED,	acrylamide/bis-acrylamide	 40%	 solution,	 Perfect	 Hyb	Buffer,	 24%	 Peg	 8000,	 EtBr	 solution,	 Tris-HCl.	 KCl	Bioultra,	 chloroform,	 trisodium	 citrate,	 HCl,	 KH2PO4,	MgSO4-7H2O,	NaHCO3,	Na-Hepes,	taurine,	BDM,	ascorbic	acid,	 phosphate	 buffered	 saline	 (PBS),	 NaOH,	 NaOAc,	EDTA,	bromophenol	blue,	xylene	cyanol,	formamide	
Thermo	Scientific	(Waltham,	MA,	USA)	 Nunc®	 cell	 culture	 dish	 (15	 cm),	 T-PER	Tissue	 Protein	Extraction	Reagent	VWR	 International	 (Radnor,	PA,	USA)	 NaCl,	CaCl2,	MgCl2.	glucose,	sucrose		
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2.1.2.	Oligonucleotides	Primers	were	synthesized	by	Integrated	DNA	Technologies	(Coralville,	IA,	USA).	Primer	sequences	are	listed	in	Table	2.2	below.	
Table	2.2	List	of	primer	sequences	
Name	 Sequence	GAPDH_FOR	 CTTGGGCTACACTGAGGAC		GAPDH_REV	 CTGTTGCTGTAGCCGTATTC		CANX1_FOR	 GCTTTGCCAGTGTTCCTT		CANX1_REV	 TTCATCCCTCTTGTTCTTCTC		HPRT_FOR	 CCTAAGATGAGCGCAAGTTGAA		HPRT_REV	 CCACAGGACTAGAACACCTGCTAA		ARBP_FOR	 GGACCCGAGAAGACCTCCTT		ARBP_REV	 GCACATCACTCAGAATTTCAATGG		DDR2_FOR	 GCATTCTAAGGCTTGCTGCT		DDR2_REV	 GAAGACGGAGTTGGATCTGG		COL1A1_FOR	 GTGTGATGGGATTCCCTGGACCTA		COL1A1_REV	 CCTGAGCTCCAGCTTCTCCATCTT		COL3A1_FOR	 ACCCCCTGGTCCACAAGGATTA		COL3A1_REV	 ACGTTCTCCAGGTGCACCAGAAT		A-VIM_FOR	 GATTTCTCTGCCTCTGCCAACCTT		A-VIM_REV	 CATTGATCACCTGTCCATCTCTGG		TNNT2_FOR	 GATCTCTGCAGATGCCATGATGCA		TNNT2_REV	 CAGTGCATCGATATTCTTGCGCCA		MLC2V_FOR	 TCTCCGTGGGTAATGATGTG		MLC2V_REV	 ACTATGTCCGGGAGATGCTG		NPPA_FOR	 ATTGACAGGATTGGAGCCCAGAGT		NPPA-REV	 TGACACACCACAAGGGCTTAGGAT		A-SKA_FOR	 TGAGACCACCTACAACAGCA		A-SKA_REV	 CCAGAGCTGTGATCTCCTTC		NPPB_FOR	 GCCAGTCTCCAGAGCAATTCA		NPPB_REV	 TGTTCTTTTGTGAGGCCTTGG		
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Table	2.2.	cont.	List	of	primer	sequences	
Name	 Sequence	B-MHC_FOR	 CTACAGGCCTGGGCTTACCT		B-MHC_REV	 TCTCCTTCTCAGACTTCCGC		CAMKK2_prox_FOR	 CCCAGCTTCGAAGAACAAAG	CAMKK2_prox_REV	 TTGCACGCACTCTACCAAAG	CAMKK2_dist_FOR	 TGGTTGAAGTTTGGGTGTGA	CAMKK2_dist_REV	 GGATAGCGGCTAGACCACAG	GSK3b_prox_FOR	 TACTGCCACACGCACATACA	GSK3b_prox_REV	 AGTACACCACTCACCGCACA	GSK3b_dist_FOR	 ATAATTGCCGTGCGAAAGAC	GSK3b_dist_REV	 GACTCTAGCACGCACACCAA	CCND2_prox_FOR	 GACTTGCCCTCACATTCCAT	CCND2_prox_REV	 CCCTTTCGCAAAAACACAAT	CCND2_dist_FOR	 CTGAGTCTGGTTGGTGCTGA	CCND2_dist_REV	 ACACCCGAGACCACAGAAAC	MTUS1_prox_FOR	 CAGGGCCAGTTTATCTTGGA	MTUS1_prox_REV	 GCTGGAAGAATGCTCAGAGG	MTUS1_dist_FOR	 TTGTGGCTGAAATTGGCTCA	MTUS1_dist_REV	 AAACACTTAAGACCACAGCTGTTCC	PPM1k_prox_FOR	 AGTAGTGGTGCCCTTTGGTG	PPM1k_prox_REV	 CCATGACACACGGGTACAGG	PPM1k_dist_FOR	 TCCCTTAGGAGGGGTCAGTT	PPM1k_dist_REV	 TCCCACCCTGAAACATTCTC	UTP6_prox_FOR	 GGAAAGCCGTCCATTTTCGG	UTP6_prox_REV	 TGTCCGCAGTTCTCAGGTTT	UTP6_dist_FOR	 AATCGTTTCCTGTGCCACCT	UTP6_dist_REV	 TCACCGAAGTGAGGCTGAAC	ETF1_prox_FOR	 AAACTGCCTCCTGTCAGCTC	ETF1_prox_REV	 TTGCTGCATTTCGCAGTGAC	ETF1_dist_FOR	 CCAGTTGGAGTGCAAAGTCA	ETF1_dist_REV	 CCTACCACCCTGGTGAGTGT	
Table	2.2.	cont.	List	of	primer	sequences	
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Name	 Sequence	ARFGEF2_prox_FOR	 TCAGGAGGTGGTGAAGGACA	ARFGEF2_prox_REV	 GAAGCTCGTGGGACTTTGGA	ARFGEF2_dist_FOR	 GAAACACCACTTCCCTCCAA	ARFGEF2_dist_REV	 CCATGCCTACGTGTGTCAAC	LRRC58_prox_FOR	 CTGGACGTGAGCGGCAAC	LRRC58_prox_REV	 TTCTAAACTCCGCAAGTTCTCG	LRRC58_dist_FOR	 TTAGGGCATCAGGTGGTCTC	LRRC58_dist_REV	 ACTGCAGCCACGAAACTCTT	KLF4_prox_FOR	 GTGCAGCTTGCAGCAGTAAC	KLF4_prox_REV	 GGAAGACGAGGATGAAGCTG	KLF4_dist_FOR	 GCCTAAATGATGGTGCTTGG	KLF4_dist_REV	 TTGCACATCTGAAACCACAG	FAF2_prox_FOR	 ATGAGTTCTGCCGCAATGCT	FAF2_prox_REV	 TGCTCACTGCTGACCTTCTG	FAF2_dist_FOR	 AGACAGTGGGCATTCCAGTC	FAF2_dist_REV	 TGGGTTTTCTGAATGGCTTC	CTC1_prox_FOR	 GACCCGAATCTCGTAGGCTG	CTC1_prox_REV	 GCCACAAAGCCAAGTTCCTG	CTC1_dist_FOR	 AACCCATCTGTATCCCCACA	CTC1_dist_REV	 AACACTCCCCACCAGTTCAC	PDZRN3_prox_FOR	 CCGACCCTGTGTGGACAATC	PDZRN3_prox_REV	 CAACACCTGCACCACAATGG	PDZRN3_dist_FOR	 GAAGTGCAAGAACGCAAACA	PDZRN3_dist_REV	 AGGCTGGTCCTTACATGTGG	SRF_prox_RACE	 CCCAGCTGCTTTACTTAAGAG	SRF_dist_RACE	 CATGGTCACATCTTCTGTACAG	CDC42_prox_RACE	 CTCCAGAACCGAAGAAGAG	CDC42_dist_RACE	 CGAACCAATGCTTTCTTGT	Usf2_prox_RACE	 GTATGCGCGTGTGTGCGT	Usf2_dist_RACE	 GACATCGACCGTGTACTCAT	
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Table	2.2.	cont.	List	of	primer	sequences	
Name	 Sequence	SPARC_prox_RACE	 GCTGCAGTCCTGAACTCTC	SPARC_dist_RACE	 CTCTCACAGCAATGTGAAGAG	GSK3b_prox_RACE	 TCTGCATCAGCTTCCAACTC	GSK3b_dist_RACE	 TGTGGAAAGTATGCTCAATGTTT	M13_REV	 CAGGAAACAGCTATGAC	Anchor	REV	 GTG	CAG	GGT	CCG	AGG	TA	Anchor	REV2	 CCA	GTG	CAG	GGT	CCG	AGG	TA	
TVN	anchor	 CCA	GTG	CAG	GGT	CCG	AGG	TAT	TTT	TTT	TTT	TTV	N	
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2.1.3.	Antibodies	Antibodies	were	obtained	from	commercial	sources,	and	are	listed	in	Table	2.3	below		
Table	2.3.	List	of	antibodies:	
Name	 Manufacturer	 Dilution	used	Rabbit	polyclonal	to	ANP	 Abcam	 1:100	Rabbit	polyclonal	to	CPEB1	 Abcam	 1:10,000	Rabbit	polyclonal	to	CPSF1	 Abcam	 1:2,000	Rabbit	polyclonal	to	CPSF6	 Abcam	 1:6,000	Rabbit	polyclonal	to	CSTF2t	 Abcam	 1:5,000	Mouse	monoclonal	to	GAPDH	 Abcam	 1:10,000	Rabbit	monoclonal	to	PABPN1	 Abcam	 1:20,000	Mouse	polyclonal	to	Symplekin	 Abcam	 1:1,000	Polyclonal	 rabbit	 anti-mouse	immunoglobulin	HRP	 Dako	 1:10,000	Polyclonal	 goat	 anti-rabbit	immunoglobulin	HRP	 Millipore	 1:10,000			
2.1.4.	Buffers	and	Solutions	
2.1.4.1.	Buffers	and	solutions	for	general	molecular	biology:	
1	x	TAE:	40	mM	Tris-HCl	(pH	8.2),	20	mM	NaAc	and	10	mM	EDTA	(pH	8.2).	
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	1x	TBE:	89	mM	Tris	(pH	7.6),	89	mM	boric	acid,	2	mM	EDTA		
1	x	TE:	10	mM	Tris-HCl	(pH7.5)	and	1	mM	EDTA.		
1	x	PAGE	elution	buffer:	2.5	M	NaAc	in	TE	buffer.			
2	x	RNA	loading	dye:	1	mM	EDTA,	0.1%	bromophenol	blue,	0.1%	xylene	cyanol,	95%	formamide.		
10	x	digest	buffer:	3	M	NaCl,	10%	Tris	(pH	7)	in	double	distilled	water	(ddH20).			20x	random	primer	mix:	35	µM	hexamers,	25	µM	T12VN		
2.1.4.2.	Buffers	and	solutions	for	cardiomyocyte	isolation	
CM	isolation	perfusion	buffer:	120.4	mM	NaCl,	14.7	mM	KCl,	0.6	mM	KH2PO4,	0.6	mM	Na2HPO4,	1.2	mM	MgSO4-7H2O,	 4.6	 mM	 NaHCO3,	 10	 mM	 Na-Hepes,	 30	 mM	 taurine,	 10	 mM	 2,3-
		 28	
butanedione	monoxime	 (BDM),	 5.5	 mM	 Glucose.	 pH	 7.3	 and	 filtered	 through	0.22	μM	filter.	Prepared	fresh	each	day.		
Collagenase	digestion	buffer:		CM	isolation	perfusion	buffer	containing	2.4	mg/ml	Type	II	Collagenase.	
	
Collagenase	stop	buffer:		CM	isolation	perfusion	buffer	containing	1	mg/ml	BSA	and	125	μM	CaCl2.		
2.1.4.3.	Buffers	and	solutions	for	Western	blotting	1x	transfer	buffer:	37	mM	Tris,	140	mM	glycine,	20%	ethanol		10x	PBS:	1.37M	NaCl,	27mM	KCl,	100mM	Na2HPO4,	18mM	KH2PO4		1x	PBS-T:	1x	PBS,	0.1%	Tween®	20		Blocking	buffer:	5%	skim	milk	powder,	1x	PBS,	0.1%	Tween®	20		Methylene	blue	solution:	
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0.02%	methylene	blue,	0.3	M	NaAc	(pH	5.5)		Enhanced	chemiluminescence	(ECL)	solution:	Solution	A:	0.4	mM	coumaric	acid,	2.5	mM	luminol,	100	mM	Tris-HCl,	pH	8.0	Solution	B:	21%	hydrogen	peroxide,	100	mM	Tris-HCl,	pH	8.0	Mix	solutions	together	1:1		
2.1.4.4.	Buffers	and	solutions	for	sucrose	density	gradient	centrifugation	Sucrose	gradient	buffer:	20	 mM	 HEPES	 (pH	 7.6	 with	 HCl),	 125	 mM	 KCl,	 5	 mM	 MgCl2,	 0.1	 mg/mL	cycloheximide,	1	mM	DTT,	0.5	M	PMSF		Lysis	buffer:	20	 mM	 HEPES	 (pH	 7.6	 with	 HCl),	 125	 mM	 KCl,	 5	 mM	 MgCl2,	 0.1	 mg/mL	cycloheximide,	 2	 mM	 DTT	 and	 0.5	 M	 PMSF,	 1x	 complete	 protease	 inhibitor,	0.5%	IGEPAL®,	100	U/mL	RNaseOUT™		
2.1.4.5.	Buffers	and	solutions	for	tissue	culture	
Noradrenaline:	10	mM	Noradrenaline	made	up	 in	30	mM	ascorbic	 acid,	 filter-sterilized	using	0.2	μm	Acrodisc	syringe	filter.	Noradrenaline	was	made	fresh	monthly.		
Gelatin/Fibronectin:	
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0.02%	gelatin	solution	made	up	in	distilled	water	then	autoclaved.	Fibronectin	was	then	added	to	the	gelatin	solution	to	a	final	concentration	of	5	μg/ml.	
	
Supplemented	Claycomb	media:	Claycomb	 media	 containing	 10%	 FBS,	 100	 μg/ml	 Pen-Strep,	 0.1	 mM	Norepinephrine	 and	 2	 mM	 L-Glutamine.	 Supplemented	 Claycomb	 media	 was	stored	in	aluminum	foil	for	a	maximum	of	two	weeks.	
	
HL-1	freezing	media:	95%	FBS,	5%	DMSO		
HL-1	wash	media:	Claycomb	media	supplemented	with	5%	FBS	and	100	μg/ml	Pen-Strep.			
2.2.	Methods	
2.2.1.	Ethics	approval	All	 animal	 studies	 were	 performed	 according	 to	 the	 Australian	 Code	 for	 the	Care	 and	 Use	 of	 Animals	 for	 Scientific	 Purposes	 8th	 Edition	 (2013)	 and	were	approved	 by	 the	 Garvan	 Institute	 of	 Medical	 Research/St	 Vincent's	 Hospital	Animal	Ethics	Committee	under	project	number	11/25.	
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2.2.2.	Induction	of	cardiac	hypertrophy	by	TAC	banding	TAC	 banding	 of	 mice	 and	 micromanometry	 analyses	 were	 performed	 by	 Dr.	Jianxin	Wu	at	the	Victor	Chang	Cardiac	Research	Institute.	Dr.	Nicola	Smith	and	Dr.	Carly	Hynes	conducted	the	dissections	of	the	heart.			TAC	 was	 performed	 on	 12-week	 old	 male	 C57BL/6J	 mice	 as	 described	previously	 (Du	 et	 al.,	 2004).	 Sham-operated	 animals	 underwent	 the	 same	procedure	 without	 permanent	 constriction	 of	 the	 aorta.	 Animals	 were	anaesthetized	 with	 an	 intraperitoneal	 injection	 (IP)	 of	 xylazine	 (20	 mg/kg),	ketamine	(75	mg/kg)	and	atropine	(1.2	mg/kg).	The	mice	were	then	intubated	and	ventilated	with	oxygen	and	1.5-2%	 isoflurane	 for	maintenance.	The	aorta	was	 constricted	 between	 the	 right	 and	 left	 carotid	 arteries	 using	 a	 27-gauge	(27-G)	 needle	 and	 7/0	 silk	 suture.	 Analgesia	 was	 provided	 the	 following	morning	with	buprenorphine	 (0.07	mg/kg)	 subcutaneously.	After	2	or	7	days	post	 surgery,	 ventricular	 systolic	 and	 diastolic	 functions	 were	 assessed	 by	micromanometry	 using	 Acqknowledge	 software	 (Biopac	 Systems	 Inc.).	 After	micromanometry,	 one	 cohort	 of	mice	was	 euthanized	 by	 cervical	 dislocation,	and	hearts	were	excised	 for	gross	morphological	and	mRNA	measurements	of	left	 ventricular	 hypertrophy.	 In	 a	 second	 cohort	 of	 mice,	 the	 mice	 were	heparinised	and	euthanized.		
2.2.3.	Isolation	of	cardiomyocytes	Cardiomyocyte	 isolation	was	performed	at	 the	Victor	Chang	Cardiac	Research	Institute	 by	 Dr.	Ming	 Li	 with	 assistance	 from	Ms.	 Sara	 Holman	 and	 Dr.	 Carly	Hynes.	Cardiomyocytes	were	isolated	as	previously	described	(O'Connell	et	al.,	2007).	 Briefly,	 excised	 hearts	 were	 mounted	 on	 a	 perfusion	 apparatus	 and	immediately	 flushed	with	a	calcium-free	CM	isolation	perfusion	buffer.	After	4	min,	the	hearts	were	perfused	with	collagenase	digestion	buffer	to	remove	the	extracellular	matrix.	After	2-3	min,	the	heart	was	digested	for	a	further	8	min	at	4ml/min	 with	 collagenase	 digestion	 buffer	 containing	 40	 μM	 CaCl2.	 Once	
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digestion	 was	 completed,	 the	 ventricles	 were	 obtained	 and	 cut	 into	 smaller	pieces.	The	heart	 tissue	was	dissociated	 further	until	all	 the	 large	pieces	were	dispersed	 into	 a	 cell	 suspension	 (3-5min).	 The	 cardiomyocytes	 were	 then	allowed	 to	 sediment	 passively	 by	 gravity	 at	 room	 temperature,	 and	 then	centrifuged	at	20g	for	3	min.	The	cells	were	then	resuspended	in	10	ml	myocyte	stopping	 buffer	 and	washed	 a	 further	 2	 times	 (total	 of	 3	washes)	with	 10	ml	myocyte	 stopping	 buffer.	 The	 final	 cells	 were	 washed	 once	 in	 PBS,	 then	centrifuged	at	low	speed.	The	pellet	was	then	dissolved	in	5mL	TRIzol®	for	RNA	extraction.			
2.2.4.	RNA	Extraction	RNA	 was	 extracted	 using	 the	 standard	 TRIzol®	 protocol	 with	 an	 additional	overnight	sodium	acetate/ethanol	precipitation	step.	The	concentration	of	RNA	was	determined	using	Nanodrop	by	the	absorbance	at	260nm,	with	one	A260	OD	unit	equivalent	 to	40	µg/ml	of	RNA.	After	RNA	 isolation,	 the	RNA	quality	was	assessed	using	an	Agilent	2100	Bioanalyzer	(Agilent)	together	with	the	reagents	in	the	RNA	6000	Nano	LabChip	kit.	Only	samples	with	an	RNA	Integrity	Number	(RIN)	>8	were	considered	suitable	for	downstream	analysis	(with	the	exception	of	RNA	extracted	from	polysome	gradients).	All	RNA	was	aliquoted	and	stored	at	-80°C.		
	
2.2.5.	DNase	treatment	of	RNA	samples	RNA	 used	 for	 real-time	 quantitative	 PCR	 (RT-qPCR)	 analysis	 of	mRNA	 and	 3’	UTR	 variants	 expression	 was	 first	 DNase	 treated	 to	 avoid	 genomic	contamination.	2	U	TURBO	DNase	was	added	to	1	μg	of	total	RNA,	in	1	x	TURBO	DNase	buffer	at	a	final	volume	of	20	μl.	The	reaction	was	incubated	at	37°C	for	30	 min.	 To	 inactivate	 the	 DNase,	 3μl	 DNase	 inactivator	 was	 added	 and	 the	sample	vortexed	and	incubated	at	RT	for	30	sec,	this	step	was	repeated	3	times.	The	 RNA	 was	 then	 centrifuged	 in	 a	 mini-centrifuge	 for	 1.5	 min	 and	 the	supernatant	transferred	to	a	new	0.2	ml	Eppendorf	tube.	
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2.2.6.	Reverse	transcription	of	mRNAs	10	μl	of	DNase	treated	RNA	(~500	ng),	2	μl	random	primer	mix	and	6	μl	water	were	 incubated	 at	 65°C	 for	 5	 min	 then	 ice	 for	 3	 min.	 1	 μl	 0.1	 M	 DTT,	 40	 U	RNaseOUT™,	 200	 U	 Superscript®	 III,	 and	 1	 x	 First-strand	 buffer	 were	 then	added,	followed	by	the	addition	of	nuclease	free	water	to	a	total	volume	of	20	μl.	The	reaction	mixture	was	incubated	at	50°C	for	2	hours,	then	75°C	for	15	min.	cDNA	was	 stored	 at	 -20°C	 and	 diluted	 1:10	 for	 individual	 expression	 by	 RT-qPCR.		
2.2.7.	Quantitative	PCR	qPCR	 analyses	 were	 performed	 according	 to	 routine	 protocols	 using	 Fast	SYBR®	Green	Master	Mix.	Each	reaction	was	performed	in	triplicate	using	2	μl	diluted	cDNA	mixed	with	8	μl	Master	Mix	(5	μl	SYBR,	0.5	μl	of	5	μM	each	primer	and	2	μl	water).	Raw	expression	values	were	normalized	to	the	reference	genes	hypoxanthine	 phosphoribosyl	 transferase	 (HPRT),	 acidic	 ribosomal	phosphoprotein	P0	 (ARBP),	and	calnexin1	(CANX1)	 for	all	applications	except	for	analyses	of	polysome	gradient	fractions,	where	raw	values	were	normalised	to	 a	 Renilla	 luciferase	 mRNA	 spiked	 into	 in	 each	 gradient	 fraction,	 and	accompanying	 values	 from	 total	 RNA	 were	 normalised	 to	 glyceraldehyde	 3-phosphate	dehydrogenase	(GAPDH).			
2.2.8.	Agarose	Gel	Electrophoresis	1-2%	 agarose	 gels	 were	 used	 in	 the	 analysis	 of	 PCR	 products.	 The	 agarose	powder	was	added	to	1	x	TAE,	heated	until	the	agarose	powder	was	dissolved	and	ethidium	bromide	(EtBr)	added	to	a	final	concentration	of	0.5	mg/ml.	Gels	were	then	poured	into	horizontal	gel	boxes	to	set.	One-tenth	the	volume	of	Ez-Vision®	 Three	 DNA	 Dye	 was	 added	 to	 the	 samples	 and	 size	 markers	 before	loading.	DNA	 gels,	were	 electrophoresed	 at	 80-100V	 for	 40-60	min.	 The	 EtBr	
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was	 visualized	 by	 medium	 wavelength	 UV	 light	 and	 photographed	 using	 the	Typhoon™	FLA	9000	(GE	Healthcare).			
2.2.9.	3’	RACE	validation	of	3’-ends		3	-́RACE	 experiments	 were	 performed	 by	 RT-PCR	 amplification	 using	 a	 TVN	anchor	primer	(12x	T,	V=C,G,A,	N=A,C,T,G).	A	superscript	mix	was	made	up	with	the	 following	components:	6	μl	5	x	First-strand	buffer,	1.5	μl	0.1	M	DTT,	60	U	RNaseOUT™,	300	U	Superscript®	III	and	1.5	μL	TVN	anchor.	0.5	μg	of	RNA	and	1	μL	10	mM	dNTPs	were	then	added	to	H2O	to	give	a	final	volume	of	12	μL.	The	reaction	 was	 incubated	 at	 65°C	 for	 5	 min,	 then	 50°C	 for	 5	 min.	 8	 μL	 of	 the	superscript	mix	was	added	to	the	RNA	mix	at	50°C,	then	the	reaction	was	mixed	at	50°C	for	1	hour,	followed	by	75°C	for	15	min.	The	cDNA	was	diluted	1:10	for	PCR	amplification.		2	μL	of	diluted	cDNA	was	then	added	to	0.4	μL	10	mM	dNTPs,	1	U	Fast	start	Taq	DNA	 polymerase,	 2	 μL	 each	 of	 forward	 specific	 primer	 and	 reverse	 anchor	primer	 (5	 μM),	 1	 x	 buffer	 to	 a	 total	 volume	 of	 20	 μL.	 The	 reaction	was	 then	amplified	 using	 the	 following	 conditions:	 heating	 at	 94°C	 for	 15	 min,	 36-38	cycles	of	94°C	for	15	sec,	60°C	for	30	sec,	70°C	for	30	sec,	followed	by	70°C	for	1	min.	The	PCR	products	were	run	with	RNA	EZ-Vision®	dye	on	a	1.5%	agarose	gel	at	100V	for	45	min.	The	appropriate	bands	were	excised	and	extracted	using	the	QIAquick	gel	extraction	kit	according	to	manufacturer’s	instructions.			4	μL	of	 the	PCR	product	was	 ligated	 into	50	mg	of	 the	pGEM®-T	Vector	with	400	 U	 of	 T4	 DNA	 Ligase	 in	 1	 x	 T4	 DNA	 Ligase	 buffer	 at	 RT	 overnight.	 The	ligation	mixture	was	then	transformed	into	competent	E.coli	cells	by	adding	50	μL	E.coli	suspension	to	each	ligation	mixture	and	incubating	on	ice	for	30	min.	The	cells	were	then	heat	shocked	at	42°C	for	45	sec	and	put	back	onto	ice	for	2	min.	200	μL	LB	media	was	added	and	the	cells	allowed	to	recover	by	incubating	them	at	37°C	for	1	hour	with	shaking	at	220	rpm.	150	μl	was	then	spread	onto	
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ampicillin	 plates	 coated	 with	 25	 μL	 ampicillin	 (100	 μg/ml),	 25	 μl	 X-gal	 (20	mg/ml)	 and	 40	 μl	 0.1	M	 IPTG	 and	 incubated	 overnight	 at	 37°C.	 Single	white	colonies	 were	 picked	 from	 the	 plate	 and	 inoculated	 into	 10	 ml	 LB	 media	containing	100	μg/ml	ampicillin,	then	incubated	overnight	at	37°C	with	shaking	at	 220	 rpm.	 Overnight	 bacterial	 cultures	 were	 incubated	 in	 vessels	 with	 a	volume	 of	 at	 least	 four	 times	 that	 of	 the	 culture	media	 to	 allow	 for	 sufficient	aeration.	 Plasmid	 purification	 was	 performed	 using	 the	 PureYield™	 Plasmid	Miniprep	 System	kit	 according	 to	 the	manufacturer’s	 instructions	 as	 outlined.	The	insert	size	was	confirmed	by	digesting	pGEM®-T	with	10	U	EcoR1	at	37°C	for	 2	 hours	 and	 running	 the	 digestion	 products	 on	 an	 agarose	 gel.	 4	 μl	 of	pGEM®-T	 containing	 the	 PCR	 insert	 was	 combined	 with	 1	 μl	 BigDye®	Terminator	v1.1	Ready	Reaction	Mix,	3.2	μL	M13	reverse	primer	(1	pmole/μl)	in	1	x	buffer	and	H2O	to	a	total	volume	of	20	μL.	The	sequencing	PCR	was	run	as	follows:	94°C	for	15	min,	30	cycles	of	96°C	for	10	sec,	50°C	for	5	sec,	60°C	for	4	min.	The	PCR	product	was	 then	precipitated	by	adding	1	μL	3	M	NaOAc,	5	μL	125	mM	EDTA	and	50	μL	100%	EtOH,	 vortexing	and	 centrifuging	 for	20	min.	The	 supernatant	 was	 removed	 and	 the	 pellet	 washed	 twice	 with	 75%	 EtOH.	Once	 dried,	 the	 samples	 were	 taken	 to	 the	 Biomolecular	 Resource	 Facility,	Canberra,	Australia,	for	BigDye®	Terminator	Sequencing.		
2.2.10.	Western	Blot	
2.2.10.1.	Preparation	of	samples		Tissues	 were	 homogenised	 in	 10x	 T-PER	 tissue	 protein	 extraction	 reagent	(Thermo-	Scientific,	 IL,	USA)	with	added	protease	 inhibitor	 (4-(2-Aminoethyl)	benzenesulfonyl	 fluoride	 hydrochloride	 (AEBSF).	 Homogenates	 were	centrifuged	at	14,000g	for	15	minutes	at	4°C.	The	supernatant	was	collected	for	use	in	Western	blot	analysis.		
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2.2.10.2.	Protein	quantification	The	 amount	 of	 proteins	 in	 tissue	 homogenates	 was	 quantitated	 with	 the	Pierce™	BCA	 Protein	 Assay	 Kit	 using	 a	 FluoSTAR	OPTIMA	 plate	 reader	 (BMG	Labtech,	Ortenberg,	Germany).		
2.2.10.3.		Polyacrylamide	gel	electrophoresis		Samples	to	be	loaded	were	diluted	1:1	(v/v)	in	sample	buffer	(2.5%	SDS,	10%	glycerol,	 5%	 mercaptoethanol,	 0.02%	 bromophenol	 blue,	 and	 62.5mM	 Tris-HCl),	and	heated	to	100°C	for	5	minutes	to	denature	proteins.		4%	sodium	dodecyl	sulfate	(SDS)	stacking	gel	(4.6mL	H2O,	1.95mL	stacking	gel	buffer	(0.5M	Tris-HCl,	0.4%	SDS,	pH	6.8),	1.0mL	acrylamide	(30%)	(Bio-Rad,	CA,	USA),	 37.5μL	 ammonium	 persulfate	 (APS)	 (10%),	 7.5μL	 TEMED)	 and	 10%	resolving	gel	 (3.3mL	H2O,	2mL	resolving	gel	buffer	 (1.5M	Tris-HCl,	0.4%	SDS,	pH	 8.8),	 2.7mL	 acrylamide	 (30%)	 (Bio-Rad,	 CA,	 USA),	 30μL	APS	 (10%),	 10μL	TEMED)	 and	 10%	 resolving	 gel	 were	 used	 to	 separate	 the	 proteins.	 50μg	 of	tissue	proteins	(protein	concentration	in	tissue	homogenates	estimated	as	per	Section	2.13)	were	loaded	in	each	well	and	electrophoresed	in	a	Mini-Protean	II	electrophoresis	 cell	 (Bio-Rad,	 CA,	 USA),	 at	 100V	 for	 ~1	 hour	 in	 a	 buffer	containing	25mM	Tris,	192mM	glycine,	0.1%	SDS.			
2.2.10.4.	Immunoblotting		Proteins	separated	by	electrophoresis	were	transferred	using	a	Mini-Protean	II	transfer	 cell	 (Bio-Rad,	 CA,	 USA)	 from	 the	 gel	 onto	 polyvinylidene-difluoride	(PVDF)	membrane	(Millipore,	USA)	at	100V	in	transfer	buffer	for	2	hours	at	4°C.	The	membrane	was	 then	 blocked	 in	 5%	milk	 in	 TBS	 buffer	 (50mM	 Tris-HCl,	pH7.4,	150mM	NaCl)	 for	1	hour	at	 room	temperature.	Following	 this	blocking	step,	 the	blots	were	probed	with	 the	primary	antibodies.	The	blots	were	 then	probed	 with	 corresponding	 secondary	 antibody	 conjugated	 to	 horse	 radish	peroxidase	 (HRP)	 (Dako),	which	was	 subsequently	 reacted	with	ECL	Western	
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blotting	 detection	 reagents,	 and	 the	 chemiluminescence	 of	 the	 bands	corresponding	to	the	tagged	proteins	were	visualised	using	a	ImageQuant	LAS	4000	CCD	camera	(GE	Healthcare,	Little	Chalfort,	BKM,	UK).			
2.2.10.5.	Densitometry	of	Western	blots	Image	 Processing	 and	 Analysis	 in	 Java	 (ImageJ)	 (https://imagej.nih.gov)	 was	used	 to	 quantify	 the	 intensity	 of	 protein	 bands	 on	western	 blots.	 Equal	 sized	rectangular	selections	were	made	for	each	lane	on	the	gel	and	the	 intensity	of	each	 band	 plotted.	 To	 remove	 background	 noise,	 a	 straight	 line	 was	 drawn	across	the	base	of	each	peak,	and	intensity	measurements	taken.	The	intensity	of	each	band	was	normalised	 to	 the	 intensity	of	 the	 loading	control	 (GAPDH),	then	normalised	to	the	gel.	Three	technical	replicates	were	conducted	for	each	protein	of	interest.		
2.2.11.	Small	RNA	Sequencing	
2.2.11.1.	Small	RNA	library	preparation	Small	RNA	library	preparation	was	performed	by	Dr.	David	Humphreys	at	 the	Victor	 Chang	 Cardiac	 Research	 Institute.	 Libraries	 were	 created	 from	 2µg	 of	total	RNA	using	 the	NEBNext®	Small	RNA	Library	Prep	Set	 for	SOLiD™	as	per	manufacturer’s	 instructions.	 The	 PCR	 amplification	 was	 modified	 from	 the	NEBNext®	 protocol	 to	 include	 the	 SOLiD™	 5’	 PCR	 Primer	 and	 SOLiD™	 3’	Barcodes	 for	each	sample	(Barcodes	2-9),	and	13	cycles	of	amplification	were	used.	PCR	products	corresponding	to	miRNA-sized	inserts	were	excised	from	a	polyacrylamide	 gel	 and	 further	 processed	 for	 sequencing	 using	 the	 SOLiD™	5500	platform	(35nt	read	length).		
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2.2.11.2.	Small	RNA	sequencing	data	analysis	HTS	 reads	were	 processed	 and	mapped	 to	 the	mouse	 genome	 by	 Dr.	 Hardip	Patel	as	described	by	Clancy	et	al.	(2014)	(Clancy	et	al.,	2014).	Briefly,	a	custom	Perl	script	was	first	used	to	trim	adaptors	and	remove	all	reads	with	an	average	Phred	score	of	<18	across	 the	read	 (Perl	 script	provided	 in	Appendix	1).	This	yielded	~2x107	high	quality	reads	≥20nt	in	length,	which	were	then	mapped	to	the	reference	mouse	genome	(assembly	version	mm10,	including	the	18s	rRNA	(NR_003278.3)	and	28s	rRNA	(NR_003279.1)	sequences)	using	Bowtie	version	1.0.0.	Reads	were	assigned	to	a	mature	miRNA	if	they	were	between	20-26nt	in	length	and	their	5’	ends	mapped	to	within	±3nt	of	a	miRNA	5’	end	as	annotated	in	miRBase	version	20.	Within	 those	constraints,	 reads	with	mapped	start-	or	end-points	 that	 exactly	 matched	 miRBase-annotations	 were	 classed	 as	canonical	 miRNA	 reads,	 whereas	 those	 that	 differed	 were	 considered	 as	representing	5’-	or	3’-	isomiRs,	respectively.	Reads	with	an	internal	nucleotide	mismatch	 were	 taken	 as	 evidence	 for	 internal	 editing	 (IE);	 those	 with	mismatches	 in	 the	 last	 two	 nucleotides	were	 indicative	 of	miRNAs	with	 non-templated	 additions	 (NTA).	 Furthermore,	 hairpin	 arm	bias	was	 calculated	 for	each	miRNA	locus	as	the	proportion	of	all	miRNA	reads	that	mapped	to	the	5’	arm	of	the	hairpin.		
2.2.12.	Poly(A)-Test	(PAT)	Sequencing	
2.2.12.1.	PAT-Seq	Library	preparation	PAT-seq	libraries	were	prepared	by	Dr.	Traude	Beilharz	(Harrison	et	al.,	2015)	and	summarized	 in	Figure	2.1.	2μg	of	RNA	 in	11μl	ddH20	was	added	to	1μl	of	100	 μM	 Biotin	 labeled	 oligo	 (Biotin-5’-CTGCTGTACGGCCAAGGCGTTTTTTTTTTTT-3’),	 heated	 at	 80°C	 for	 5	 min	 and	briefly	 centrifuged.	 The	 heated	 RNA	was	 then	 added	 to	 1μl	 0.1	M	 DTT,	 40	 U	RNaseOUT,	1μl	10mM	dNTPs,	5	U	Klenow	polymerase	Exo	in	1X	SuperScript™	III	First-strand	buffer	at	37°C.	The	reaction	was	mixed,	briefly	centrifuged	and	incubated	 at	37°C	 for	1	hour,	 followed	by	80°C	 for	5	min.	While	 still	 at	 80°C,	
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80μl	digest	solution	(10μl	10	x	digest	buffer,	1μg	carrier	RNA	and	70μl	ddH20)	was	added	and	then	incubated	at	80°C	for	a	further	10	min.	The	end-extended	RNA	was	 cooled	on	 ice	 for	5	min,	 then	 added	 to	 a	 pre-cooled	Phase	Lock	Gel	tube	containing	100μl	cold	10	x	digest	buffer	and	10U	RNase	T1	and	incubated	on	 ice	 for	1	min.	Then,	 the	 tube	was	vortexed	briefly,	 returned	 to	 ice	and	 the	reaction	 terminated	 by	 adding	 200μl	 50:50	 phenol:chloroform.	 The	 reactions	were	 shaken	 vigorously	 and	 centrifuged	 at	 16,000g	 for	 5	min,	 then	 extracted	once	with	chloroform.	The	aqueous	layer	was	transferred	to	a	new	1.5	ml	tube	containing	 100μl	 5mg/ml	 streptavidin	 magnetic	 beads	 prewashed	 in	 1	 x	binding	buffer.	 The	DNA:RNA	duplexes	were	 incubated	with	 the	beads	 for	15	min	 at	 37°C	 with	 shaking.	 The	 beads	 were	 washed	 once	 with	 300μl	 1	 x	 RT	buffer	 at	 55°C,	 then	 washed	 again	 with	 100μl	 1	 x	 T4	 DNA	 ligase	 buffer	(containing	 ATP)	 at	 37°C	with	 shaking.	 The	 beads	were	 then	 resuspended	 in	20μl	 1	 x	 T4	 DNA	 ligase	 buffer.	 10	 U	 Polynucleotide	 Kinase	 (PNK)	 was	 then	added	 to	 the	 20μl	 RNase	 T1	 fragments,	 and	 incubated	 at	 37°C	 for	 30	 min,	followed	 by	 heat	 inactivation	 at	 70°C	 for	 10	 min.	 Once	 cooled	 to	 room	temperature,	200μl	of	1	x	RT	buffer	was	added	to	the	beads.	5’	SOLiD	adaptors	were	then	ligated	using	the	SOLiD™	Total	RNA-Seq	kit.	The	beads	were	added	to	2μl	5’	Adaptor	mix,	3μl	Hyb	 solution	and	2μl	ddH2O	on	 ice,	 then	 incubated	at	65°C	for	10	min	and	16°C	for	5	min.	10μl	2	x	ligase	buffer	and	2μl	RNA	ligase	2	were	added,	and	the	mix	incubated	at	16°C	for	16	hours.	To	reverse	transcribe	the	 fragment	 containing	 the	 5’	 linker,	 the	 ligation	 product	 was	 added	 to	 2μl	0.1M	 DTT,	 40	 U	 RNaseOUT,	 2μl	 10	 mM	 dNTPs,	 in	 1X	 SuperScript™	 III	 First-strand	 buffer	 (total	 volume	 39μl),	 then	 incubated	 at	 70°C	 for	 5	 min,	 briefly	centrifuged,	 incubated	 at	 55°C	 for	 1	min	before	 adding	200	U	 Superscript	 III.	The	reaction	was	mixed,	briefly	centrifuged	and	incubated	at	55°C	for	a	further	60	 min.	 The	 cDNA	 products	 were	 then	 separated	 by	 PAGE	 gel.	 Products	approximately	 70-300nt	 in	 size	 were	 excised	 from	 the	 gel	 and	 purified	 by	centrifuging	 through	 a	 Corning®	 Costar®	 Spin-X®	 Plastic	 Centrifuge	 Tube	Filter	 and	 then	 precipitating	 in	 isopropanol	 and	 10	 μg	 glycogen.	 The	 purified	cDNA	 were	 then	 PCR	 amplified	 by	 standard	 protocols	 for	 15	 cycles,	 then	
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prepared	for	sequencing	using	Emulsion	PCR	(e-PCR)	on	the	SOLiD®	EZ	Bead™	Emulsifier	 according	 to	 manufacturer’s	 instructions.	 The	 libraries	 were	 then	sequenced	using	the	SOLiD™	5500	platform	(75nt	read	length).		
2.2.12.2.	PAT-Seq	data	analysis	
2.2.12.2.1.	Read	alignment	to	genome	and	transcriptome	First,	a	custom	Perl	script	(Appendix	1)	was	used	to	trim	adaptors	and	remove	all	 reads	 with	 a	 mean	 Phred	 score	 of	 <18,	 retaining	 a	 base	 call	 accuracy	 of	~98%.	This	yielded	~4.4x107	high	quality	 reads	per	 library,	which	were	 then	mapped	 to	 the	 mouse	 genome	 in	 three	 stages.	 In	 the	 first	 stage,	 reads	 were	mapped	to	the	reference	mouse	genome	(mm10,	including	18s	(NR_003278.3)	and	 28s	 (NR_003279.1)	 rRNA	 sequences)	 using	 Bowtie	 version	 1.0.0	(Langmead	et	al.,	2009).	Mapping	parameters	were	chosen	to	allow	for	up	to	3	mismatches	 in	 the	 first	20nt	 ‘seed’	region,	and	the	alignment	was	extended	to	the	full	length	of	the	read	if	the	sum	of	the	Phred	scores	at	mismatch	positions	did	not	exceed	150.	Reads	were	allowed	to	map	to	up	to	20	locations.	Reads	that	failed	to	align	to	the	genome	were	mapped	to	the	mouse	transcript	sequences	(Ensembl	v77)	to	capture	exon	junction-spanning	reads.	In	this	second	stage	of	mapping,	 reads	were	 allowed	 to	match	 to	 up	 to	 200	 locations,	 retaining	 only	mapping	 locations	 with	 minimum	 mismatches.	 RNA	 alignments	 were	 then	transferred	to	genomic	coordinates.	Reads	that	could	neither	be	mapped	to	the	genome	 nor	 the	 transcriptome	 may	 contain	 the	 beginning	 of	 a	 poly(A)	 tail.	Thus,	 in	 the	 third	 stage	 of	 mapping,	 unmapped	 reads	 were	 mapped	 to	 the	genome	using	 the	 first	21nt	 seed	of	 the	 read,	 allowing	up	 to	3	mismatches	 in	this	region.	Reads	were	allowed	to	map	to	up	to	200	 locations	with	minimum	mismatches.	 Seed	 alignments	were	 extended,	 retaining	minimum	mismatches	between	 the	 polyA	 tail	 and	 the	 templated	 region	 of	 the	 read.	 All	 three	alignments	(i.e.	genome,	RNA	and	seed	alignments)	were	then	merged	into	one	alignment	file	per	sample	for	further	downstream	analysis.		
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2.2.12.2.2.	Defining	PAT-seq	peaks	Read	alignments	were	processed	to	identify	expression	contigs.	Corresponding	PAT-Seq	peaks	with	≥10	reads	present	in	at	least	2	libraries	and	>75nt	in	length	were	 selected	 for	 further	 downstream	 analysis.	 The	 peaks	 were	 categorized	based	on	their	location	relative	to	the	last	stop	codon	(for	protein	coding	genes)	or	 the	 longest	 transcript	 3’	 end	 (for	 ncRNA)	 of	 known	 genes	 as	 annotated	 in	Ensembl	v.77.	Peak	classifications	are	illustrated	in	Figure	2.1,	and	the	R	scripts	are	 provided	 in	 Appendix	 2.	 Peaks	 located	 upstream	 of	 the	 annotated	 stop	codon/transcript	end	were	termed	‘exon’	or	‘intron’	peaks,	depending	on	their	overlap	with	exonic	or	intronic	features.	For	peaks	that	did	not	overlap	with	a	known	 gene,	 the	 opposite	 strand	was	 searched	 for	 genomic	 features.	 If	 there	was	 an	 annotated	 gene	 on	 the	 opposite	 strand,	 the	 peak	was	 classified	 as	 an	‘antisense’	peak.	Unassigned	peaks	 located	within	20kb	downstream	of	a	stop	codon/transcript	 end	 were	 defined	 as	 ‘downstream’	 peaks	 belonging	 to	 the	closest	upstream	gene.	Peaks	that	did	not	overlap	with	a	known	gene	on	either	strand,	 and	were	 further	 than	 20kb	 downstream	 from	 the	 closest	 gene,	were	defined	as	‘unannotated’	peaks.		
	
Figure	2.1.	PAT-seq	method	and	hierarchical	classification	of	peaks.	
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	To	 identify	 expression	 of	 novel	 3’UTRs	 in	 our	 dataset,	 we	 compared	 the	 end	position	of	all	peaks	(or	 the	start	of	 the	poly(A)	 tail	 for	peaks	containing	non-templated	 poly(A))	with	 annotated	 transcript	 ends	 reported	 in	 Ensembl	 v77.	Peaks	 located	 >100nt	 upstream	 or	 downstream	 of	 annotated	 3’ends	 were	defined	as	‘novel’	(Figure	2.2).			
	
Figure	 2.2.	 Identification	 of	 known	 and	 novel	 3’UTRs	 in	 the	
cardiomyocyte.	 Where	 PAT-seq	 peaks	 map	 to	 regions	 within	 100nt	 of	 an	annotated	3’UTR	end,	the	peak	is	classified	as	“known”.	Where	it	maps	outside	of	these	regions,	it	is	classified	as	“Novel	shorter,	intermediate,	or	longer,	based	on	its	alignment.			
2.2.13.	Differential	analyses	
2.2.13.1.	Differential	gene	expression	Differential	 expression	 analyses	 for	 miRNAs,	 protein-coding	 genes,	 and	unannotated	peaks	were	performed	using	the	edgeR	package	(Robinson	et	al.,	2010)	 (R	 scripts	 provided	 in	 Appendix	 2).	 Differential	 expression	 analysis	 of	long	non-coding	RNAs	were	conducted	using	DESeq2	(Love	et	al.,	2014)	by	Dr	Maurits	Evers	(R	scripts	provided	in	Appendix	2).		For	 the	 differential	 expression	 analyses	 of	 protein	 coding	 genes,	 counts	 from	‘downstream’	 protein-coding	 peaks	 associated	 with	 the	 same	 gene	 ID	 were	
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added	together	to	obtain	an	expression	value	that	was	proportional	to	the	total	expression	of	that	gene	(Figure	2.3);	which	is	henceforth	referred	to	as	the	total	gene	 expression.	 Expression	 counts	were	 normalized	 to	 account	 for	 different	library	sizes.	3	pairwise	analyses	were	performed:	2	day	TAC	versus	all	sham,	7	day	TAC	versus	all	sham	and	all	TAC	versus	all	sham.			
		
Figure	 2.3.	 Merging	 downstream	 3’-end	 peaks	 for	 differential	 gene	
expression	 analysis.	 Counts	 from	 ‘downstream’	 protein-coding	 peaks	associated	with	the	same	gene	ID	were	added	together	to	obtain	an	expression	value	that	was	proportional	to	the	total	expression	of	that	gene.		
2.2.13.2.	Differential	processing	of	miRNAs	and	mRNA	3’UTRs	Differential	analyses	of	miRNA	variant	expression	and	mRNA	3’UTR	expression	between	TAC	and	sham	were	performed	by	Dr.	Maurits	Evers	using	the	DESeq2	R	 package	 (Love	 et	 al.,	 2014)	 (R	 Scripts	 provided	 in	Appendix	 2).	 Expression	counts	were	normalized	to	account	for	different	library	sizes,	and	shrunk	using	an	empirical	Bayes	approach	 to	account	 for	 events	with	 low	counts	and	 large	dispersion.	The	normalized	data	were	modeled	using	a	 two-factor	generalized	linear	 model	 (GLM),	 with	 factors	 corresponding	 to	 condition	 (TAC	 vs	 sham),	and	 processing	 (for	miRNA:	 expression	 of	 variant	 vs.	 total;	 for	mRNA	 3’UTR:	expression	 of	 distal	 vs.	 proximal).	 The	 interaction	 term	 evaluates	 the	dependence	of	changes	in	processing	on	the	condition.		In	 analyzing	 differential	 miRNA	 processing,	 the	 four	 different	 variants	 (5’	isomiRs,	3’	 isomiRs,	non-templated	additions	(NTA),	and	 internal	editing	(IE))	
+
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were	 first	 separately	 analyzed	with	 respect	 to	 total	 expression	 of	 the	mature	miRNA.	Additionally,	for	the	analysis	of	differential	arm	bias,	expression	of	the	5’	arm	of	miRNAs	was	also	investigated	with	respect	to	total	expression	of	the	miRNA	 precursor.	 The	 per-miRNA	 fold	 change	 in	 variant	 processing	 between	the	 conditions,	 TAC	 and	 sham,	was	 given	 by	 the	 coefficient	 of	 the	 interaction	term	in	the	GLM	equation:	log! !"# !"#$"%&!"# !"!#$ − log! !"#$ !"#$"%&!"#$ !"!#$ 																																														(1)		For	 differential	 polyadenylation	 (DPA)	 of	 mRNAs,	 genes	 with	more	 than	 one	3’UTR	 peak	were	 analyzed.	 If	 an	mRNA	 had	more	 than	 two	 3’UTR	 peaks,	 all	possible	combinations	of	proximal	and	distal	UTRs	were	considered	in	separate	GLMs	(Figure	2.4).	The	per-comparison	fold-change	in	proximal	and	distal	UTR	expression	 between	 the	 conditions	 TAC	 and	 sham	 was	 again	 given	 by	 the	coefficient	of	the	interaction	in	the	GLM	equation:		log! !"# !"#$%&!"# !"#$%&'( − log! !"#$ !"#$%&!"#$ !"#$%&'( 																																													(2)		
 
Figure	 2.4.	 Multiple	 pairwise	 comparisons	 conducted	 for	 genes	 with	 ≥2	
3’UTRs.	
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2.2.13.3.	Tests	for	statistical	significance	False	Discovery	Rate	(FDR)-controlled	p-values	were	obtained	by	adjusting	for	multiple	testing	following	the	procedure	of	Benjamini	and	Hochberg	(Benjamini	and	Hochberg,	1995).	For	all	differential	analyses,	an	FDR	significance	 level	of	5%	was	chosen.			
2.2.14.	Gene	ontology	and	gene	set	enrichment	analyses	Gene	ontology	(GO)	term	enrichment	was	assessed	using	DAVID	(Huang	da	et	al.,	 2009)	 (http://david.abcc.ncifcrf.gov/).	 All	 genes	 from	 the	 cardiomyocyte	PAT-Seq	analysis	with	average	expression	of	≥2	CPM	were	used	as	background	genes.	 Gene	 set	 enrichment	 analyses	 (GSEA)	were	 conducted	 using	 the	 GSEA	software	v2.2.1	(Broad	Institute)	(Subramanian	et	al.,	2005).	The	ranked	gene	list	 input	 was	 constructed	 based	 on	 the	 fold-changes	 of	 the	 interaction	 term	(see	Eq.	(1)	and	(2)),	which	measures	the	dependence	of	changes	in	processing	on	the	changing	conditions	TAC	and	sham.	Statistical	significance	was	assessed	by	performing	1,000	random	gene	set	permutations.	An	FDR	significance	level	of	 25%	was	 chosen	 for	 all	 gene	 set	 enrichment	 analyses.	 In	 both	 DAVID	 GO	analysis	 and	 GSEA	 analysis,	 we	 adopted	 a	 significance	 level	 of	 FDR<25%	(Subramanian	et	al.,	2005).		
2.2.15.	Prediction	of	miRNA-3’UTR	interactions	Potential	 miRNA	 target	 sites	 were	 assessed	 using	 miRmap	 (Vejnar	 and	Zdobnov,	 2012)	 tools	 in	 Python	 as	 previously	 described,	 with	 modifications.	The	region	between	the	stop	codon	and	the	start	of	the	poly(A)	tail	(or	the	distal	edge	 of	 the	 peak	 for	 peaks	 lacking	 a	 poly(A)	 tract)	 were	 considered	 as	 the	sequence	for	each	3’UTR.	miRmap	was	run	on	the	3’UTR	sequences	to	calculate	context	 scores	 of	 potential	 binding	 sites	 for	 the	 120	most	 abundant	 miRNAs	detected	 in	 our	 cardiomyocyte	 small	 RNA-seq	 dataset.	 Default	 settings	 were	employed	 as	 described	 (Vejnar	 and	 Zdobnov,	 2012)	 (7mer	 seed	 match	minimum),	 employing	all	 scoring	 criteria.	Where	more	 than	one	 target	 site	of	
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the	same	miRNA	occurred	in	a	3’UTR,	the	scores	between	one	miRNA	and	one	3’UTR	 target	 were	 summed	 (Vejnar	 and	 Zdobnov,	 2012).	 Only	 miR-mRNA	interactions	 with	 a	 context	 score	 of	 <	 -0.3	 were	 considered	 for	 further	downstream	 analyses.	 For	 mRNAs	 with	 two	 or	 more	 3’UTRs,	 an	 overall	interaction	score	for	the	gene	was	calculated,	weighted	based	on	the	proportion	of	each	expressed	3’UTR	variant	(R	script	provided	in	2).	To	determine	whether	there	 was	 a	 net	 change	 in	 the	 weighted	 interaction	 score	 between	 TAC	 and	sham,	a	one-sample	Student’s	 t-test	was	conducted.	Significance	was	accepted	at	p<0.05.			
2.2.16.	Analysis	of	poly(A)	signal	(PAS)	motif	Hexameric	 PAS	motifs	 (both	 canonical	 and	 the	 12	 non-canonical	 PAS	motifs)	were	searched	within	50nt	of	a	cleavage	site	(Perl	script	provided	in	Appendix	1).	 Assignment	 of	 PAS	 was	 hierarchical,	 with	 a	 canonical	 PAS	 defined	 as	 the	likely	functional	PAS	for	that	peak.	If	no	canonical	PAS	could	be	found	within	50	nt,	then	the	closest	non-canonical	PAS	was	assigned	to	that	peak.	The	position	of	the	PAS	motif	was	counted	from	the	5’	start	of	the	hexanucleotide	motif.	
2.2.16.1.	Differential	expression	of	PAS	motif		To	 test	 whether	 PAS	 usage	 is	 independent	 of	 sham	 or	 TAC	 treatment,	 a	 Chi-squared	Test	was	performed	(R	scripts	provided	 in	Appendix	2).	Additionally,	differential	analyses	of	PAS	preference	between	TAC	and	sham	was	performed	using	the	DESeq2	R	package	(Love	et	al.,	2014)	(R	scripts	provided	in	Appendix	2).	 In	 this	analysis,	 the	 fold-change	 in	PAS	usage	between	 the	conditions,	TAC	and	 sham,	 was	 given	 by	 the	 coefficient	 of	 the	 interaction	 term	 in	 the	 GLM	equation:		
log! !"# !"#$#%!"&!"# !"!!!"#$#%!"& − log! !"#$ !"#$#%!"&!"#$ !"!!!"#$#%!"& 																																													(2)	
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2.2.17.	HL-1	Tissue	Culture	The	 HL-1	 cell	 line	 was	 provided	 by	 W.C.	 Claycomb	 (Claycomb	 et	 al.,	 1998).	Flasks	or	wells	were	pre-coated	with	gelatin/fibronectin	and	incubated	at	37°C	overnight.	 Excess	 gelatin/fibronectin	 solution	was	 removed	by	 aspiration	 just	prior	to	adding	cells	to	the	flasks.	HL-1	cells	were	maintained	in	supplemented	Claycomb	media,	with	fresh	media	added	daily.	To	passage	cells,	each	flask	was	rinsed	with	 PBS	warmed	 to	 37°C,	 and	 3	ml	 of	 0.05%	 trypsin/EDTA	 per	 T-75	flask	 (flask	with	75	cm2	 surface	area)	added	and	 incubated	at	37°C	 for	1	min.	The	 trypsin/EDTA	 was	 then	 removed,	 and	 fresh	 0.05%	 trypsin/EDTA	 added	then	 incubated	 for	an	additional	2	min	at	37°C.	7	ml	of	HL-1	wash	media	was	added	and	the	cells	collected	in	a	15	ml	centrifuge	tube.	After	centrifuging	for	5	min	at	500g,	the	supernatant	was	removed	and	the	pellet	gently	resuspended	in	3	ml	of	supplemented	Claycomb	media	ready	to	be	re-plated.			
2.2.18.	Polysome	gradient	analysis	
2.2.18.1.	Preparation	of	sucrose	gradient	17.5%,	25.6%,	33.8%,	41.9%	and	50%	(w/v)	sucrose	solutions	were	prepared	by	 dissolving	 the	 required	 amount	 of	 sucrose	 in	 sucrose	 gradient	 buffer,	followed	by	 filtering	 through	a	0.2	µm	filter.	Starting	with	 the	highest	density	sucrose,	 2	mL	was	 carefully	 laid	 at	 the	 bottom	 of	 a	 14	 x	 89	mm	polyallomer	centrifuge	tube,	and	placed	in	a	-80°C	freezer	for	a	minimum	of	15	min	before	applying	 the	 next	 layer.	 This	 process	was	 repeated	 until	 all	 sucrose	 densities	were	layered.	Sucrose	gradients	were	stored	at	-80°C	for	several	months.	Prior	to	polysome	analysis,	sucrose	gradients	were	thawed	overnight	at	4°C.		
2.2.18.2.	Preparation	of	cell	lysate	HL-1	cells	were	plated	in	a	15	cm	dish	at	a	density	of	7	x	106	cells	(approx.	80-90%	 confluent).	 24	 h	 post-plating,	 the	 cells	 were	 treated	 with	 0.1	 mg/mL	
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cycloheximide	 for	 3	min	 at	 37°C,	 placed	 on	 ice,	 and	 the	media	 removed.	 The	cells	were	washed	 twice	 in	 ice-cold	PBS	 containing	0.1	mg/mL	cycloheximide	and	drained	for	2	min.	The	cells	were	lysed	in	800	µL	lysis	buffer,	scraped	into	an	Eppendorf	tube	and	vortexed	for	2	min	at	4°C.	The	lysate	was	incubated	on	ice	 for	10	min	 followed	by	centrifugation	at	16,000	x	g	at	4°C	 for	10	min.	The	cleared	lysate	was	carefully	layered	on	top	of	the	thawed	sucrose	gradient	and	centrifuged	 at	 35,000	 rpm	 for	 2	 h	 and	 15	 min	 at	 4°C	 using	 SW40Ti	 rotor	(Beckman	Coulter).		
2.2.18.3.	Polysome	profiling	and	fraction	collection	Gradients	were	displaced	from	the	bottom	up	by	a	chase	solution	(60%	sucrose	in	ddH2O)	at	a	 rate	of	0.75mL/min,	passed	 through	a	UV	detector	 to	obtain	a	continuous	A254	profile,	and	collected	into	12	fractions	using	a	Brandel	BR-188	system	at	4°C.			
2.2.18.4.	Preparation	of	polysome	fractions	for	RNA	extraction	Each	gradient	fraction	was	spiked	with	200	pg	of	in	vitro	transcribed	3xB	Rluc	mRNA,	 20µg	 of	 glycogen	 added,	 then	 precipitated	 with	 1.5	 mL	 of	 ethanol	overnight	at	−80°C.	The	fractions	were	then	centrifuged	at	20,000g	for	20	min,	and	 the	 pellets	 resuspended	 in	 1	mL	of	 Trizol	 (Life	 Technologies).	 Total	 RNA	purification	 was	 then	 performed	 according	 to	 manufacture’s	 instructions,	followed	 by	 an	 additional	 sodium	 acetate/ethanol	 precipitation.	 Purity	 was	assessed	 by	 spectrophotometry	 and	 integrity	 by	 agarose	 gel.	 1µg	 of	 total	 or	gradient	 fraction	 RNA	were	 reverse	 transcribed	 using	 random	 hexamers	 and	superscript	III	(Life	Technologies).	 	
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Chapter	3.			
3.1.	Introduction	Previous	work	in	the	lab	had	generated	a	model	of	cardiac	hypertrophy	in	mice,	and	 sequenced	 the	 small-	 and	 polyadenylated-	 RNAs	 extracted	 from	 the	cardiomyocytes	 of	 these	mice.	 This	 chapter	 provides	 background	 data	 on	 the	cardiac	 hypertrophy	 model	 generated,	 and	 summarizes	 the	 small	 RNA-	 and	PAT-sequencing	libraries	that	are	further	investigated	in	Chapters	4	and	5.	The	sequencing	 data	 from	 which	 this	 chapter	 is	 derived	 has	 previously	 been	reported	in	the	PhD	thesis	of	Dr	Carly	Hynes,	with	some	modifications	such	as	the	re-mapping	of	the	sequencing	libraries	to	an	updated	version	of	the	mouse	genome	assembly.		
3.2.	Results	and	Discussion	
3.2.1.	Establishment	of	cardiac	hypertrophy	in	mice	Transverse	aortic	constriction	(TAC)	 is	a	widely	accepted	experimental	model	for	 pressure	 overload-induced	 cardiac	 hypertrophy	 (Rockman	 et	 al.,	 1991,	deAlmeida	et	al.,	2010).	This	 technique	 involves	constricting	 the	aorta	using	a	suture	 against	 a	 needle	 to	 decrease	 the	 diameter	 of	 the	 aorta.	 It	 has	 been	previously	shown	that	 in	8-week-old	C57BL/6	mice,	 the	diameter	of	a	normal	aorta	 at	 the	 site	 of	 constriction	 is	 1.2	mm,	 and	 aortic	 constriction	with	 a	 7-0	nylon	suture	against	a	27-G	needle	 results	 in	a	0.4	mm	reduction	 in	diameter	(Rockman	 et	 al.,	 1991).	 This	 reduction	 in	 the	 diameter	 of	 the	 aorta	 increases	blood	pressure,	which	 is	 offset	 by	hypertrophic	 growth	of	 the	 cardiomyocyte.	TAC	 closely	 resembles	 aortic	 coarctation	 (a	 congenital	 condition	 resulting	 in	narrowing	of	 the	 aorta),	 aortic	 stenosis,	 and	hypertension	 in	 a	 clinical	 setting	(Zhao	 et	 al.,	 2004).	 This	 model	 of	 cardiac	 hypertrophy	 is	 more	 reproducible	than	 other	 experimental	 models	 such	 as	 drug-induced	 hypertrophy	 and	complete	 occlusion	 of	 the	 left	 anterior	 descending	 (LAD)	 coronary	 artery	(deAlmeida	et	al.,	2010).	
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While	 TAC	 is	 initially	 a	model	 of	 compensated	 hypertrophy,	 previous	 studies	have	 shown	 that	 the	 response	 to	 the	 TAC-induced	 pressure	 could	 eventually	result	 in	 heart	 failure	 (deAlmeida	 et	 al.,	 2010,	 van	 Nierop	 et	 al.,	 2013).	 The	length	of	time	required	for	the	progression	to	heart	failure	is	dependent	on	the	tightness	 of	 the	 aortic	 constriction,	 with	 severe	 TAC	 leading	 to	 impaired	 LV	function	 as	 early	 as	 7	 days	 (van	 Nierop	 et	 al.,	 2013).	 It	 has	 been	 previously	shown	that	at	2	days	post-surgery,	mild	TAC	using	a	27-G	needle	did	not	result	in	 a	 significant	 difference	 in	 LV	 wall	 thickness,	 but	 the	 LV	 wall	 thickness	progressively	 increases	until	10	days	post-surgery	(Nakamura	et	al.,	2001).	 In	this	project,	we	aimed	to	examine	the	effects	of	cardiac	hypertrophy	specifically,	prior	to	 its	progression	to	heart	 failure.	Furthermore,	we	were	also	 interested	in	studying	early	processes	that	may	be	causative	to	the	downstream	signaling	process	 that	 results	 in	 hypertrophy.	 Thus,	 TAC	 surgery	 was	 performed	 in	C57BL/6	mice	using	a	27-G	needle	to	induce	mild	LVH.	Sham-operated	animals	underwent	 the	 same	 procedure	without	 permanent	 constriction	 of	 the	 aorta.	Samples	 and	 measurements	 were	 taken	 at	 2d	 post-surgery	 to	 analyze	 pre-hypertrophic	 responses,	 and	 at	 7d	 post-surgery	 to	 study	 changes	 during	compensated	LVH	(Figure	3.1).	A	total	of	64	mice	were	used	(32	sham,	32	TAC),	with	 44	 mice	 used	 for	 isolation	 of	 the	 left	 ventricle	 (LV)	 for	 verification	 of	cardiac	 hypertrophy,	 and	 20	 mice	 used	 for	 cardiomyocyte	 enrichment.	 The	surgery	was	performed	by	Dr.	Jian	Xin	Wu	at	the	Victor	Chang	Cardiac	Research	Institute.	 	
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Figure	 3.1.	 Experimental	 overview.	 64	 twelve-week	 old	 C57Bl/6	 mice	underwent	 either	 sham	or	 trans-aortic	 constriction	 (TAC)	 operations.	 Tissues	were	 harvested	 at	 an	 early,	 pre-hypertrophic	 (2	 days	 post	 TAC)	 and	 a	 late,	hypertrophic	state	(7	days	post	TAC).	Cardiomyocytes	were	enriched,	and	RNA	was	extracted	 from	20	mice.	Next-generation	sequencing	was	performed	on	8	mice	(2	TAC	and	2	sham	mice	from	each	time	point,	small	RNA	sequencing	and	Poly(A)	tail	focused	RNA	sequencing).			 	
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To	confirm	differential	pressure	across	the	LV	and	to	assess	changes	in	cardiac	function,	 micromanometry	 was	 performed	 on	 live	 animals	 with	 comparable	depth	of	anaesthesia,	as	assessed	by	equivalent	heart	rates	(Figure	3.2A).	TAC	led	to	a	consistent	increase	in	systolic	blood	pressure	(BP)	in	both	the	aorta	and	the	LV	(Figure	3.2B).	There	was	a	slight	decrease	in	aortic	diastolic	BP	at	2	days,	which	 normalized	 at	 7	 days,	 with	 no	 significant	 change	 in	 LV	 end	 diastolic	pressure	(EDP)	(Figure	3.2C).	There	was	a	significant	decrease	in	the	maximum	rate	of	pressure	 change	 in	 the	LV	 (dP/dtmax)	 in	TAC	animals	 at	2	days,	which	normalized	at	7	days,	and	no	significant	changes	to	minimum	rate	of	pressure	change	 (dP/dtmin)	 (Figure	 3.2D).	 Thus,	 micromanometry	 data	 shows	 that	 the	aortic	 banding	 was	 successful,	 resulting	 in	 increased	 blood	 pressure	 and	subsequent	pressure	overload	of	the	heart.	In	examining	the	samples	for	gross	morphological	 changes,	 it	 was	 found	 that	 whole	 heart	 and	 LV	 mass	 were	significantly	 increased	 at	 7	 days	 (Figure	 3.3A-B).	 There	 are	 no	 significant	differences	 in	 lung,	 or	 right	 ventricular	mass	 after	 TAC	 (Figure	 3.3C-D).	 LVH	was	 thus	 considered	 ‘compensated’	 as	 there	 were	 no	 signs	 of	 heart	 failure	(indicated	by	pleural	effusions,	increased	lung	mass,	and	right	ventricular	mass;	Figure	3.3C-D).	
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Figure	 3.2.	 TAC	 leads	 to	 pressure	 overload,	 early	 loss	 of	 left	 ventricular	
systolic	 function	and	 compensated	hypertrophy	by	day	7	 in	C57BL/6J	mice.	Micromanometry	was	performed	on	unconscious	animals	with	 comparable	depth	of	anaesthesia	(assessed	by	equivalent	heart	rates)	(A).	B)	Systolic	blood	pressure	in	the	aorta	(i)	and	the	left	ventricle	(ii).	C)	Diastolic	blood	pressure	in	the	aorta	(i)	and	end	diastolic	pressure	in	the	left	ventricle	(ii).	D)	Left	ventricular	function	and	contractility	as	measured	by	dP/dtmax	(i)	and	dP/dtmin	(ii).	Bars	represent	the	mean	with	error	bars	representing	standard	error	(n=11-14).	(*	p	<0.05,	**	p	<0.01,	***	p<0.001,	****	p<0.0001,	 two-tailed,	 two-sample	Student’s	 t-test).	Micrometry	data	was	generated	by	Dr.	Nicola	Smith	and	Dr.	Carly	Hynes.	  
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Figure	 3.3.	 TAC	 leads	 to	 physiological	 left	 ventricular	 hypertrophy	 without	
heart	failure.	A)	Total	heart	weight	relative	to	total	body	weight	(i)	or	tibia	length	(ii).	B)	Left	ventricle	weight	relative	to	total	body	weight	(i)	or	tibia	length	(ii).	C)	Right	 ventricle	 weight	 relative	 to	 total	 body	 weight	 (i)	 or	 tibia	 length	 (ii).	 D)	Measurement	of	 lung	wet	weight	 (WW)	 relative	 to	body	weight	 (BW,	 i)	 and	 tibia	length	 (TW,	 ii)	 as	 an	 assessment	 of	 progression	 to	 decompensated	 hypertrophy	(heart	 failure).	 Bars	 represent	 the	 mean	 with	 error	 bars	 representing	 standard	error	(n=7-16).	(*	p	<0.05,	**	p	<0.01,	***	p<0.001,	****	p<0.0001,	two-tailed,	two-sample	Student’s	t-test).	Data	was	generated	by	Dr.	Carly	Hynes	at	the	Victor	Chang	Cardiac	Research	Institute.		 	
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The	re-activation	of	cardiac	fetal	genes,	such	as	atrial	natriuretic	peptide	(ANP),	β-myosin	heavy	chain	(β-MHC),	brain	natriuretic	peptide	(BNP),	and	α-skeletal	actin	 (α-Ska),	 is	 a	 commonly	 used	 marker	 in	 the	 detection	 of	 cardiac	hypertrophy.	To	 further	confirm	that	LVH	has	been	 induced	 in	our	model,	Dr.	Carly	Hynes	also	measured	the	expression	of	these	genes	by	RT-qPCR.	TAC	led	to	 the	 increased	 expression	 of	 the	 hypertrophic	markers	 at	 both	 time	 points,	confirming	the	induction	of	LVH	(Figure	3.4).		Thus,	a	range	of	morphological,	physiological,	and	molecular	changes	indicated	successful	 implementation	of	 the	TAC-induced	 cardiac	hypertrophy.	Dr	Nicola	Smith	 and	 Dr	 Carly	 Hynes	 performed	 dissections	 of	 the	 LV	 after	 the	micromanometry	assessments.				
		
Figure	 3.4.	 TAC	 leads	 to	 increased	 expression	 of	 cardiac	 hypertrophy	
markers.	The	expression	of	hypertrophy	markers	ANP,	β-MHC,	BNP,	and	α-Ska	 in	the	left	ventricle	of	sham	and	TAC	mice	were	measured	by	RT-qPCR.	Levels	in	TAC-banded	 mice	 are	 expressed	 relative	 to	 sham-operated	 controls	 (n=6-9	 pairs,	mean±SEM;	blue	*p<0.05,	**p<0.01,	***p<0.001,	****<<0.0001,	two-tailed	Student’s	t-test).	Data	was	generated	by	Dr.	Carly	Hynes	at	the	Victor	Chang	Cardiac	Research	Institute.	I	performed	the	re-analysis	and	illustration	of	the	data.	
		 57	
	The	 cardiomyocytes	 from	 the	 freshly	 excised	 hearts	 of	 20	 mice	 (5	 mice	 per	treatment	 group)	were	 then	 purified	 by	Dr	Ming	 Li,	Ms	 Sara	Holman,	 and	Dr	Carly	 Hynes.	 The	 enriched	 cardiomyocyte	 preparations	 were	 microscopically	homogeneous,	and	purity	was	confirmed	by	qPCR	for	enrichment	of	markers	of	cardiomyocytes,	 and	 depletion	 of	markers	 of	 non-cardiomyocytes	 (fibroblasts	and	endothelial	cells)	(Figure	3.5).	RNA	for	further	transcriptomic	analyses	was	obtained	from	these	enriched	cardiomyocyctes.		
	
Figure	 3.5.	 Enrichment	 of	 cardiomyocytes.	 Purity	 of	 the	 cardiomyocyte	samples	were	assessed	by	RT-qPCR	of	cardiomyocyte	markers	troponin	T	type	2	(Tnnt2)	and	myosin	light	chain	2v	(Mlc2v),	and	non-cardiomyocyte	(fibroblast	and	endothelium)	markers	collagen	type	1	alpha	1	(Col1a1)	and	type	3	alpha	1	(Col3a1),	 vimentin	 and	 discoidin	 domain-containing	 receptor	 2	 (Ddr2)	 (n=20;	*p<0.01,	two-tailed	and	two-sample	Student’s	t-test).	Data	was	generated	by	Dr.	Carly	Hynes	at	the	Victor	Chang	Cardiac	Research	Institute.	I	performed	the	re-analysis	and	illustration	of	the	data.			
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3.2.2.	Features	of	the	small	RNA	sequencing	library	To	 assess	 the	 hypertrophic	 response	 on	 miRNA	 expression	 and	 processing,	small	RNA	libraries	were	prepared	from	the	cardiomyocytes	(two	samples	per	treatment	 group).	 The	 library	 preparation	 was	 performed	 by	 Dr	 David	Humphreys	at	the	Victor	Chang	Cardiac	Research	Institute	using	the	NEBNext®	Small	RNA	Library	Prep	Set	for	SOLiD™.	This	yielded	an	average	of	2	×	107	high	quality	sequence	reads	per	library	(19-35	nucleotides	(nt)	in	length),	which	was	mapped	 to	 the	 mouse	 genome	 mm10	 assembly	 by	 Dr	 Hardip	 Patel	 (Figure	3.6A).	 I	completed	the	secondary	analysis,	 including	graphical	representations	and	differential	expression	analyses.	Further	analyses	of	the	sequencing	data	were	focused	on	reads	that	overlapped	with	miRNA	loci,	requiring	that	the	reads	started	within	±	3nt	of	the	5’	end	of	a	known	miRNA	in	miRBase	v20,	and	were	between	20-26	nt	in	length	(~26%	of	reads;	Figure	3.6B).	Without	any	abundance	 threshold,	1,150	distinct	miRNAs	were	 identified.	 Setting	 a	 threshold	 for	 expression	 (≥10	 counts	 per	 million	(CPM)	 across	 all	 libraries)	 retained	 471	miRNAs	 for	 further	 investigation.	 As	previously	 seen	 (Humphreys	 et	 al.,	 2012b),	 the	 most	 abundant	 miRNA	 read	length	was	22nt	(Figure	3.6C)	and	the	majority	of	the	tags	were	dominated	by	a	small	 number	 of	 abundant	 miRNAs	 (for	 example,	 the	 top	 10	 most	 abundant	miRNAs	represented	69%	of	all	miRNA-mapped	reads;	Figure	3.6D).		 	
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Figure	 3.6.	 General	 features	 of	 the	 small	 RNA/miRNA	 populations	 in	
cardiomyocytes.	A)	Mapping	statistics	of	the	libraries.	Shown	is	the	number	of	raw	 reads	 sequenced	 (orange),	 the	 number	 of	 reads	 >18	 nucleotides	 long	(green),	 the	 number	 of	 reads	 with	 >18	 mean	 quality	 value	 (blue),	 and	 the	number	of	reads	mapped	to	the	reference	genome	(purple).	B)	Distribution	of	all	mapped	 reads	 across	 the	mouse	 genome.	 For	 this	 analysis,	 each	 read	was	assigned	 to	 only	 one	 genomic	 position	 and	 one	 Ensembl-defined	 biotype.	 C)	Distribution	of	lengths	of	miRNA	mapped	reads.	D)	Distribution	of	read	counts	across	 the	100	most	 abundant	miRNAs.	 Contribution	of	 individual	miRNAs	 to	total	 read	count	 (solid	 lines)	or	cumulative	read	count	 (dotted	 line)	 is	plotted	against	ranked	miRNA	abundance.			 	
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3.2.3.	Features	of	the	PAT-	sequencing	library	To	 create	 a	 comprehensive	map	of	RNA	 cleavage	 and	polyadenylation	 events,	PAT-seq	 libraries	were	prepared	by	Dr	Traude	Beilharz	at	Monash	University	from	 the	purified	 cardiomyocytes	 (the	 same	samples	as	 the	RNA	used	 for	 the	small-RNA	 sequencing	 described	 above).	 This	 library	 preparation	 method	detects	 genome-encoded	 sequences	 just	 upstream	 of	 the	 poly(A)	 tail,	 while	avoiding	internal	priming	artifacts	inherent	to	direct	oligo(dT)	extension-based	methods	(Harrison	et	al.,	2015,	Janicke	et	al.,	2012).	Mapping	of	the	reads	was	then	 done	 by	 Dr	 Hardip	 Patel.	 Reads	 mapped	 to	 the	 mouse	genome/transcriptome	(genome	assembly	mm10;	Ensembl	v77)	at	an	average	depth	of	~2.7	×	107	reads	per	library	(Figure	3.7).				
	
Figure	3.7.	General	features	of	the	PAT-seq	libraries.	Shown	is	the	number	of	raw	reads	sequenced	(orange),	 the	number	of	reads	with	>18	mean	quality	value	(blue),	the	number	of	reads	mapping	to	the	genome	(purple),	the	number	of	 reads	 mapping	 to	 the	 transcriptome	 (green),	 and	 the	 number	 of	 reads	mapped	by	the	seed	and	extended	to	the	polyA	(brown).		To	establish	a	full	set	of	cardiomyocyte	RNA	3’	end	annotations,	reads	from	all	libraries	 were	 assembled	 into	 PAT-seq	 peaks	 (Figure	 3.8A).	 After	 thresholds	(≥10	reads	present	 in	at	 least	2	 libraries,	 and	with	a	peak	width	≥75nt)	were	
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applied,	 113,524	 3’-ends	 of	 polyadenylated	 RNAs	 were	 identified.	 We	 then	annotated	 the	 position	 of	 the	 peaks	 relative	 to	 known	 genes	 (bottom	 panel,	Figure	 3.8A).	 The	 breakdown	 of	 peak	 annotations	 is	 shown	 in	 Figure	 3.8B-D.	Peaks	were	assigned	to	a	genomic	feature	if	they	were	within	20kb	downstream	of	 a	 stop	 codon	 or	 transcript	 end.	 This	 20kb	 cut-off	 is	 longer	 than	 previous	studies	 that	 have	 used	 5	 or	 8kb	 to	 assign	 3’-end	 peaks	 to	 upstream	 genes	(Lianoglou	et	al.,	2013,	Ulitsky	et	al.,	2012).	However,	a	more	recent	study	have	discovered	that	putative	lincRNAs	were	actually	3’UTRs	belonging	to	upstream	genes	 (Miura	 et	 al.,	 2013).	 Moreover,	 3’UTRs	 up	 to	 19kb	 in	 length	 has	 been	validated	by	Northern	Blotting	(Miura	et	al.,	2013).	Therefore,	we	deemed	20kb	as	a	more	suitable	cut-off	 in	defining	3’UTR	to	retain	any	 long	and	potentially	novel	3’UTRs.	Peaks	that	did	not	overlap	a	known	gene	and	were	further	than	20	kb	downstream	from	the	closest	gene	were	classed	as	“Unannotated”	peaks	and	makes	up	24%	of	peaks.	This	proportion	is	similar	with	another	study	that	found	22.5%	of	 detected	3’	 end	 sites	discovered	using	NGS	 in	Zebrafish	were	unannotated	 (Ulitsky	 et	 al.,	 2012).	 Peaks	 that	 were	 also	 further	 than	 20	 kb	downstream	from	the	closest	gene,	but	overlapped	with	a	gene	present	 in	 the	opposite	strand	were	categorized	as	“Antisense”	peaks	(19%	of	peaks).		The	 peaks	 that	 overlapped	 a	 known	 gene	 were	 annotated	 based	 on	 their	location	 relative	 to	 the	 annotated	 stop	 codon	 or	 canonical	 transcript	 end.	Internal	peaks	located	upstream	of	the	stop	codon	were	termed	“Exon”	(3%)	or	“Intron”	(21%)	peaks.	Peaks	located	within	20	kb	downstream	of	a	stop	codon	or	 transcript	 end	were	defined	 as	 “Downstream”	peaks	 (33%	of	 peaks).	Non-coding	RNAs	known	to	undergo	polyadenylation,	such	as	lincRNAs	and	miRNAs,	represent	15%	of	peaks	(Cai	et	al.,	2004,	Mercer	et	al.,	2009)	(Figure	3.8C).	42%	of	peaks	are	associated	with	protein	coding	mRNAs	(Figure	3.8C),	of	which	65%	are	 located	 downstream	 of	 the	 stop	 codon.	 Overall,	 peaks	 downstream	 of	known	genes,	 those	 associated	with	protein	 coding	 genes,	 or	 those	with	 both	attributes	each	had	higher	coverage	than	peaks	in	other	locations	(Figure	3.8B-D,	 right	 panels).	 At	 the	 other	 extreme,	 peaks	 located	 in	 unannotated	 genome	regions,	 which	 likely	 represent	 previously	 unobserved	 ncRNAs,	 had	 the	 least	
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coverage	 (Figure	 3.8B-C).	 Overall,	 these	 findings	 confirm	 expectations	regarding	 typical	 abundance	 of	 different	 RNA	 types;	 for	 example,	 protein-coding	 mRNAs	 are	 generally	 more	 abundant	 than	 ncRNAs	 (Cai	 et	 al.,	 2004,	Harrison	et	al.,	2015).			
	
		 63	
	
		 64	
	
	
	
Figure	3.8.	Alignment	of	polyadenylated	RNA	3’-ends.	A)	Schematic	of	PAT-Seq	method	and	hierarchical	peak	classification	(see	Materials	and	Methods	for	details).	B)	Left,	distribution	of	PAT-seq	peaks	by	genomic	region.	Right,	 their	abundance	based	on	the	read	count,	presented	as	cumulative	 fraction.	C)	Left,	distribution	 of	 PAT-seq	 peaks	 associated	 with	 protein	 coding,	 non-coding	 or	unannotated	regions	of	 the	genome.	Right,	 cumulative	 fraction	of	all	 classified	peaks	 based	 on	 the	 read	 count.	 D)	 Left,	 distribution	 of	 protein	 coding	 peaks	found	 in	 introns,	exons	or	within	20	kb	downstream	of	 the	stop	codon.	Right,	cumulative	fraction	of	all	protein	coding	peaks	based	on	their	read	count.	 	
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3.3.	Summary	A	model	for	cardiac	hypertrophy	was	successfully	established	in	C57BL/6	mice	through	 TAC.	 Using	 the	 purified	 cardiomyocytes	 of	 these	 mice,	 we	 recorded	transcription	 events	 dispersed	 throughout	 the	 genome,	 and	 resolved	 the	complexity	of	different	processing	variations	at	 recognized	genes.	Overall,	 the	findings	match	 expectations	 (Harrison	 et	 al.,	 2015)	 regarding	 the	 distribution	and	 transcription	 frequencies	 of	 different	 RNA	 types.	 Importantly,	 they	underscore	the	quality	of	our	sequencing	data.	These	small-RNA	seq	and	PAT-seq	datasets	form	the	basis	of	this	thesis.	
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Chapter	4.	
Non-coding	 RNAs	 in	 the	
cardiomyocyte	 	
		 68	
4.1.	Introduction	Although	 protein-coding	 genes	 accounts	 for	 only	 <3%	 of	 the	 genome,	 the	Encyclopedia	 of	 DNA	Elements	 (ENCODE)	 consortium	 revealed	 that	 83.7%	of	the	human	genome	undergoes	pervasive	 transcription	(Djebali	et	al.,	2012).	A	growing	number	of	studies	have	shown	that	these	ncRNAs,	such	as	miRNAs	and	lncRNAs,	play	important	roles	in	heart	development	and	diseases	(Schonrock	et	al.,	2012,	Thum	and	Condorelli,	2015).	Earlier	studies	on	ncRNA	expression	in	the	 heart	 were	 based	 on	microarrays	 or	 PCR	 techniques	 (Cheng	 et	 al.,	 2007,	Sayed	et	al.,	2007,	Tatsuguchi	et	al.,	2007,	van	Rooij	et	al.,	2006,	Bagnall	et	al.,	2012).	These	approaches	require	a	priori	knowledge	of	 the	RNAs,	and	are	not	able	 to	 address	 previously	 unannotated	 transcripts.	 Furthermore,	 these	methods	 are	 generally	 not	 sensitive	 enough	 to	 distinguish	 between	 different	processing	 variations.	 Although	 two	 recent	 studies	 used	 NGS	 to	 profile	 the	miRNA	 expression	 in	whole	 LV	 samples	 7	 days	 after	 TAC	 banding	 (Hu	 et	 al.,	2012,	 Yang	 et	 al.,	 2012),	 neither	 investigated	 the	 sequencing	 variants	 of	 the	expressed	 miRNAs.	 Thus,	 the	 extent	 of	 their	 expression	 and	 their	 changes	during	cardiac	hypertrophy	remain	largely	unknown.	These	processing	variants	have	previously	been	shown	to	have	different	targeting	pools	than	the	canonical	miRNA	(e.g.	 (Humphreys	et	al.,	2012b)),	and	 therefore	may	be	of	 relevance	 in	disease	progression.	
This	 chapter	 aims	 to	 characterize	 the	 expression	 of	 ncRNAs	 in	 the	 heart.	We	first	used	our	 small	RNA-seq	data	 to	analyze	 the	miRNA	expression	profile	 in	normal,	 pre-,	 and	 hypertrophic	 cardiomyocytes.	 We	 also	 documented	 the	expressed	 processing	 variants	 of	 miRNAs,	 and	 investigated	 their	 changes	during	 cardiac	 hypertrophy.	 Since	many	 other	 ncRNAs,	 such	 as	 lncRNAs,	 are	polyadenylated	(Kung	et	al.,	2013,	Quinn	and	Chang,	2016),	we	also	mined	our	PAT-seq	data	to	characterize	the	expression	profile	of	polyadenylated	ncRNAs	in	 the	 cardiomyocyte.	 We	 further	 analyzed	 the	 data	 to	 study	 the	 differential	expression	 of	 lncRNA	 as	 well	 as	 other	 polyadenylated,	 previously	uncharacterized	transcripts	during	cardiac	hypertrophy.	
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4.2.	Results	
4.2.1.	miRNA	expression	in	the	cardiomyocyte	
4.2.1.1.	Differential	miRNA	expression	during	cardiac	hypertrophy	Differential	 expression	 analysis	 between	 TAC	 and	 sham	 surgery	 yielded	 7	miRNAs	showing	increased	expression,	and	2	with	decreased	expression	at	an	FDR<5%	(Figure	4.1A-C;	Appendix	3).	Interestingly,	we	saw	more	pronounced	dysregulation	 at	 7d	 than	 at	 2d	 (Figure	 4.1A-C),	with	 only	 3	miRNAs	 showing	statistically	significant	changes	at	2d.	This	may	suggest	that	miRNA	changes	are	less	 involved	 in	 the	 instigation	 of	 hypertrophy	 than	 with	 the	 adaptation	 to	hypertrophic	cardiomyocyte	growth.	Dysregulation	of	all	but	one	of	the	differentially	expressed	miRNAs	in	our	data	has	 been	 reported	 previously	 in	 murine	 TAC/Left	 Ventricular	 Hypertrophy	(LVH)	models	(van	Rooij	et	al.,	2006,	Sayed	et	al.,	2007,	Tatsuguchi	et	al.,	2007,	Cheng	et	al.,	2007,	Yang	et	al.,	2012,	Hu	et	al.,	2012).	While	miR-330-5p	has	not	previously	been	 shown	 to	be	 regulated	 in	murine	TAC/LVH	model,	 one	 study	has	 reported	 its	 deregulation	 in	 human	 end-stage	 dilated	 cardiomyopathy.	Many	 miRNAs	 have	 been	 consistently	 documented	 to	 be	 deregulated	 in	 the	hypertrophic	 response.	 We	 curated	 a	 set	 of	 119	 hypertrophy-associated	miRNAs	 derived	 from	 studies	 that	 looked	 at	 the	 expression	 of	 miRNAs	 in	murine	TAC/LVH	models	(Cheng	et	al.,	2007,	Hu	et	al.,	2012,	Sayed	et	al.,	2007,	Tatsuguchi	et	al.,	2007,	van	Rooij	et	al.,	2006,	Yang	et	al.,	2012).	We	examined	the	 log2	 fold	change	 in	expression	of	 these	miRNAs	between	TAC	and	sham	in	our	 data,	 regardless	 of	 their	 statistical	 significance.	 We	 found	 that	 the	expression	changes	generally	 trend	 in	 the	expected	direction	(van	Rooij	et	al.,	2006,	Sayed	et	al.,	2007,	Tatsuguchi	et	al.,	2007,	Cheng	et	al.,	2007,	Yang	et	al.,	2012,	 Hu	 et	 al.,	 2012),	 albeit	 outside	 our	 strict	 statistical	 significance	 level	(Figure	4.2).		 	
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Figure	 4.1.	 Differential	 expression	 of	 cardiomyocyte	 miRNAs	 during	
cardiac	 hypertrophy.	 A)	 Heat	 map	 of	 differentially	 expressed	 miRNAs	between	 TAC	 and	 sham	 surgery	 at	 an	 FDR<5%.	 Black	 cross:	 differential	expression	previously	reported;	red	cross:	reported	as	pro-hypertrophic;	green	cross:	 differential	 expression	 previously	 reported	 for	 the	 other	 strand	 of	 the	miRNA	hairpin	(Cheng	et	al.,	2007,	Hu	et	al.,	2012,	Sayed	et	al.,	2007,	Tatsuguchi	et	 al.,	 2007,	 van	 Rooij	 et	 al.,	 2006,	 Yang	 et	 al.,	 2012).	 B-C)	 MA	 plots	 of	 all	detected	miRNAs	comparing	all	sham	samples	against	B)	2d	and	C)	7d	TAC.	X-axes	show	mean	miRNA	expression	across	samples;	y-axes	show	fold	change	in	expression	 between	 TAC	 and	 sham.	 Differentially	 expressed	 mRNAs	 with	FDR<5%	are	shown	in	red.		
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Figure	4.2	(previous	page).	miRNA	expression	changes	in	other	models	of	
cardiac	hypertrophy	were	commonly	observed	in	our	study.	MiRNAs	were	compiled	from	6	previous	studies	(Cheng	et	al.,	2007,	Hu	et	al.,	2012,	Sayed	et	al.,	2007,	Tatsuguchi	et	al.,	2007,	van	Rooij	et	al.,	2006,	Yang	et	al.,	2012),	and	are	grouped	as	either	’up-regulated’	or	 ‘down-regulated’.	Heat	map	shows	log2	fold	change	(TAC/sham)	at	each	time	point.		
4.2.1.2.	Processing	diversity	of	cardiomyocyte	miRNAs	As	mentioned	in	Chapter	1,	one	miRNA	hairpin	can	result	in	several	processing	variants.	These	variants	could	arise	from	the	use	of	both	strands	of	the	miRNA	hairpin,	 variations	 at	 the	 start	 or	 end	 position	 (termed	 5’	 and	 3’	 isomiRs,	respectively),	non-templated	additions,	as	well	as	internal	RNA	editing	(Figure	4.3A).	 It	 is	 postulated	 that	 these	 miRNA	 modifications	 could	 alter	 miRNA	biogenesis	 and	 half-life,	 subcellular	 localization,	 and	 targeting	 specificity.	 We	examined	 our	 small	 RNA-seq	 datasets	 for	 the	 presence	 of	 these	 miRNA	processing	variants	in	the	cardiomyocyte.	We	considered	processing	variants	to	be	substantially	expressed	 if	 they	contributed	≥20%	of	 the	 total	expression	of	the	miRNA.		While	most	miRNAs	 displayed	 strong	 hairpin	 arm	 bias	 (Figure	 4.3B,	 left),	 22	miRNA	 loci	 had	 relatively	 even	 expression	 from	 both	 arms	 (expression	 from	either	 5p-	 or	 the	 3p-	 arm	 ≥20%;	 Appendix	 4).	 Interestingly,	 this	 includes	therapeutically	 relevant	 examples	 such	 as	 the	 miRNA-208a	 hairpin.	 We	observed	strong	expression	of	miR-208a-5p	(59.3%	of	total),	even	though	miR-208a-3p	 was	 initially	 considered	 to	 be	 the	 ‘mature’	 miRNA,	 and	 targeted	 by	anti-miR	inhibition	to	block	LVH	(van	Rooij	and	Olson,	2012).		We	next	mined	 our	 small	 RNA-seq	data	 for	more	 subtle	 variations	 such	 as	 5’	and	 3’	 isomiRs,	 NTA,	 and	 IE.	 Since	 the	 majority	 of	 the	 sequence	 of	 these	processing	variants	 is	 the	 same	as	 the	 canonical	miRNA,	 they	will	bind	 to	 the	same	 microarray	 probe	 and	 will	 often	 be	 detected	 with	 the	 same	 RT-qPCR	primers	as	the	canonical	miRNA.	 	Next-generation	sequencing	however	allows	
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the	 detection	 of	 these	 subtle	 processing	 differences.	 5’isomiR	 variants	 were	present	 in	122	miRNAs,	while	3’isomiR	variants	were	present	 in	437	miRNAs.	Reads	for	most	miRNAs	mapped	to	one	main	5’	start	position,	while	variability	in	the	3’-end	position	was	very	common	(Figure	4.3B,	right).	For	example,	in	the	highly	 abundant,	 anti-hypertrophic	miRNA-133a-3p,	 5’-isomiR	 variants	 of	 the	miRNA	constituted	58%	of	its	expression,	while	3’-isomiR	variants	contributed	to	90%	of	its	expression.	Since	most	of	the	pairing	specificity	between	a	miRNA	and	its	target	is	provided	by	the	5’	“seed”	region	of	the	miRNA,	5’-isomiRs	may	have	 different	 targeting	 properties	 from	 one	 another.	 This	 differential	mRNA	targeting	 by	 different	 5’isomiRs	 of	 the	 same	miRNA	 has	 been	 experimentally	demonstrated	 in	 miR-133a	 (Humphreys	 et	 al.,	 2012).	 The	 functions	 of	 3’-isomiRs	 are	 less	 obvious,	 as	 3’-isomiRs	 share	 a	 common	 seed	 sequence.	However,	 it	has	been	shown	that	3’-isomiRs	are	dynamically	regulated	during	development	(Fernandez-valverde	et	al.,	2010)	and	therefore	are	likely	to	also	have	 biologically	 important	 roles.	 It	 has	 been	 suggested	 that	 these	 3’-end	variants	 can	 alter	 miRNA	 turnover	 (Doench	 et	 al.,	 2012)	 and	 cellular	localizations	(Chi	et	al.,	2012),	and	preferentially	associate	with	different	AGO	proteins	 (Burroughs	 et	 al.,	 2011).	 NTA	was	 very	 common	 at	 low	 proportions	(Figure	 4.3B,	 right)	 and	 reached	≥20%	 for	 127	miRNAs.	 As	 expected,	 IE	was	detected	 primarily	 at	 very	 low	 levels	 (Figure	 4.3B,	 right).	 Detailed	 views	 of	miRNA	variant	expression,	generated	with	the	miRSpring	tool	(Humphreys	and	Suter,	 2013),	 are	 provided	 in	Appendix	 5	 	 as	 a	 resource	 to	 facilitate	 accurate	cardiac	miRNA	target	predictions	or	the	design	of	miRNA	detection	assays.	 	
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Figure	4.3.	Processing	diversity	of	cardiomyocyte	miRNAs.	A)	Schematic	of	the	 different	miRNA	 processing	 variants	 considered	 here:	 5p/3p	 armbias,	 5’-isomiR,	3’-isomiR,	internal	editing	(IE),	and	non-templated	additions	(NTA).	B)	Diversity	 of	 miRNA	 processing	 variant	 expression.	 Violin	 plots	 incorporate	boxplots,	 where	 white	 segments	 represent	 the	 median	 variant	 proportion	across	all	microRNAs,	black	‘boxes’	represent	interquartile	range	and	‘whiskers’	represent	the	variability	outside	the	upper	and	lower	quartiles;	kernel	density	plots	of	 the	probability	distribution	are	 shown	 in	blue.	Graphs	display	pooled	data	 from	 all	 eight	 samples	 for	 miRNAs	 with	 an	 average	 expression	 of	>10CPM/library.	 	
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4.2.1.3.	 Changes	 in	 miRNA	 processing	 variant	 expression	 during	 cardiac	
hypertrophy	We	 next	 determined	whether	 the	 proportion	 of	 arm	 bias,	 5’-	 and	 3’-	 isomiR,	NTA,	and	IE	are	changed	during	cardiac	hypertrophy.	We	found	that	there	were	no	 significant	 global	 changes	 in	miRNA	 processing	 during	 hypertrophy	 apart	from	 small	 decreases	 in	 bulk	 NTA	 and	 3’isomiR	 levels	 (Figure	 4.4;	 ~5%	 and	~0.7%,	 respectively).	 NTAs	 are	 generally	 associated	 with	 changes	 in	 miRNA	function	or	 stability.	Both	stabilizing	and	destabilizing	effects	on	mRNAs	have	been	 reported	 (Kai	 and	 Pasquinelli,	 2010),	 and	 thus	 their	 relevance	 here	remains	 unclear.	 The	 observed	 change	 in	 3’isomiR	 levels	 likely	 reflects	 the	changes	 in	 NTA;	 the	 non-templated	 addition	 of	 an	 A	 or	 U	 nucleotide	 to	 the	miRNA	could	inadvertently	match	the	miRNA	precursor	template,	which	would	result	 in	 a	 miRNA	 NTA	 variant	 that	 is	 indistinguishable	 from	 its	 3’isomiR	variant.	 Thus,	 a	 fraction	 of	 the	 NTA	 processing	 variants	 would	 have	 been	classified	as	3’isomiR	variants	during	read	mapping.			Evidence	 for	 hypertrophy-induced	 processing	 changes	 of	 individual	 miRNAs	was	 also	 largely	 absent	 from	 our	 data	 (Figure	 4.5,	 Appendix	 6).	 The	 only	exception	 was	 miR-330,	 which	 shifted	 5p/3p	 arm	 bias	 from	 ~1:2	 in	 sham	towards	1:14	in	TAC	(Figure	4.5	Aii)	at	7d	post	TAC	surgery.	miR-330	is	thus	a	candidate	 for	 future	work,	although	 little	 is	known	about	 its	 role	 in	 the	heart.	Taken	 together,	 these	 findings	 indicate	 that	 the	 hypertrophic	 response	 of	murine	 cardiomyocytes	 does	 not	 involve	 pronounced	 alterations	 to	 miRNA	processing.			
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Figure	 4.4.	 Boxplots	 comparing	 overall	 changes	 in	 miRNA	 processing	
variants	 between	 TAC	 and	 sham	 surgery	 (blue	 ***p<0.001,	 ****<<0.0001,	two-tailed,	one-sample	Student’s	t-test).	
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Figure	 4.5	 (previous	 page).	 Changes	 in	 the	 proportion	 of	 miRNA	
processing	 variants	 during	 cardiac	 hypertrophy.	 MA	 plots	 displaying	changes	in	the	ratio	of	the	5p	arm	(A),	5’	isomiR	(B),	3’isomiR	(C),	NTA	(D),	and	IE	(E)	to	the	total	expression	of	the	miRNA	between	TAC	and	sham	samples	at	2d	(i)	and	7d	(ii).	For	A,	each	point	represents	a	miRNA	hairpin;	 for	B-E,	each	point	represents	a	mature	miRNA.	X-axes	show	mean	expression	of	the	miRNA	across	 samples;	 y-axes	 show	 fold	 change	 in	 processing	 variant	 expression	between	TAC	and	sham.	Peak	pairs	exceeding	statistical	 cut-offs	are	shown	 in	colour	(FDR<5%:	red;	FDR<10%:	orange).	MA	plots	of	fold	change	in	expression	versus	 abundance	 (CPM)	 for	 2d	 (B)	 and	 7d	 (C).	 Red	 dot,	 FDR<5%	 (statistical	analysis	conducted	using	EdgeR).		 	
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4.2.2.	 The	 expression	 of	 other	 polyadenylated	 non-coding	 RNAs	 in	 the	
cardiomyocyte	We	next	analyzed	our	PAT-seq	data	for	the	expression	of	polyadenylated	non-coding	 RNAs	 in	 the	 heart.	 As	 described	 in	 Chapter	 3,	 7,683	 peaks	 were	associated	with	known	ncRNA	genes,	of	which	4,136	were	situated	downstream	of	 annotated	 3’	 exon	 boundaries	 (Figure	 3.8).	 This	 suggests	 unexpected	transcription	of	 longer	variants	of	 these	ncRNAs,	perhaps	 the	result	of	APA	 in	non-coding	 transcripts.	 PAT-Seq	 revealed	 a	 considerable	 diversity	 of	polyadenylated	 ncRNAs	within	 cardiomyocytes	 (Figure	 4.6A).	 The	 transcripts	derived	from	pseudogenes,	processed	transcripts,	retained	intron,	and	lincRNA	represents	 lncRNA	 (>200nt)	 and	 represents	 the	 majority	 of	 polyadenylated	ncRNA	transcripts	in	the	cardiomyocyte.	Small	RNAs	such	as	miRNAs,	snRNAs,	and	snoRNAs	on	the	other	hand	makes	up	only	a	small	proportion	of	the	peaks.	Furthermore,	 the	 small	 RNA	 peaks	 detected	 typically	 have	 lower	 reads	compared	to	lncRNAs	(Figure	4.6B).		
	
	
Figure	 4.6.	 Polyadenlyated	 non-coding	 RNAs	 in	 the	 cardiomyocyte.	 A)	Percentage	 of	 peaks	 annotated	 to	 non-coding	 RNAs	 of	 various	 types.	 B)	Cumulative	 fraction	 of	 peaks	 associated	 with	 non-coding	 RNA	 annotated	regions	of	the	genome	based	on	abundance	(number	of	reads).		
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We	 then	 searched	 for	 the	 presence	 of	 PAS	 in	 these	 non-coding	 peaks.	 The	conserved	 canonical	 PAS	 (AAUAAA)	 or	 its	 single-nucleotide	 variants	 (non-canonical	PAS;	discussed	in	Chapter	1)	are	the	main	signals	used	to	determine	the	site	of	cleavage	and	polyadenylation	(Tian	et	al.,	2005).	The	canonical	PAS	was	searched	for	within	50	nt	upstream	of	the	poly(A)	for	peaks	containing	the	poly(A),	 or	within	 the	3’	 seq	peak	and	50	nt	downstream	of	 the	3’	 end	of	 the	peak	for	peaks	without	poly(A).	Peaks	without	the	canonical	PAS	in	this	region	were	 next	 interrogated	 for	 the	 presence	 of	 a	 non-canonical	 PAS.	 70%	 of	 the	non-coding	 PAT-seq	 peaks	 contained	 either	 the	 canonical	 PAS	 or	 one	 of	 the	twelve	non-canonical	PAS	variants	 (Figure	4.7).	These	are	very	similar	 to	PAS	usage	in	protein	coding	transcripts	as	reported	in	previous	studies	(Elkon	et	al.,	2013,	 Hollerer	 et	 al.,	 2014b).	 The	 next	 most	 commonly	 used	 non-canonical	motif	 in	 ncRNAs	 is	 AUUAAA,	 which	 again	 is	 the	 same	 as	 in	 protein	 coding	transcripts	(Elkon	et	al.,	2013).			 	
		
Figure	 4.7.	 Sequences	 of	 polyadenylation	 signal	 motifs	 associated	 with	
non-coding	 RNA	 peaks.	 Analysis	 was	 restricted	 to	 peaks	 containing	 a	 non-templated	3’	poly(A)	stretch	in	their	sequence	and	to	within	50	nt	upstream	of	the	cleavage	site.	The	expression	of	non-canonical	PAS	motifs	are	shown	on	the	right.			
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4.2.2.1.	Differential	expression	of	lncRNAs	during	cardiac	hypertrophy	We	 conducted	 a	 differential	 expression	 analysis	 of	 all	 ncRNA	 transcripts	present	 in	 our	 data	 using	 DESeq2.	 Our	 analysis	 found	 that	 dysregulation	 in	ncRNA	expression	is	more	pronounced	early	in	the	hypertrophic	process	(at	2d	TAC),	 with	many	 ncRNA	 peaks	 returning	 to	 a	 similar	 expression	 level	 as	 the	sham	controls	at	7d	post	TAC	surgery	(Figure	4.8A).	We	also	 found	that	 there	are	more	ncRNA	peaks	that	are	up-regulated	during	cardiac	hypertrophy	than	down-regulated.		Since	there	has	been	an	increased	interest	in	the	expression	of	lncRNAs	during	cardiac	 diseases,	 we	 also	 performed	 a	 differential	 expression	 analysis	specifically	for	lncRNA	peaks	between	TAC	and	sham.	Most	changes	in	lncRNA	expression	 occurred	 early	 in	 the	 hypertrophic	 process	 (124	 differentially	expressed	 lncRNAs	 at	 2d	 TAC),	 and	 returned	 to	 normal	 levels	 at	 7d	 (only	 7	differentially	expressed	lncRNA)	(Figure	4.8	B-D).	Furthermore,	the	majority	of	differentially	expressed	lncRNAs	were	up-regulated	(102	lncRNAs	up-regulated	versus	 only	 22	 lncRNAs	 down-regulated	 at	 2d).	 This	 similarity	 to	 the	differential	 expression	 analysis	 of	 all	 ncRNA	peaks	 is	 unsurprising,	 given	 that	the	large	majority	of	the	non-coding	peaks	in	our	PAT-seq	data	are	lncRNAs,	as	described	previously.	The	list	of	differentially	expressed	lncRNAs	is	provided	in	Appendix	 7.	 Interestingly,	 the	 two	 lncRNAs	 previously	 reported	 to	 be	 up-regulated	 during	 cardiac	 hypertrophy	 are	 not	 statistically	 significantly	differentially	 expressed	 in	 our	 data.	Mhrt,	 for	 example,	which	was	 previously	reported	to	be	down-regulated	during	cardiac	hypertrophy	by	Han	et	al.	(2014)	(Han	 et	 al.,	 2014),	 is	 changed	 only	 by	 0.61	 fold	 (FDR	 15.2%)	 in	 our	 data	(Appendix	7).			
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Figure	 4.8.	 Differential	 expression	 of	 non-coding	 RNAs	 during	 cardiac	
hypertrophy.	 	 A)	 Heat	 map	 of	 all	 non-coding	 RNA	 peaks	 differentially	expressed	at	FDR	<5%.	B)	Heat	map	of	lncRNA	peaks	differentially	expressed	at	FDR	5%.	The	fold	changes	between	individual	day	TAC	and	all	sham	samples	for	all	 peaks	 is	 shown.	 C&D,	 MA	 plots	 of	 lncRNAs	 comparing	 all	 sham	 samples	against	 (C)	2d	TAC	samples	and	 (D)	7d	TAC	samples.	Differentially	 expressed	lncRNAs	with	FDR	<5%	are	shown	in	red.	
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4.2.2.2.	Differential	expression	of	unannotated	peaks	during	cardiac	hypertrophy	We	also	used	our	data	to	analyze	the	differential	expression	of	unannotated	and	antisense	 peaks.	 It	 has	 previously	 been	 demonstrated	 that	 transcription	 of	these	 regions	 of	 the	 genome,	 resulted	 in	 the	 production	 of	 a	 large	 number	 of	lncRNAs	 (Hangauer	 et	 al.,	 2013).	 The	 low	 but	 widespread	 coverage	 of	 our	unannotated	 and	 antisense	 peaks	 is	 consistent	 with	 pervasive	 transcription,	and	 thus	 it	 is	 plausible	 that	 these	peaks	 are	derived	 from	as	 yet	unannotated	lncRNAs.	 Differential	 expression	 analysis	 of	 these	 unannotated	 and	 antisense	peaks	 between	 TAC	 and	 sham	 surgery	 yielded	 many	 more	 differentially	expressed	peaks	at	2d	than	at	7d	(Figure	4.9	A-C).	Thus,	similar	 to	changes	 in	annotated	 ncRNAs,	 the	 dysregulation	 is	 again	 more	 pronounced	 early	 in	 the	hypertrophic	 process	 which	 normalizes	 at	 7d.	 Also	 similar	 to	 the	 ncRNA	differential	expression	profile,	there	are	again	more	peaks	that	are	statistically	significantly	up-regulated	than	down-regulated	during	cardiac	hypertrophy.			
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Figure	4.9.	Differential	expression	of	unannotated	peaks	 in	hypertrophy.	A&B,	MA	plots	of	unannotated	and	antisense	peaks	comparing	all	sham	samples	against	 A)	 2d	 TAC	 samples	 and	 B)	 7d	 TAC	 samples.	 Differentially	 expressed	peaks	 with	 FDR	 <5%	 are	 shown	 in	 red.	 C).	 Heat	 map	 of	 unannotated	 and	antisense	 peaks	 differentially	 expressed	 during	 cardiac	 hypertrophy.	 The	 fold	change	 between	 individual	 day	 TAC	 and	 all	 sham	 samples	 for	 all	 peaks	 is	shown.	Peaks	were	organised	by	hierarchical	clustering	(Euclidean	distance).		 	
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4.3.	Discussion	This	chapter	analyses	the	expression	of	non-coding	RNAs	in	the	heart.	We	have	used	the	small	RNA	and	PAT-seq	datasets	to	first	profile	the	expression	of	these	ncRNA	 in	 the	 cardiomyocyte,	 and	 then	 to	 study	 their	 differential	 expression	during	cardiac	hypertrophy.			
4.3.1.	The	expression	of	miRNAs	and	their	processing	variants		A	 small	 number	 of	 miRNAs	 were	 identified	 with	 a	 significant	 expression	difference	between	the	Sham	and	TAC	samples	in	the	cardiomyocyte.	Consistent	with	a	previous	study	which	looked	at	the	whole	LV,	we	found	that	there	were	more	miRNAs	that	are	up-regulated	than	down-regulated	(Hu	et	al.,	2012).	This	observation	may	be	due	to	a	lag	period	for	miRNA	elimination	resulting	in	less	detectable	down-regulated	miRNAs	(Hu	et	al.,	2012).	Even	if	the	locus	becomes	transcriptionally	 silenced,	 it	 could	 take	 a	 considerable	 amount	 of	 time	 before	the	 existing	miRNAs	are	 cleared.	miRNAs	are	 generally	 considered	 to	be	 very	stable,	 and	 it	 is	also	known	 that	 the	 turnover	 rate	 can	be	miRNA	specific.	For	instance,	miR-208a	 has	 a	 half-life	 greater	 than	 12	 days	 in	 rat	 hearts,	 so	 even	after	repression	of	 transcription,	 it	would	 take	several	days	before	any	down-regulation	would	be	visible	(van	Rooij	et	al.,	2007).		Although	the	general	trend	in	expression	change	in	our	study	is	consistent	with	that	 found	 in	 previous	 studies,	 many	 miRNAs	 previously	 reported	 to	 be	dysregulated	 during	 cardiac	 hypertrophy	 were	 not	 statistically	 significantly	changed	in	our	data.	There	are	a	number	of	reasons	why	this	could	be	the	case.	Firstly,	 the	 criteria	 used	 to	 define	 “differentially	 expressed”	 miRNAs	 are	 not	consistent	 between	 studies.	 Some	 of	 the	 earlier	 studies	 did	 not	 apply	 a	statistical	 threshold	 but	 instead	used	 only	 the	 fold	 change	 as	 an	 indication	 of	differential	 regulation	 (van	 Rooij	 et	 al.,	 2006).	 Furthermore,	 another	 next-generation	sequencing	study	had	five	biological	replicates	per	group	and	could	therefore	confidently	detect	changes	as	small	as	25%	(Hu	et	al.,	2012).	To	detect	smaller	effect	sizes	with	statistical	confidence,	a	 larger	number	of	replicates	is	
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required	(Pawitan	et	al.,	2005).	It	is	possible	that	if	we	changed	the	criteria	used	to	 detect	 differential	 expression,	 or	 included	 more	 biological	 replicates	 for	sequencing,	 then	 the	 overlap	 in	 statistically	 significantly	 changed	 miRNAs	would	be	greater.	Secondly,	the	miRNAs	enriched	may	be	specific	to	cell	types	other	 than	 cardiomyocytes.	 For	 example,	 members	 of	 the	 miR-23~27~24	cluster	are	reported	to	be	up-regulated	7	days	post-TAC	in	multiple	studies,	yet	the	fold	changes	found	in	our	data	are	minimal	(Cheng	et	al.,	2007,	Sayed	et	al.,	2007,	 Yang	 et	 al.,	 2012).	 The	 miR-23~27~24	 cluster	 is	 highly	 expressed	 in	endothelial	cells	and	thus	the	levels	of	these	miRNAs	would	have	been	reduced	during	cardiomyocyte	enrichment	(Zhou	et	al.,	2011).	Our	study	 is	 the	 first	 to	document	the	differential	expression	of	miRNAs	during	cardiac	hypertrophy	in	purified	cardiomyocytes.	Therefore,	 although	yet	undefined,	 it	 is	possible	 that	some	 of	 the	 other	 miRNAs	 that	 did	 not	 make	 our	 cut-off	 for	 statistical	significance	 are	 derived	 from	 other	 cell	 types	 in	 the	 heart.	 Finally,	 our	 study	examines	miRNA	expression	changes	very	early	 in	 the	hypertrophic	response,	while	previous	studies	have	typically	chosen	much	later	time	points.	As	can	be	seen	from	Figure	4.1	and	4.2,	differential	expression	in	miRNA	appears	to	be	a	slower	response	in	the	hypertrophic	process,	with	the	large	majority	of	changes	occurring	at	 the	7d	time	point	rather	than	the	early	2d	time	point.	 It	could	be	implied	that	even	more	miRNAs	are	differentially	expressed	at	time	points	after	7d	 post	 TAC	 operation.	 Most	 previous	 reported	 have	 studied	 the	 changes	 at	later	time	points,	which	may	explain	why	they	have	identified	more	statistically	significantly	 changed	miRNAs	 than	 in	 our	 study.	 It	 was	 originally	 anticipated	that	miRNAs	were	a	component	of	the	initial	response	to	cardiac	stress.	If	this	were	true,	then	we	would	expect	to	see	expression	changes	on	or	before	the	2d	time	 point.	 Instead,	 we	 found	 that	 only	 three	 miRNAs	 were	 statistically	significantly	dysregulated	at	2d	TAC,	while	most	of	the	changes	were	observed	at	the	7d	time	point.	This	suggests	that	changes	in	miRNA	expression	is	perhaps	more	 involved	 with	 the	 adaptation	 to	 hypertrophic	 growth	 rather	 than	 its	instigation.	Our	examination	of	pre-hypertrophic	cardiomyocytes	thus	provides	more	insight	into	the	role	of	miRNA	regulation	in	hypertrophy.	
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We	 also	 documented	 the	 expression	 of	miRNA	posttranscriptional	 variants	 in	the	 heart	 and	 analysed	 their	 changes	 during	 cardiac	 hypertrophy.	 We	 have	found	that	there	is	a	widespread	presence	of	miRNA	processing	variants	in	the	cardiomyocyte.	We	 found	22	miRNA	hairpins	with	more	than	20%	of	 the	 tags	derived	 from	 both	 strands.	 Of	 these,	 20	 were	 expressed	 in	 the	 HL-1	cardiomyocytes	(Humphreys	et	al.,	2012b).	Identifying	the	predominant	strand	expressed	in	the	biological	system	of	interest	is	very	important,	particularly	in	studying	the	functional	or	clinical	potential	of	a	miRNA.	For	instance,	miR-9	was	a	 miRNA	 of	 interest	 for	 therapy	 of	 heart	 disease,	 and	 functional	 studies	 had	been	performed	to	elucidate	its	role	and	targets	in	systems	including	the	heart.	miR-9-5p	was	previously	defined	as	the	mature	miR-9.	Yet	in	our	data,	67.5%	of	miR-9	 is	 actually	 derived	 from	 the	 less-studied	 miR-9-3p	 strand.	 Another	therapeutically	 relevant	 example	 is	 the	 miRNA-208a	 hairpin.	 We	 observed	strong	expression	of	miR-208a-5p	(59.3%	of	 total),	 even	 though	miR-208a-3p	was	 initially	 considered	 to	 be	 the	 ‘mature’	 miRNA,	 and	 targeted	 by	 anti-miR	inhibition	 to	 clinically	 block	 LVH	 (van	 Rooij	 and	 Olson,	 2012).	 Thus,	 strand	expression	is	important	when	inhibiting	or	overexpressing	a	whole	pre-miRNA	hairpin,	 as	 it	 cannot	 be	 assumed	 that	 only	 one	 strand	 would	 be	 expressed.	While	we	have	shown	 that	 several	miRNA	hairpins	had	miRNAs	derived	 from	both	strands,	only	one	miRNA,	miR-330,	shifted	5p/3p	arm	bias	between	sham	and	TAC.	miR-330	is	thus	a	candidate	for	future	work,	although	little	is	known	about	its	role	in	the	heart.		Other	more	 subtle	miRNA	processing	 variations,	 such	 as	 5’-isomiR,	 3’-isomiR,	and	 NTA,	 were	 also	 very	 commonly	 expressed	 in	 the	 cardiomyocyte.	Approximately	20%	of	the	miRNAs	we	detected	had	greater	than	20%	of	their	tags	derived	 from	5’	 isomiRs,	 including	13	miRNAs	 that	have	previously	been	studied	 in	 hypertrophy.	 Consistent	 with	 other	 studies,	 95%	 of	 miRNAs	 had	variation	 at	 the	 3’	 end	 (Landgraf	 et	 al.,	 2007,	 Morin	 et	 al.,	 2008,	 Ruby	 et	 al.,	2006).	As	miRNAs	rely	on	the	5’	end	for	targeting	specificity,	there	is	a	greater	evolutionary	 pressure	 to	 maintain	 constant	 5’	 ends	 (Starega-Roslan	 et	 al.,	2011),	 which	 perhaps	 explains	 the	 tendency	 for	 miRNAs	 to	 have	 greater	 3’-
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isomiR	 variants	 than	 5’-isomiR	 variants.	 Furthermore,	 while	 it	 has	 been	postulated	that	the	reason	behind	miRNA	start	and	end	heterogeneity	is	relaxed	Drosha	and	Dicer	cleavage	specificity	(Morin	et	al.,	2008,	Ruby	et	al.,	2006,	Wu	et	 al.,	 2009),	 3’	 isomiRs	may	 also	 derive	 from	 other	 post-processing	 addition	and/or	trimming	events.	127	miRNAs	have	≥20%	of	its	expression	contributed	to	by	NTA	variants,	while	over	half	of	 the	 the	miRNAs	 in	our	study	have	non-templated	nucleotides	at	lower	levels.	Several	of	the	miRNAs	we	detected	with	NTA	such	as	miR-143-5p,	have	similar	proportions	 in	other	studies	(Chiang	et	al.,	2010,	Wyman	et	al.,	2011).	As	mentioned	previously,	there	is	a	one	in	four	chance	that	the	NTA	will	coincidentally	match	the	genomic	sequence,	masking	any	true	NTA	events.	In	this	instance,	the	true	NTA	event	would	be	classified	as	3’-isomiR	 in	 our	 data.	 A	 study	 by	 Westholm	 et	 al.	 used	 mirtrons	 (miRNAs	spliced	 out	 of	 introns	 independently	 of	Drosha)	 to	 examine	NTA	 as	 the	 exact	cleavage	 position	 is	 defined	 (Westholm	 et	 al.,	 2012),	 and	 found	 that	miRNAs	with	NTA	are	quite	abundant	once	the	nucleotides	that	 fortuitously	match	the	genomic	sequence	are	accounted	for.		Thus,	the	NTA	events	detected	in	our	data	may	be	an	underestimate	of	the	true	NTA	events	 in	the	cell.	We	also	searched	for	IE	of	the	miRNA.	While	RNA	editing	has	been	reported	to	be	common	in	the	murine	brain,	our	data	suggests	that	it	is	relatively	rare	in	the	heart.	The	editing	of	 pri-miRNAs	 is	 more	 common	 then	 mature	 miRNAs,	 and	 can	 alter	 their	processing	 by	 suppressing	 either	 Drosha	 or	 Dicer	 cleavage	 (Kawahara	 et	 al.,	2007,	Yang	et	al.,	2006).	It	is	possible	then	that	A-to-I	editing	does	occur	more	frequently	in	the	heart	on	pri-miRNA	segments	that	do	not	get	cleaved	into	the	mature	miRNA	strand,	and	thus	are	not	detected	in	out	data.		In	 analyzing	 changes	 in	 miRNA	 processing	 during	 cardiac	 hypertrophy,	 we	found	 that	 there	 was	 no	 difference	 in	 5’-isomiRs,	 3’-isomiRs,	 NTA,	 and	 IE	 of	individual	miRNAs	between	the	Sham	and	the	TAC	samples.	We	also	found	no	significant	global	changes	in	miRNA	processing	during	hypertrophy	apart	from	small	 decreases	 in	 bulk	 NTA	 and	 3’isomiR	 levels.	 The	 observed	 change	 in	3’isomiR	levels	 likely	reflects	the	changes	in	NTA;	as	previously	described,	the	non-templated	 addition	 of	 an	 A	 or	 U	 nucleotide	 to	 the	 miRNA	 could	
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inadvertently	 match	 the	miRNA	 precursor	 template,	 which	 would	 result	 in	 a	true	NTA	event	being	classified	as	3’-isomiR	in	our	data.	Alteration	of	the	3’	end	of	 a	miRNA	 can	 alter	 its	 loading	 into	 specific	 AGO	 complexes	 or	 its	 turnover	(Burroughs	 et	 al.,	 2011,	 Katoh	 et	 al.,	 2009).	 Accordingly,	 NTAs	 are	 generally	associated	 with	 changes	 in	 miRNA	 function	 or	 stability.	 However,	 both	stabilizing	 and	 destabilizing	 effects	 on	 mRNAs	 have	 been	 reported	 (Kai	 and	Pasquinelli,	 2010),	 and	 thus	 their	 relevance	 during	 cardiac	 hypertrophy	remains	unclear	and	should	be	explored	in	the	future.		In	 summary,	 we	 have	 documented	 in	 detail	 the	 widespread	 expression	 of	miRNA	 processing	 variants	 in	 the	 heart,	 and	 shown	 that	 miRNA	 processing	variants	 produced	 generally	 remained	 consistent	 during	 the	 cellular	 stress	induced	by	cardiac	hypertrophy.	Regardless	of	the	lack	of	change	during	cardiac	hypertrophy,	it	is	still	very	interesting	to	discover	the	widespread	occurance	of	these	processing	variants	 in	 the	heart.	 It	would	be	 interesting	 in	 the	 future	 to	gain	 more	 insights	 into	 whether	 isomiRs	 have	 separate	 functions	 than	 the	canonical	 form.	For	example,	 it	would	be	 interesting	 to	determine	their	 target	mRNAs	 and	 infer	 the	 broad	 biological	 pathways	 regulated	 by	 the	 different	isomiRs.			
4.3.2.	 The	 expression	 of	 polyadenylated	 ncRNAs	 during	 cardiac	
hypertrophy	Our	PAT-Seq	data	revealed	a	considerable	diversity	in	polyadenylated	ncRNAs	within	the	cardiomyocyte.	The	majority	of	polyadenylated	ncRNAs	we	observed	in	 the	 heart	was	 represented	 by	 lncRNAs.	 Some	 small	 RNAs	 such	 as	miRNAs,	snRNAs,	and	snoRNAs	were	also	present	 in	our	polyA	 libraries,	but	makes	up	only	a	small	proportion	of	the	peaks.	This	observation	matches	the	expectations	based	on	previous	studies	 that	 looked	at	 the	polyadenylation	status	of	ncNAs;	for	 example,	 a	 previous	 study	 looked	 at	 the	 polyadenylation	 of	 nine	 human	miRNAs	and	 found	 that	pri-miRNAs	contain	poly(A)	 tails,	but	mature	miRNAs	do	not	(Cai	et	al.,	2004).	On	the	other	hand,	it	has	previously	been	demonstrated	
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that	 the	 majority	 of	 lncRNAs	 are	 transcribed	 by	 RNA	 Pol	 II	 and	 are	polyadenylated	 (Quinn	and	Chang,	2016).	 Interestingly,	 our	data	 indicate	 that	54%	of	ncRNA	peaks	were	 situated	downstream	(≤20kb)	of	 the	annotated	3’-end	boundaries.	This	may	suggest	unexpected	 transcription	of	 longer	variants	of	 these	 ncRNAs,	 perhaps	 the	 result	 of	 APA	 in	 non-coding	 transcripts.	 This	phenomenon	 has	 not	 been	 widely	 reported	 previously,	 and	 may	 be	 an	interesting	 avenue	 to	 study	 further	 in	 the	 future.	 Our	 PAT-seq	 data	 also	identified	 transcripts	 that	 do	not	 overlap	with	 currently	 annotated	 regions	 of	the	 genome	 (>20kb	 downstream	 of	 any	 annotated	 genomic	 features).	 As	described	 in	 Chapter	 3,	 these	make	 up	~43%	of	 our	 PAT-seq	 peak.	 Based	 on	their	 PAS	 and	 expression	 characteristics,	 it	 is	 likely	 that	 they	 represent	 novel	lncRNAs.	 Further	 studies	 validating	 their	 expression	 and	 functions	 would	 be	required.			The	 majority	 of	 the	 differentially	 expressed	 non-coding	 and	 unannotated	transcripts	were	up-regulated	during	cardiac	hypertrophy,	with	most	changes	occurring	early	in	the	hypertrophic	process	at	2	days	post	TAC.	These	changes	returned	 to	 normal	 levels	 at	 7d	 post	 TAC.	 During	 cardiac	 hypertrophy,	 it	 is	known	that	there	is	a	uniform	increase	in	total	RNA	synthesis	that	accounts	for	the	30-50%	increase	in	cell	volume	(Abdellatif	et	al.,	1998).	This	is	achieved	by	an	increase	in	the	activity	of	RNA	Pol	I	(McDermott	et	al.,	1991),	Pol	II	and	Pol	III	 (Cutilletta	 et	 al.,	 1978)	 during	 the	 disease.	 Thus,	 this	 generalized	 increase	could	 account	 in	 part	 for	 the	 larger	 number	 of	 up-regulated	 transcripts	compared	 to	 down-regulated	 ones	 in	 the	 TAC	 samples.	 It	 also	 suggests	 that	perhaps	 the	up-regulation	of	ncRNA	 is	 a	 compartment	of	 a	 generalized	 stress	response	 during	 disease,	 rather	 than	 a	 specific	 pathway	 that	 instigates	 the	hypertrophic	process.			
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4.3.3.	Conclusions	This	 chapter	 aimed	 to	 document	 the	 expression	 of	 ncRNAs	 in	 healthy	 and	hypertrophic	hearts.	While	there	is	now	a	large	body	of	literature	reporting	the	differential	expression	of	miRNAs	during	cardiac	hypertrophy,	our	study	marks	the	first	to	examine	the	phenomenon	in	purified	cardiomyocytes.	Furthermore,	we	 also	 analysed	 the	 expression	 of	 processing	 variants,	 discovering	 ample	evidence	of	 arm	bias,	 5’-	 and	3’-	 isomiRs,	 and	NTA	 for	 cardiac	miRNAs.	All	 of	these	 variants	 provide	 a	 mechanism	 to	 potentially	 modify	 the	 function	 of	 a	given	 miRNA	 locus	 without	 changing	 the	 genomic	 sequence.	 Interestingly,	however,	 these	 processing	 variants	 generally	 remained	 unchanged	 during	cardiac	hypertrophy.	Despite	this,	 the	existence	of	miRNA	variants	 is	still	vital	when	 determining	 the	 mRNA	 network	 that	 one	 miRNA	 can	 regulate.	 This	network	could	be	further	complicated	by	the	processing	variants	of	mRNAs	that	the	miRNA	 interacts	with	 (this	 is	 further	 investigated	 in	 Chapter	 Five	 of	 this	thesis).	 We	 also	 analysed	 the	 expression	 of	 lncRNAs	 as	 well	 as	 other	polyadenylated	 ncRNAs.	 Despite	 attempts	 in	 previous	 studies	 to	 characterize	the	 expression	 of	 lncRNAs	 in	 different	 states	 of	 the	 heart,	 the	 regulation	 of	cardiac	pathways	by	lncRNAs	is	still	poorly	understood.	Our	analysis	indicated	that	 many	 of	 these	 transcripts	 are	 up-regulated	 early	 in	 the	 hypertrophic	process,	and	may	represent	a	generalized	response	to	stress.			 	
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Chapter	5.		
mRNA	expression	in	the	
cardiomyocyte	 	
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5.1.	Introduction	Although	 much	 attention	 has	 been	 given	 to	 characterizing	 gene	 expression	changes	 during	 cardiac	 hypertrophy,	 relatively	 little	 is	 known	 about	 the	contribution	 of	 alternative	 3’-UTR	processing	 in	 the	heart.	 APA	patterns	 have	been	 shown	 to	 be	 tissue-specific;	 for	 example,	 mRNAs	 in	 the	 brain	 typically	have	 longer	3’-UTRs,	whereas	 those	 in	 the	 testes	have	shorter	3’-UTRs	(Liu	et	al.,	 2007,	 Zhang	 et	 al.,	 2005,	 Miura	 et	 al.,	 2013).	 Furthermore,	 3’-UTRs	 are	shortened	 at	 proliferative	 stages,	 such	 as	 during	 oncogenesis	 and	 T-cell	expansion,	and	lengthened	during	differentiation	and	development	(Elkon	et	al.,	2013,	Hollerer	et	al.,	2014b).	This	chapter	investigates	the	expression	of	3’UTR	variants	in	the	heart	and	their	changes	during	cardiac	hypertrophy		This	chapter	focuses	on	the	31,110	‘downstream’	peaks	derived	from	the	PAT-seq	 dataset	 of	 normal	 and	 hypertrophic	 mice	 described	 in	 Chapter	 3.	 These	peaks	represent	mRNA	3’-ends	derived	from	13,951	protein-coding	genes.	We	have	 used	 the	 data	 to	 first	 analyze	 overall	 gene	 expression	 during	 cardiac	hypertrophy	and	corroborate	previous	studies.	Then,	we	have	analysed	the	3’-end	 features	 of	 protein	 coding	 transcripts	 in	 the	 cardiomyocyte,	 and	documented	 a	 complete	 annotation	 of	 mRNA	 3’-ends	 in	 the	 cardiomyocyte.	Finally,	we	 have	 used	 the	 data	 to	 investigate	whether	 cardiac	 hypertrophy	 is	associated	with	changes	in	3’-UTR	length.			
5.2.	Results		
5.2.1.	 Changes	 in	 the	 expression	 of	 protein	 coding	 genes	 during	 cardiac	
hypertrophy	Previous	 studies	 have	 shown	 that	 NGS	 of	 3’	 ends	 can	 accurately	 be	 used	 for	overall	 gene	 expression	 analysis,	 yielding	 results	 that	 are	 similar	 to	 those	obtained	with	normal	RNA	sequencing,	microarrays	and	RT-qPCR	(Wang	et	al.,	
		 95	
2013,	Derti	et	al.,	2012,	Beck	et	al.,	2010).	Thus,	to	gain	a	more	complete	picture	of	the	transcriptome	profile	during	cardiac	hypertrophy,	we	mined	our	PAT-seq	data	for	overall	differential	gene	expression.	The	3’UTR	peaks	of	protein	coding	genes	 associated	 with	 the	 same	 gene	 ID	 were	 first	 combined	 (Figure	 2.3;	described	in	Chapter	2),	resulting	in	the	31,101	peaks	combined	to	give	13,951	genes.	The	data	was	then	normalized	by	the	Trimmed	Mean	of	M-values	(TMM)	normalization	 method,	 and	 filtered	 for	 genes	 that	 are	 expressed	 at	≥2CPM,	yielding	8,222	genes.	To	detect	genes	that	are	differentially	expressed	between	the	TAC	banded	mice	and	the	sham	controls,	pairwise	comparisons	between	2d	TAC	versus	all	sham,	7d	TAC	versus	all	sham,	and	all	TAC	versus	all	sham	were	made	using	the	edgeR	package.		623	genes	were	differentially	expressed	at	one	or	both	time	points	during	TAC	(FDR<5%)	(Figure	5.1A-C).	Most	changes	in	mRNA	expression	were	evident	by	2	days	(205	genes	upregulated,	108	genes	downregulated	only	at	2	days;	137	genes	upregulated,	108	genes	downregulated	at	both	2	and	7	days).	Few	genes	were	altered	exclusively	at	7d	(60	genes	upregulated,	5	genes	downregulated).	These	findings	contrast	with	the	slower	changes	in	miRNA	expression	(Chapter	4).	 Additionally,	 they	 indicate	 that	 we	 primarily	 captured	 early	 responses	 to	pressure	overload	and	the	transcriptional	remodelling	driving	LVH,	rather	than	later	secondary	effects.	9	Genes	that	are	differentially	expressed	during	TAC	at	FDR<5%	were	 randomly	 chosen	 for	 validation	 through	RT-qPCR	 (Figure	5.2).	Of	these,	all	tested	genes	except	for	Calm1	followed	the	same	trend	as	the	NGS	data,	 and	6	 reached	 statistical	 significance	 (p<0.05)	when	 analyzed	using	RT-qPCR.			
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Figure	5.1.	TAC-induced	changes	in	cardiomyocyte	mRNA	expression.	Read	counts	from	 ‘downstream’	 PAT-Seq	peaks	were	 combined	 to	 generate	 expression	 values	 for	protein-coding	genes.	A)	Heat	map	of	differentially	expressed	genes	between	TAC	and	sham	surgery	at	an	FDR<5%.	B&C)	MA	plots	of	all	detected	mRNAs	comparing	all	sham	samples	 against	 B)	 2d	 and	 C)	 7d	 TAC.	 X-axes	 show	 mean	 mRNA	 expression	 across	samples;	y-axes	show	fold	change	in	expression	between	TAC	and	sham.	Differentially	expressed	mRNAs	with	FDR<5%	are	shown	in	red.		
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Figure	 5.2.	 Validation	 of	 differentially	 expressed	 genes	 by	RT-qPCR.	 n=5	pairs,	mean±SEM;	 blue	 *p<0.05,	 **p<0.01,	 ***p<0.001,	 two-tailed,	 two-sample	Student’s	t-test.	Shown	underneath	are	the	per-comparison	fold	changes	(log2)	between	 TAC	 and	 sham	 from	 the	 PAT-seq	 data.	 Full	 names	 for	 the	 nine	investigated	 genes	 are	 as	 follows:	 Calponin	 1	 (Cnn1),	 Clusterin	 (Clu),	Calmodulin	 1	 (Calm1),	 Secreted	 Protein	 Acidic	 And	 Cysteine	 Rich	 (Sparc),	Hydroxyacyl-CoA	 Dehydrogenase	 	 (Hadh),	 NADH:Ubiquinone	 Oxidoreductase	Subunit	A1(Ndufa1),	Acyl-CoA	Synthetase	Long-Chain	Family	Member	1	(Acsl1),	Kruppel-Like	Factor	15	(Klf15),	Pyruvate	Dehydrogenase	Kinase	4	(Pdk4).		
5.2.1.1.	Gene	Ontology	(GO)	enrichment	To	 determine	whether	 particular	 cellular	 functions	were	 dysregulated	 during	cardiac	hypertrophy,	we	conducted	a	gene	ontology	enrichment	analysis	using	the	Database	 for	Annotation,	Visualization,	and	 Integrated	Discovery	 (DAVID).	The	data	was	interrogated	for	enrichment	in	biological	processes	(Figure	5.3A),	molecular	function	(Figure	5.3B),	and	cellular	components	(Figure	5.3C)	against	a	background	of	all	genes	expressed	at	>2	CPM.		
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GO	 terms	 enriched	 among	 differentially	 expressed	 genes	 reflected	 well-recognised	 aspects	 of	 LVH.	There	was	 an	 early	 and	 sustained	decrease	 in	 the	expression	of	genes	related	to	fatty	acid	metabolism,	which	is	consistent	with	a	change	 in	 fuel	 preference	 from	 fatty	 acids	 to	 carbohydrates	 (Doenst	 et	 al.,	2010).	In	agreement	with	known	morphological	and	contractile	changes	in	LVH	(Lorell	 and	 Carabello,	 2000,	 Ehler,	 2015),	 genes	 affecting	 intracellular	structures	were	induced	early,	whilst	extracellular	matrix	organization	and	cell	adhesion	 genes	 were	 mostly	 induced	 at	 7d.	 We	 also	 observed	 a	 transient	induction	 of	 ribosome	 biogenesis	 genes,	which	 supports	 the	 need	 to	 increase	capacity	for	protein	synthesis	during	cardiac	hypertrophy	(Hannan	et	al.,	2003).	Up-regulation	 of	 immune	 system	 processes	 was	 seen,	 likely	 a	 result	 of	 the	cardiomyocytes	 expressing	 various	 stress-activated	 cytokines	 (Mann,	 2003)	and	 some	 immune	 cell	 infiltration	 that	 persisted	 in	 our	 cardiomyocyte	preparation.				
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Figure	5.3.	Enriched	Gene	Ontology	terms	in	genes	that	are	differentially	
expressed	 during	 cardiac	 hypertrophy	 at	 FDR<20%.	 A)	 Enriched	 GO	Biological	Process	terms.	B)	Enriched	GO	Molecular	Function	terms.	C)	Enriched	Cellular	Compartment	terms.					
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5.2.1.2.	Comparison	of	differentially	expressed	mRNAs	to	previous	studies	 in	TAC	
LVH	To	 identify	 novel	 mRNA	 changes,	 we	 compared	 the	 list	 of	 differentially	expressed	 mRNAs	 in	 our	 data	 to	 other	 studies	 that	 have	 documented	 gene	expression	changes	during	TAC-induced	cardiac	hypertrophy	(Park	et	al.,	2011,	Zhao	et	al.,	2004,	van	den	Bosch	et	al.,	2006,	Hu	et	al.,	2012).	The	experimental	designs	of	these	studies	are	summarized	in	Table	5.1.	 	
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Table	 5.1.	 	 Experimental	 designs	 of	 previous	 studies	 reporting	 gene	
expression	profile	during	TAC-induced	cardiac	hypertrophy	
Study	 TAC	size	 Hypertrophic	
time	points	
Tissue	sample	 Strategy	
Our	study	
	
27-G	needle	 2	and	7	days	 Purified	cardiomyocytes	from	whole	hearts	
PAT-seq	
Park	et	al	
(2011)	
28-G	needle	(tighter	constriction)	
1,	3,	and	12	weeks	 Whole	LV	 Microarrays	
Van	den	
Bosch	et	
al	(2006)	
27-G	needle	 2	days,	1,	2,	3,	8	weeks	 Whole	LV	 Microarrays	
Zhao	et	al	
(2004)	
27-G	needle	 2,	10,	and	21	days	 Whole	hearts	 Microarrays	
Hu	et	al	
(2012)	
26-G	needle	(looser	constriction)	
1	week	 Whole	hearts	 RNA-seq	
	While	 our	 gene	 sets	 overlapped	 with	 those	 of	 other	 gene	 expression	 studies	during	TAC/LVH	(Park	et	al.,	2011,	Zhao	et	al.,	2004,	van	den	Bosch	et	al.,	2006,	Hu	et	al.,	2012)	as	described	above,	395	genes	were	unique	to	our	study	(Figure	5.4).	Thus,	our	data	adds	new	texture	to	the	range	of	affected	genes	within	well-known	processes	during	LVH	progression.	Much	of	the	variability	is	 likely	due	to	differences	in	implementation	of	TAC/LVH,	while	it	may	also	reflect	our	focus	on	early	changes	specifically	in	cardiomyocytes.	
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Figure	 5.4.	 Comparison	 between	 differentially	 expressed	 mRNAs	 and	
published	data.		A)	The	overlap	between	differentially	expressed	mRNAs	with	a	 FDR	 <5%	 and	 mRNAs	 previously	 reported	 to	 be	 differentially	 expressed	during	 LVH.	 B)	 Overlap	 in	 the	 number	 of	 differentially	 expressed	 mRNAs	 in	previous	studies	(Park	et	al.,	2011,	Zhao	et	al.,	2004,	van	den	Bosch	et	al.,	2006,	Hu	et	al.,	2012).		
5.2.2.	Characteristics	of	protein	coding	peaks	We	next	analysed	the	3’UTR	peaks	for	their	association	with	mRNAs.	Consistent	with	 previous	 studies	 (Ulitsky	 et	 al.,	 2012,	 Spies	 et	 al.,	 2013),	 we	 found	 an	average	of	2.3	3’UTRs	per	gene	and	a	median	3’UTR	 length	of	1101nt	 (Figure	5.5A-B).	We	conducted	a	GO	analysis	for	genes	with	more	than	one	3’UTRs,	and	we	 found	 that,	 as	 previously	 noted	 (Lianoglou	 et	 al.,	 2013),	 terms	 relating	 to	regulatory	 functions,	 such	 as	 post-translational	 modifications,	 signaling	 and	transcription	were	enriched	 in	 these	genes	 (Figure	5.5	C).	Thus,	 the	mRNA	3’	peaks	mapped	here	match	multiple	criteria	for	bona	fide	3’UTRs.		
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Figure	5.5.	The	3’UTR	of	protein	coding	genes.	A)	The	number	of	transcripts	with	1-8	3’	UTRs.	B)	The	location	of	peaks	from	the	stop	codon	in	protein	coding	transcripts.	 C)	 Enrichment	 of	 gene	 ontology	 (Biological	 Processes:	 BP,	Molecular	 Function:	 MF)	 and	 KEGG	 pathway	 terms	 among	 genes	 expressing	more	than	one	3’UTR.	The	associated	number	of	genes	is	shown	in	parentheses.	
	
	We	next	focused	on	the	individual	peaks	within	protein	coding	genes.	First,	we	analyzed	 the	 presence	 of	 PAS	 in	 the	 3’seq	 peaks.	 The	 canonical	 PAS	 was	searched	within	50nt	upstream	of	the	poly(A)	site,	or	within	50nt	downstream	of	 the	3’-end	of	 the	peak	 for	peaks	without	detectable	poly(A).	Peaks	without	the	 canonical	PAS	 in	 this	 region	were	 then	 interrogated	 for	 the	presence	of	 a	non-canonical	 PAS.	 Of	 peaks	 where	 read	 coverage	 included	 the	 poly(A)	 tail,	57%	 had	 the	 canonical	 AAUAAA	 PAS	 motif	 and	 a	 further	 27%	 had	 non-canonical	motifs	(Figure	5.6A).	We	did	not	detect	any	evidence	of	PAS	for	16%	of	the	peaks.	These	match	previous	reports	on	the	prevalence	of	different	PAS	motifs	(Elkon	et	al.,	2013,	Hollerer	et	al.,	2014b).	PAS	variants	were	found	at	a	
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mean	distance	of	17.5nt	from	the	5’	end	of	the	motif	to	the	poly(A)	tail	(Figure	5.6B),	 which	 again	 corroborates	 previous	 studies	 (Elkon	 et	 al.,	 2013,	Danckwardt	 et	 al.,	 2008)	 (Figure	 5.1B).	 For	 genes	 with	 more	 than	 2	 UTR	variants,	 we	 next	 investigated	 whether	 or	 not	 there	 was	 a	 differential	preference	for	canonical	or	non-canonical	PAS.	We	found	that	the	distal	3’UTR	has	 statistically	 significantly	 more	 canonical	 PAS	 than	 the	 proximal	 3’UTR	(Figure	5.6C).		 	
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Figure	5.6.	PAS	motif	 in	mRNA	3’-end.	A)	Frequency	of	PAS	variants	within	‘downstream	peaks	for	protein	coding	genes.	B)	Distance	between	closest	PAS	and	the	poly(A)	tail.	C)	Association	of	proximal	and	distal	3’UTRs	with	canonical	or	non-canonical	PAS	motifs			
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5.2.3.	Novel	3’UTRs	of	protein	coding	peaks	We	next	interrogated	our	data	for	the	expression	of	novel	3’-ends	in	the	heart.	To	do	 this,	 the	3’-end	peaks	derived	 from	our	PAT-seq	data	was	compared	 to	transcript	 ends	 annotated	 in	 Ensembl	 version	 77.	 52%	 of	 the	mRNA	 3’-ends	detected	here	coincided	with	previously	annotated	3’UTRs	(based	on	Ensembl	version	77),	while	the	remaining	48%	of	peaks	represent	14,933	novel	3’UTRs,	more	 often	 indicating	 expression	 of	 novel	 shorter	 rather	 than	 longer	 mRNA	variants	(Figure	5.7A).	Thus	we	report	at	least	one	novel	3’UTR	for	7,348	genes.	For	 some	 mRNAs	 with	 only	 one	 3’UTR,	 the	 3’UTR	 we	 detected	 was	 not	 the	annotated	3’-end	in	Ensembl.	Almost	all	genes	with	more	than	one	3’UTR	had	a	novel	 variant	 associated	 with	 it	 (Figure	 5.7B,	 left).	 Notably,	 when	 inspecting	known	 mRNA	 targets	 of	 the	 therapy-related	 miR-208a-3p	 (van	 Rooij	 et	 al.,	2009),	we	found	novel	3’UTR	variants	for	four	of	these	(Sex	Determining	Region	Y-Box	 6	 (Sox6),	 Purine-Rich	 Element	 Binding	 Protein	 B	 (PurB),	 Chromobox	Homolog	 1	 (Cbx1),	 and	 Sp3	 Transcription	 Factor	 (Sp3)),	 including	 two	examples,	PurB	and	Cbx1,	with	shorter	3’UTRs	that	lack	the	miR-208a-3p	target	sites.	Further	illustrating	the	impact	of	APA	on	miRNA	regulation,	we	found	at	least	one	novel	3’UTR	for	~70%	of	genes	predicted	to	be	targeted	by	miR-208a-5p	(Figure	5.7B,	right).	We	 independently	 tested	the	presence	of	PAT-Seq	mapped	3’-ends	 for	several	genes	through	3’RACE.	The	location	of	the	3’	seq	peak	could	be	validated	for	all	mRNAs	investigated	(Figure	5.8).	Furthermore,	the	cleavage	sites	present	in	the	3’	 sequencing	 data	 were	 often	 visible	 using	 conventional	 sequencing	 (Figure	5.8).	 The	 documentation	 of	 novel	 3’UTR	 annotation	 would	 improve	 future	exploration	 of	 miRNA	 targets	 and	 functions.	 For	 example,	 serum	 response	factor	 (SRF)	 mRNA	 encodes	 a	 pro-hypertrophic	 transcription	 factor	 and	 its	annotated	 3’UTR	 harbors	 predicted	 binding	 sites	 for	 four	 miRNAs	 that	 have	been	 implicated	 in	 cardiac	 hypertrophy:	 miR-9,	 miR22-3p,	 miR101a/b,	 and	miR150	 (van	 Rooij	 et	 al.,	 2006).	 We	 found	 a	 novel	 shorter	 SRF	 3’UTR	 that	retains	only	one	of	these	miRNA	binding	sites	(Figure	5.8A).	Taken	together,	we	provide	 an	 in-depth	 compendium	 of	 extant	mRNA	 3’UTRs	 in	 cardiomyocytes	
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that	 can	 provide	 better	 insight	 into	 post-transcriptional	 regulation	 of	 cardiac	mRNA	expression.				
		
Figure	5.7.	Novel	3’-ends	in	the	cardiomyocyte.	A)	Classification	of	PAT-Seq	mapped	mRNA	3’-ends	based	on	3’UTR	coordinates	 listed	 in	Ensembl	v77.	B)	Distribution	of	known	and	novel	mRNA	3’UTRs	by	frequency	of	mapped	3’UTRs	per	gene	(pooled	data	from	all	eight	samples).	Results	are	shown	for	all	protein-coding	genes	(left),	and	for	a	set	of	miR-208a-5p	target	genes,	as	predicted	by	miRmap	(right;	see	Chapter	6	for	details).	
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Figure	5.8.	Validations	of	novel	3’UTRs	in	the	cardiomyocyte	by	3’RACE.	A)	Validation	 of	 a	 novel	 truncated	 3’UTR	 of	 serum	 response	 factor	 (SRF).	 B)	microtubule	associated	 tumor	suppressor	1	 (MTUS1).	C)	 cell	division	cycle	42	(CDC42).	 D)	 glycogen	 synthase	 kinase	 3	 beta	 (GSK3b).	 E)	 secreted	 protein,	acidic,	 cysteine-rich,	 (SPARC).	 F)	 upstream	 transcription	 factor	 2	 (USF2).	 The	annotated	 full-length	3’UTR	 is	depicted	on	 top	 in	blue,	with	predicted	miRNA	target	sites	shown	as	aqua	rectangles.	PAT-Seq	peak	coverage	 is	shown	in	the	middle	 with	 change	 from	 genomically	 encoded	 sequence	 to	 poly(A)	 tail-indicated	 by	 shift	 from	 grey	 to	 red	 colour.	 Independent	 3’RACE-validation	 of	both	 SRF	 mRNA	 3’-ends	 is	 shown	 below.	 Expanded	 sequence	 key:	 genomic	sequence	 (blue),	 sequence	 identified	 by	 conventional	 sequencing	 (orange),	canonical	 PAS	 (purple),	 non-canonical	 PAS	 (green).	 Predominant	 and	 minor	cleavage	 sites	 based	 on	 PAT-Seq	 data	 are	marked	 by	 red	 and	 grey	 triangles,	respectively.	
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5.2.4.	Changes	in	3’UTR	length	during	cardiac	hypertrophy	To	 understand	 the	 effect	 of	 TAC	 on	 mRNA	 3’-end	 preference,	 we	 compared	proximal	 to	 distal	 3’-end	 peak	 ratios	 between	 sham	 and	TAC	 for	 2,981	 genes	with	 ≥2	 peaks	 at	 2d	 and	 2,979	 genes	 at	 7d	 (≥10%	 expression	 per	 gene-associated	 peak).	We	 considered	 all	 possible	 pairwise	 combinations	 of	 3’-end	peaks	 for	 a	 given	 gene	 (Figure	 2.4;	 described	 in	 Chapter	 2).	 A	 statistically	significant	 overall	 shift	 toward	 more	 proximal	 mRNA	 3’-ends	 was	 observed	during	 TAC	 that	 was	 more	 prominent	 at	 2d	 than	 at	 7d	 (~12%	 and	 ~6%,	respectively)	(Figure	5.9A).	The	phenomenon	was	most	pronounced	for	mRNAs	with	a	high	proportion	of	distal	3’-ends	(Figure	5.9B)	and	for	those	with	lower	FDR	 (Figure	 5.9C).	 This	 indicates	 that	 a	 moderate	 widespread	 shift	 in	 APA	towards	proximal	3’-end	cleavage	sites	is	part	of	the	early	processes	in	cardiac	hypertrophy.	Gene-specific	 shifts	 in	 APA	 balance	 were	 often	 subtle,	 posing	 challenges	 to	statistically	 reliable	 quantification	 by	 PAT-Seq.	 As	 a	 means	 to	 identify	candidates	 for	 follow-up,	we	 filtered	 for	 genes	with	 substantial	 changes	 in	3’-end	preference	(log2FC	≥	±1.5).	This	yielded	359	genes	at	2d,	225	of	which	were	shortened	 during	 TAC	 (237	 genes	 at	 7d;	 of	 which	 143	 were	 shortened).	 A	subset	of	 these	also	passed	stringent	statistical	criteria	(20	genes	at	FDR<5%;	65	genes	at	FDR	10%)	(Figure	5.9B).	From	the	above	lists	we	selected	13	genes	based	 on	 FDR,	 magnitude	 of	 change	 but	 also	 recognized	 relevance	 to	 heart	biology	 for	 independent	 validation.	 We	 employed	 an	 RT-qPCR	 strategy	 with	primers	 that	 probed	 either	 both	 the	 proximal	 and	 distal	 3’UTRs,	 or	 only	 the	distal	variant	(Figure	5.10,	top).	The	expected	shift	in	mRNA	3’-end	preference	was	seen	for	most	examples	in	a	 larger	set	of	 five	biological	replicates	(Figure	5.10).	This	indicates	that	multiple	individual	genes	show	strong	shifts	towards	either	 more	 proximal	 or	 distal	 mRNA	 3’-ends,	 which	 superimpose	 onto	 the	moderate	transcriptome-wide	trend	towards	more	proximal	mRNA	3’-ends.		
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Figure	 5.9.	 Changes	 in	 mRNA	 3’-end	 preference	 during	 cardiac	
hypertrophy.	A)	Boxplot	displaying	changes	 in	 the	 ratio	of	distal	 to	proximal	mRNA	3’-end	peak	 coverage	between	TAC	and	 sham	samples.	 For	 genes	with	more	 than	 two	 mapped	 3’-ends	 all	 possible	 pairwise	 comparison	 were	considered	(blue	****	p<<0.0001).	B)	Genes	that	contained	a	large	proportion	of	distal	 3’UTRs	 in	 the	 sham	 samples	 showed	 the	 largest	 changes	 toward	3’UTR	shortening	 during	 TAC.	 C)	 Comparisons	 with	 lower	 FDRs	 showed	 more	pronounced	change	towards	more	proximal	3’UTRs	during	TAC.	D)	MA	plot	of	data	from	panel	A	at	(i)	2d	and	(ii)	7d	TAC.	X-axes	show	mean	mRNA	expression	across	samples;	y-axes	show	fold	change	in	expression	between	TAC	and	sham.	Peak	 pairs	 exceeding	 statistical	 cut-offs	 are	 shown	 in	 colour	 (FDR<5%:	 red;	FDR<10%:	orange).	
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Figure	 5.10.	 	 RT-qPCR	 validation	 of	 changes	 in	 3’-end	 preference.	 Grey	bars:	 amplification	 using	 primers	 measuring	 combined	 abundance	 of	 mRNAs	with	 both	 proximal	 and	 distal	 3’-ends;	 Black:	 amplification	 using	 primers	specific	 for	 the	mRNA	with	distal	3’-end	(n=5	pairs,	mean±SEM;	blue	*p<0.05,	**p<0.01,	 ***p<0.001,	 two-tailed,	 two-sample	 Student’s	 t-test	 comparing	 the	distal+proximal	 3’UTR	 and	 the	 distal	 3’UTR	 only	 between	 TAC	 and	 sham).	Genes	 are	 sorted	 from	 left	 to	 right	 by	magnitude	 of	 3’-end	 shift	measured	by	PAT-Seq	at	2d.	Shown	underneath	are	the	per-comparison	fold	changes	(log2)	in	proximal	and	distal	UTR	expression	between	 the	 conditions	TAC	and	sham	from	 the	PAT-seq	data;	 text	 colours	 indicate	 statistical	 significance	 level	 from	PAT-seq	 data	 (FDR<5%:	 red;	 FDR<10%:	 orange).	 Full	 names	 for	 the	 thirteen	investigated	genes	are	as	follows:	ADP-Ribosylation	Factor	Guanine	Nucleotide-Exchange	 Factor	 2	 (ARFGEF2),	 Leucine	 Rich	 Repeat	 Containing	 58	 (LRRC58),	Protein	 Phosphatase,	 Mg2+/Mn2+	 Dependent,	 1K	 (PPM1K),	 Kruppel-Like	Factor	 4	 (KLF4),	 Glycogen	 Synthase	 Kinase	 3	 Beta	 (GSK3B),	Calcium/Calmodulin-Dependent	Protein	Kinase	Kinase	2	 (CAMKK2),	Cyclin	D2	(CCND2),	 Fas	 Associated	 Factor	 Family	 Member	 2	 (FAF2),	 Microtubule	Associated	Tumor	Suppressor	1	(MTUS1),	Eukaryotic	Translation	Termination	Factor	 1	 (ETF1),	 U3	 small	 nucleolar	 RNA-associated	 protein	 6	 (UTP6),	 PDZ	Domain	 Containing	 Ring	 Finger	 3	 (PDZRN3),	 CTS	 Telomere	 Maintenance	Complex	Component	1	(CTC1).	
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5.3.	Discussion	This	chapter	describes	the	expression	of	mRNAs	and	their	3’UTR	variants	in	the	murine	cardiomyocyte,	and	their	changes	in	TAC-induced	cardiac	hypertrophy.	We	first	 looked	at	the	overall	gene	expression	changes,	before	focusing	on	the	individual	 3’UTR	 variants	 within	 the	 genes.	 The	 data	 was	 interrogated	 for	features	 of	 polyadenylation,	 and	 then	 used	 to	 generate	 a	 compendium	 of	 all	3’UTRs	 expressed	 in	 the	 cardiomyocyte.	 We	 then	 examined	 the	 data	 for	 the	presence	of	alternative	polyadenylation	during	cardiac	hypertrophy.		
5.3.1.	Gene	expression	changes	during	cardiac	hypertrophy	We	 identified	623	genes	 that	 are	differentially	 expressed	during	TAC-induced	LVH.	 Of	 these,	 395	 have	 not	 been	 previously	 reported	 in	 other	 studies.	Differences	 in	detection	 technology,	 severity	 of	TAC,	 and	our	unique	 focus	on	cardiomyocyte	 gene	 expression	may	 in	 part	 explain	 these	 discrepancies.	 The	previous	studies	have	mostly	used	microarray	as	a	measure	of	gene	expression,	while	we	have	used	HTS.		It	is	possible	that	the	microarrays	did	not	have	probes	for	all	of	the	genes	that	we	have	detected.	Furthermore,	our	study	represents	an	early	 response	 to	 hypertrophy	 exhibited	 in	 the	 purified	 cardiomyocytes	specifically.	 Other	 studies	 on	 the	 other	 hand	 have	 typically	 focused	 more	 on	changes	at	 later	stage	of	hypertrophy,	and	 interrogated	expression	changes	 in	whole	 LV	 or	 even	 whole	 hearts.	 The	 mammalian	 heart	 contains	 several	 cell	types	 other	 than	 cardiomyocytes,	 such	 as	 cardiac	 fibroblasts	 and	 endothelial	cells.	 Fibroblasts,	 for	 example,	 are	 known	 to	 have	 different	 gene	 expression	responses	 compared	 to	 cardiomyocytes	 during	 mechanical	 and	 radiation	stresses	(Boerma	et	al.,	2005).	Given	these	differences	in	experimental	designs,	a	 different	 gene	 expression	 profile	 could	 be	 expected.	 In	 fact,	 only	 very	 few	mRNAs	 are	 differentially	 regulated	 in	 all	 of	 the	 four	 studies	 we	 used	 as	comparisons,	 highlighting	 the	 differences	 between	 the	 different	 studies	themselves.	 For	 example,	 Zhao	 et	 al.	 (2004)	 and	Van	 den	Bosch	 et	 al.	 (2006)	used	 microarrays	 to	 measure	 mRNA	 expression	 over	 time	 in	 whole	 hearts,	
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starting	 at	 2d.	 They	 reported	 conflicting	 results;	 the	 former	 observing	 a	 slow	build-up	of	change	while	the	latter	saw	a	temporal	pattern	similar	to	ours.		mRNA	expression	changes	during	LVH	yielded	patterns	of	GO	term	enrichment	that	 reflect	 recognized	 aspects	 of	 hypertrophy.	 Amongst	 the	 most	 strikingly	enriched	biological	processes	of	down-regulated	genes	were	those	 involved	 in	the	cellular	metabolic	process.	This	is	in	concordance	with	the	known	metabolic	changes	in	the	heart	during	times	of	stress.	The	heart	requires	a	large	amount	of	energy	 to	 maintain	 its	 contractile	 functions	 (Neubauer,	 2007).	 Normal	 heart	cells	 derive	 the	 majority	 of	 their	 ATP	 through	 mitochondrial	 oxidative	phosphorylation	 (Grynberg	 and	 Demaison,	 1996).	 While	 the	 heart	 can	 use	 a	variety	of	 fuel	 sources	 (e.g.	 fatty	acids,	 amino	acids,	 glucose,	 lactate,	 ketones),	the	preferred	fuel	of	the	normal	heart	is	fatty	acids,	which	accounts	for	60-90%	of	 its	 ATP	 production	 (Dolinsky	 and	 Dyck,	 2006).	 However,	 during	 cardiac	hypertrophy,	 there	 is	 a	drastic	decrease	 in	 fatty	 acid	metabolism	as	 the	heart	changes	 its	 fuel	 preference	 from	 fatty	 acids	 to	 carbohydrates	 (Allard	 et	 al.,	1994).	 These	well-documented	 phenomena	 confirm	 our	 GO-term	 enrichment.	However,	 contrary	 to	 the	 expected	metabolic	 changes	 towards	 an	 increase	 in	glycolysis	(Nascimben	et	al.,	2004),	we	saw	no	enrichment	of	GO	terms	related	to	up-regulation	of	glycolysis.	The	timing	of	glycolysis	up-regulation,	relative	to	down-regulation	 of	 oxidation,	 varies	 between	 animal	 models	 of	 LVH	(Sankaralingam	and	Lopaschuk,	2015).	Furthermore,	consistent	with	our	data,	other	 studies	have	 found	no	 significant	 changes	 in	 the	expression	of	 enzymes	involved	 in	 the	 glycolytic	 pathway.	 It	 is	 thought	 that	 the	 increase	 in	 glucose	uptake	and	in	glycolysis	is	due	to	an	increase	in	the	activity	of	these	enzymes.		For	genes	 that	were	up-regulated,	one	of	 the	most	significantly	enriched	gene	ontologies	 was	 the	 biogenesis	 of	 cellular	 components,	 such	 as	 ribosome	biogenesis	 and	 translation.	This	 is	 consistent	with	 the	generalized	 increase	 in	protein	levels	often	associated	with	cardiac	hypertrophy	(Abdellatif	et	al.,	1998,	Swynghedauw	 et	 al.,	 1984)	 and	 directly	 related	 to	 an	 increase	 in	 ribosome	translational	capacity	(Hannan	et	al.,	2003).	Gene	ontology	terms	for	biological	structure	 and	 adhesion	 were	 also	 enriched	 in	 up-regulated	 mRNAs.	
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Interestingly,	it	appears	that	changes	in	intra-cellular	structures	(such	as	actin	cytoskeleton	organization)	occurred	at	both	2	and	7	days,	whilst	 inter-cellular	structure	 changes	 (e.g.	 extracellular	matrix	organisation)	occurred	exclusively	at	 7	 days.	 These	 changes	 are	 consistent	 with	 disease	 progression,	 where	cardiomyocyte	hypertrophy	precedes	gross	morphological	changes	and	cardiac	fibrosis	 (Lorell	 and	 Carabello,	 2000).	 Up-regulation	 of	 immune	 system	processes	was	also	seen.	This	is	likely	a	result	of	the	cardiomyocytes	expressing	various	 stress-activated	 cytokines	 (Mann,	 2003),	 and	 some	 immune	 cell	infiltration	that	persisted	in	our	cardiomyocyte	preparation.	In	 interpreting	 GO-term	 enrichment	 analysis,	 it	 is	 important	 to	 note	 the	limitations	 of	 this	 method.	 GO	 analysis	 does	 not	 incorporate	 the	 degree	 of	change	of	the	gene.	For	example,	a	gene	that	is	highly	up-regulated	would	carry	the	same	weight	as	a	gene	that	is	only	slightly	up-regulated.	However,	we	have	tested	 for	 the	 extent	 to	which	 this	 limitation	 affects	 our	 interpretation	 of	 the	data	 by	 also	 conducting	 a	 gene	 set	 enrichment	 analysis	 (GSEA).	 This	method	assigns	a	weighting	to	each	gene	used	in	the	analysis	that	is	based	on	the	effect	sizes.	 Interestingly,	we	found	similar	pathways	enriched	 in	GSEA	compared	to	our	GO	analysis	(data	not	shown),	giving	us	confidence	that	this	 limitation	did	not	affect	the	results.	Another	limitation	of	GO-term	enrichment	analysis	is	the	difference	 in	 the	 depth	 of	 annotation	 of	 different	 pathways.	 Some	 gene	ontologies	have	been	studied	 in	more	detail	 than	others,	and	 therefore	would	have	more	genes	annotated	within	 that	GO-term.	This	could	explain	why	only	pathways	 that	 are	 well	 known	 to	 change	 during	 cardiac	 hypertrophy	 are	significantly	enriched	in	our	data.		Our	GO	patterns	resemble	those	seen	with	previous	mRNA	expression	studies	of	 TAC/LVH	 (Zhao	 et	 al.,	 2004,	 Park	 et	 al.,	 2011,	 van	 den	Bosch	 et	 al.,	 2006).	This	 is	 remarkable	 given	 the	 modest	 overlap	 in	 affected	 genes	 between	individual	 studies.	 To	 conclude,	 while	 the	 same	 pathways	 have	 remained	enriched,	we	have	identified	many	novel	differentially	expressed	mRNAs	within	those	 pathways,	 thereby	 unfolding	 the	 hypertrophic	 process	 in	 finer	 detail.	These	 novel	 differentially	 expressed	 mRNAs	 may	 potentially	 serve	 as	
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therapeutic	targets	in	the	future.			
5.3.2.	The	expression	of	mRNA	3’UTR	 isoforms	and	 their	 changes	during	
cardiac	hypertrophy.	We	have	generated	a	more	detailed	map	of	 the	3’UTRs	available	 in	 the	heart,	identifying	14,933	novel	3’UTRs.	The	3’UTR	harbors	many	regulatory	sequence	elements,	 such	 as	 miRNA	 and	 RBP	 binding	 sites	 (Elkon	 et	 al.,	 2013).	 This	renders	 the	 3’UTR	 very	 important	 in	 determining	 stability,	 cellular	localizations,	 and	 translation	 efficiency	 of	 the	 transcript	 (Elkon	 et	 al.,	 2013).	Having	 a	 complete	 compendium	 of	 3’UTRs	 in	 the	 cardiomyocyte	 would	 be	useful	in	more	accurately	predicting	binding	sites	for	miRNAs	and	RBPs.		When	 we	 tested	 for	 a	 net	 change	 in	 mRNA	 3’UTR	 preference	 across	 all	transcripts	 during	 cardiac	 hypertrophy,	 we	 found	 a	 small	 but	 statistically	significant	overall	shift	toward	shorter	3’UTR.	In	further	support	of	our	finding,	this	 shortening	 of	 3’UTR	 during	 heart	 disease	 has	 previously	 reported	 by	others.	A	recent	study	by	(Creemers	et	al.,	2016))	found	that	numerous	genes	in	failing	human	hearts	expressed	shorter	3’UTRs.	Another	 study	by	 (Park	et	al.,	2011),	had	reported	it	in	TAC-induced	cardiac	hypertrophy.	In	their	study,	Park	
et	 al.	 measured	 mRNA	 expression	 at	 one,	 four	 and	 twelve	 weeks	 using	microarrays	 and	 found	 evidence	 for	 widespread	 alternative	 splicing	 towards	more	 proximal	 mRNA	 3’-end	 formation	 (Park	 et	 al.,	 2011).	 We	 add	 to	 this	knowledge	a	more	accurate	and	complete	compendium	of	mRNAs	with	changed	3’UTRs	during	cardiac	hypertrophy.	Using	the	PAT-seq	method,	we	have	based	our	observations	on	extant	cardiomyocyte	3’UTRs.	 Importantly,	we	found	that	APA	 change	 was	 most	 pronounced	 at	 2d,	 a	 time	 point	 not	 included	 in	 the	previous	work.		In	 searching	 for	 individual	mRNAs	with	 changed	3’UTR	 length,	we	 found	359	genes	with	substantial	changes	in	3’-end	preference	at	2d	(log2FC	≥	±1.5),	225	of	 which	 were	 shortened	 during	 TAC.	 Only	 65	 genes	 reached	 statistical	significance	 at	 FDR<	 10%.	 While	 this	 may	 seem	 like	 a	 small	 number	 of	statistically	significant	genes	compared	to	those	found	in	other	previous	studies	
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on	 APA	 (for	 example,	 Park	 et	 al.,	 found	 211	 genes	 that	 are	 statistically	significantly	 shortened	 during	 TAC	 LVH),	 one	 should	 note	 the	 differences	 in	statistical	stringencies	between	the	studies.	Park	et	al.	filtered	their	data	for	an	unadjusted	 p-value	 of	 0.1.	 In	 our	 study,	 we	 have	 chosen	 a	 more	 stringent	statistical	 cut	 off	 of	 FDR	<10%.	Furthermore,	 in	 our	mRNA	DPA	analysis,	 one	gene	may	have	multiple	pair-wise	 comparisons	between	 its	3’UTR	peaks	 (See	Section	2.2.13.2.).	 In	 these	 cases,	multiple	 fold-changes	 belonging	 to	 the	 same	gene	will	not	be	 independent	of	 each	other,	 resulting	 in	p-values	 that	may	be	correlated.	Thus	it	is	important	to	note	that	the	adjustment	for	multiple	testing	may	 lead	 to	 FDR	 estimations	 that	 are	 too	 conservative,	 which	 needs	 to	 be	considered	 in	 interpreting	 the	 number	 of	 genes	 that	 show	 a	 ‘statistically	significant’	change	in	APA.		The	 tendency	 for	 mRNAs	 to	 generally	 express	 shorter	 3’UTR	 during	hypertrophy	 incites	 a	 number	 questions:	 What	 causes	 the	 change	 in	 mRNA	3’UTR	length?	What	are	the	biological	consequences	of	3’UTR	shortening?	More	importantly,	 does	 the	 change	 in	 3’UTR	 preference	 drive	 the	 progression	 of	cardiac	hypertrophy,	or	is	it	a	downstream	effect	of	the	disease?	Some	possible	answers	to	these	questions	are	explored	Chapter	6.			
5.3.3.	Conclusions	In	 this	 chapter,	 we	 have	 studied	 gene	 expression	 changes	 during	 cardiac	hypertrophy,	and	described	 the	3’	UTRs	expressed	 in	murine	cardiomyocytes.	Our	data	provides	an	 important	resource	for	the	3’	UTRs	present	 in	the	heart,	particularly	when	most	novel	3’	UTRs	are	tissue	specific	(Derti	et	al.,	2012).	 It	can	 be	 used	 for	miRNA	 target	 predictions,	 as	well	 as	 to	 identify	 novel	 cis-	 or	
trans-	 regulatory	 elements.	 We	 have	 also	 demonstrated	 that	 a	 number	 of	mRNAs	 changed	 the	 proportion	 of	 their	 3’	 UTRs	 in	 response	 to	 hypertrophy,	which	can	be	used	to	 identify	miRNA	and	RBP	 interactions	with	hypertrophy-specific	 3’	 UTRs.	 Furthermore,	 we	 found	 a	 statistically	 significant	 net	 change	toward	more	proximal	3’UTRs	during	cardiac	hypertrophy.	Chapter	6	explores	
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why	 and	 how	 this	 overall	 3’UTR	 shortening	 is	 present	 during	 cardiac	hypertrophy.		 	
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Chapter	6.	
Explorations	into	3’UTR	
changes	during	cardiac	
hypertrophy	 	
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6.1.	Introduction	The	3’UTR	of	mRNAs	contains	many	cis-acting	elements	that	serve	as	a	docking	platform	for	many	miRNAs	and	RBPs,	and	are	therefore	crucial	in	regulating	the	stability,	 translation,	 and	 localization	 of	 the	 mRNA	 (Elkon	 et	 al.,	 2013).	 In	Chapter	5,	we	have	shown	that	the	3’UTR	for	several	genes	are	changed	during	cardiac	hypertrophy.	Furthermore,	there	was	a	statistically	significant	net	shift	toward	 more	 proximal	 3’UTR	 across	 all	 mRNAs.	 This	 chapter	 aims	 to	investigate	the	consequences	of	this	change	in	3’UTR	preference	for	the	cell.	We	also	explore	possible	mechanisms	that	could	have	driven	the	overall	shortening	we	observed	during	cardiac	hypertrophy.			
6.2.	Results	
6.2.1.	Consequences	of	alternative	3’UTR	usage	
6.2.1.1.	Enriched	gene	sets	To	 begin	 to	 discern	 whether	 the	 change	 in	 3’UTR	 might	 have	 biological	implications	 in	 the	 progression	 of	 hypertrophy,	 we	 first	 examined	 whether	particular	 pathways	 are	 enriched	 in	 genes	 that	 are	 shortened	 or	 lengthened	during	 the	 disease.	 We	 conducted	 a	 Gene	 Set	 Enrichment	 Analysis	 (GSEA),	which	 determines	 whether	 any	 gene	 sets	 from	 the	 Molecular	 Signature	Database	 (MSigDB)	 are	 enriched	 in	 association	 with	 the	 changes	 in	 3’UTR	lengths.	All	2,981	genes	included	in	the	DPA	analysis	were	considered	for	GSEA.	Where	 multiple	 peak	 comparisons	 were	 present	 for	 a	 gene,	 the	 peak	comparison	 with	 the	maximum	 log	 fold	 change	 between	 TAC	 and	 Sham	was	used.	 The	 genes	were	 ranked	based	 on	 the	 log	 fold	 change	between	TAC	 and	sham;	genes	with	the	most	positive	log	fold	changes	were	ranked	at	the	top	of	the	list,	and	genes	with	the	most	negative	log	fold	changes	ranked	at	the	bottom	of	 the	 list.	 GSEA	 provides	 an	 enrichment	 score	 to	 assess	 how	 the	 genes	belonging	 to	 a	 defined	 Gene	 Set	 are	 distributed	 across	 the	 ranked	 list.	 This	allows	small,	statistically	insignificant	changes	in	DPA	to	be	included	in	a	global	
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pathway	 enrichment	 analysis.	 This	 is	 ideal	 for	 our	 dataset,	 where	 we	 saw	 a	significant	global	change	in	3’UTR	lengths,	but	only	a	relatively	small	number	of	individual	genes	that	made	the	threshold	for	statistical	significance.		Our	GSEA	analysis	primarily	found	enriched	sets	at	2d	(Figure	6.1).	Specifically,	gene	sets	associated	with	RNA	metabolism/splicing,	protein	ubiquitination	and	phosphorylation,	 as	 well	 as	 intracellular	 signaling	 were	 enriched	 with	 genes	that	 shifted	 towards	proximal	mRNA	3’-ends	 in	hypertrophy.	These	pathways	are	 known	 to	 be	 important	 early	 in	 the	 development	 of	 cardiac	 hypertrophy	(Frey	and	Olson,	2003),	thus	suggesting	that	the	3’UTR	shortening	of	the	genes	involved	 in	the	pathways	may	be	of	biological	 importance	 in	the	hypertrophic	process.			
	
Figure	 6.1	 Enriched	 gene	 sets	 (FDR<25%)	 in	 genes	with	more	 proximal	
3’UTRs	 during	 2	 or	 7d	 TAC.	 Results	 are	 based	 on	 GSEA	 of	 the	 full	 list	 of	protein-coding	genes	(≥2	CPM	and	≥2	3’UTRs)	ranked	based	on	the	fold-change	of	the	ratio	of	distal:proximal	expression	between	TAC	and	sham.			
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6.2.1.2.	Effect	on	miRNA	regulation	Now	 that	 we	 have	 determined	 that	 3’UTR	 shortening	 is	 associated	 with	pathways	that	are	 intimately	 linked	to	hypertrophic	growth,	we	next	explored	possible	 ways	 that	 3’UTR	 shortening	 could	 affect	 these	 pathways.	 As	 mRNA	3’UTR	contains	many	binding	sites	for	miRNAs,	we	hypothesised	that	a	change	in	mRNA	3’UTR	preference	during	hypertrophy	affects	 regulation	by	miRNAs.	We	used	miRmap,	a	miRNA	target	prediction	method	developed	by	Vejnar	et	al.	(2012),	 to	predict	miRNA-mRNA	 interactions	based	on	 the	miRNA	and	mRNA	3’UTR	 variants	 that	we	 identified	 in	 our	 small	 RNA	 and	PAT-seq	 datasets.	 Dr	Stuart	 Archer	 from	 the	 Australian	 Bioinformatics	 Platform	 conducted	 the	miRNA	target	predictions,	and	I	conducted	the	downstream	analyses,	including	reformatting	 of	 the	 data,	 differential	 analyses	 between	 sham	 and	 TAC,	 and	graphical	representations	of	the	results.		We	 have	 documented	 the	 cardiomyocyte-specific	 miRNA	 interactions	 for	 the	top	120	most	 abundant	miRNAs	 in	Appendix	 9-10.	We	next	 used	 this	 data	 to	assess	 the	 consequences	 of	 APA	 on	miRNA-target	 interactions	 during	 cardiac	hypertrophy.	miRmap	(Vejnar	and	Zdobnov,	2012)	provides	a	context	score	for	each	site	as	a	measure	of	the	strength	of	miRNA-target	interaction.	We	used	the	miRmap	 scores	 to	 calculate	weighted	miRNA	 interaction	 scores	 for	 each	gene	based	on	the	number	and	strength	of	miRNA	target	sites	 in	each	of	 the	gene’s	3’UTR	variants	and	the	relative	proportions	of	the	3’UTRs.	Changes	in	the	latter	parameter	caused	differences	in	these	scores	between	sham	and	TAC,	which	are	plotted	 as	 heat	 maps	 for	 the	 top	 10	 most	 abundant	 miRNAs	 in	 the	 heart	 in	Figure	 6.2.	 This	 illustrates	 how	 APA	 perturbs	 miRNA	 action:	 genes	 with	 an	increased	proportion	of	 longer	3’UTR	variants	become	more	strongly	targeted	by	a	miRNA,	and	genes	with	an	increased	proportion	of	shorter	3’UTR	variants	become	 less	 strongly	 targeted.	 Although	 both	 weakened	 and	 strengthened	interactions	 were	 observed	 frequently,	 a	 trend	 towards	 overall	 weaker	interactions	 with	 hypertrophy	 reached	 statistical	 significance	 for	 several	individual	 miRNAs.	 This	 included	 the	 disease-related	 miRNA-208a-5p	 (van	Rooij	and	Olson,	2012)	(e.g.	p=0.0057	at	2d,	Figure	6.2A),	as	well	as	overall	for	
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the	 120	 appreciably	 expressed	 miRNAs	 included	 in	 our	 miRmap	 analysis	(Figure	 6.2	 B).	 This	 net	 weaker	 miRNA-mRNA	 interactions	 during	 cardiac	hypertrophy	concurred	with	the	observed	overall	trend	towards	shorter	mRNA	3’UTRs.		
 
Figure	6.2.	Changes	in	miRNA	targeting	strength	due	to	changes	in	mRNA	
3’-end	 preference.	 A)	 Heat	 maps	 showing	 the	 difference	 in	 weighted	interaction	 scores	 for	 target	 genes	 of	 the	 ten	 most	 abundant	 cardiomyocyte	miRNAs	as	well	as	miR-208a-5p	at	2d	(top)	and	7d	(bottom).	Red	reflects	 less	repression	 by	 the	miRNA	 during	 TAC;	 blue	 indicates	more	 repression	 during	TAC.	B)	Overall	changes	in	miRNA	targeting	during	TAC.	Histogram	shows	the	difference	 in	 the	 weighted	 3’UTR	 score	 between	 TAC	 and	 sham	 for	 the	combined	 mRNA	 targets	 of	 the	 top	 120	 miRNAs	 expressed	 in	 the	cardiomyocyte.	 Top:	 2d,	 Bottom:	 7d	 (blue	 ****	 p<<0.0001,	 two-tailed,	 one-sample	Student’s	t-test). 	
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6.2.1.3.	Effect	on	translational	efficiency	We	next	checked	whether	3’UTR	isoform	variants	of	the	same	gene	is	translated	at	different	efficiencies.	Assessing	changes	in	mRNA	translation	due	to	shifts	in	3’UTR	variant	proportion	would	be	difficult	 to	assess	directly	 in	 the	TAC/LVH	model.	 Thus,	 we	 used	 an	 experimental	 approach	 combining	 RT-qPCR	 with	sucrose	 density	 gradient	 ultracentrifugation	 (Figure	 6.3)	 in	 HL-1	cardiomyocytes	 (Claycomb	 et	 al.,	 1998).	 While	 the	 HL-1	 context	 does	 not	completely	 mimic	 cardiomyocytes	 in	 the	 heart	 or	 indeed	 the	 effects	 of	hypertrophy,	 it	 can	 provide	 evidence	 that	 different	 3’UTRs	 associate	 with	distinct	 translation	 outcomes.	 We	 therefore	 assessed	 the	 translation	 state	 of	three	different	mRNAs	with	3’-end	variants	 in	PAT-Seq	(Figure	6.3,	panels	 ‘i’).	The	experiments	were	conducted	with	assistance	from	Dr.	Tony	Duan.		Although	 PAT-Seq	 had	 revealed	 a	 novel	 shorter	 3’UTR	 for	 Prkaa2	 mRNA	 in	native	cardiomyocytes,	there	was	no	detectable	expression	of	this	variant	in	HL-1	cells	(Figure	6.3Bii).	Thus,	both	primer	pairs	returned	an	identical	polysome	profile,	i.e.	that	of	the	longer	mRNA	variant	(Figure	6.3Biii),	and	this	served	as	a	positive	control	for	the	robustness	and	reproducibility	of	the	overall	approach.	Analysis	 of	 GSK3b	 illustrated	 how	 a	 complex	 combination	 of	 alternative	promoter	 usage	 and	 splicing	 can	 generate	 mRNA	 variants	 differing	 in	 3’-end	position.	 HL-1	 cells	 expressed	 both	 mRNA	 variants	 (Figure	 6.3Cii)	 and	 two	distinct	polysome	profiles	were	 recorded	 (Figure	6.3Ciii).	Of	note,	 the	 ‘longer’	variant	 of	 GSK3b	 mRNA	 sediments	 into	 denser	 polysomal	 regions	 than	 its	‘shorter’	 variant,	 likely	due	 to	overriding	 repressive	 elements	 in	 the	 alternate	upstream	exons	of	the	latter	variant.	Finally,	SRF	emerged	as	a	clear	example	of	a	 single	 transcript	 structure	 with	 variants	 differing	 solely	 in	 3’UTR	 length	(Figure	6.3Di).	 	 Again,	 distinct	 polysome	profiles	were	 seen	with	 each	primer	pair	 (Figure	6.3Dii&iii).	The	SRF	profiles	 can	be	 interpreted	solely	 in	 terms	of	3’UTR	length;	here	we	see	the	expected	trend	of	more	efficient	translation	of	the	shorter	 variant	 as	 compared	 to	 the	 longer	 variant.	 This	 illustrates	 how	hypertrophy-induced	APA	has	the	capacity	to	affect	the	utilisation	of	mRNA	for	protein	synthesis. 
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Figure	 6.3.	 Effect	 of	 mRNA	 3’-end	 preference	 on	 polysome	 association.	Lysates	 of	 HL-1	 murine	 cardiomyocytes	 were	 separated	 by	 sucrose	 density	gradient	 ultracentrifugation.	 A)	 Upper	 panel:	 Representative	 absorbance		profile	with	different	 ribosomal	 complexes	marked	 above	 and	 fractions	 taken	for	RNA	extraction	below.	Lower	panel:	Representative	electrophoresis	 image	showing	 the	 integrity	 of	 RNA	 isolated	 from	 gradient	 fractions.	 B-D)	 RT-qPCR	analyses	as	in	Fig.	6C	to	assess	polysome	association	of	different	mRNA	3’-end	variants	 for	 B),	 Protein	 Kinase,	 AMP-Activated,	 Alpha	 2	 Catalytic	 Subunit	(PRKAA2),	C),	GSK3b,	and	D),	SRF.	Panels	i),	transcript	structures	for	each	gene	as	 annotated	 in	 Ensembl	 v.81.	 Panels	 ii),	 RT-qPCR	 analysis	 whole	 cell	 lysate	RNA	 (n=5-7,	 mean±SEM;	 blue	 *p<0.05,	 **p<0.01,	 two-tailed,	 two	 sample	Student’s	 t-test);	 Panels	 iii),	 RT-qPCR	analysis	 of	RNA	 from	gradient	 fractions	(n=5,	mean±SEM).	RT-qPCR	values	for	gradient	fractions	were	normalized	to	a	Renilla	 Luciferase	 RNA	 spike-in	 to	 generate	 authentic	 gradient	 distribution	profiles.	 Grey	 bars:	 amplification	 using	 primers	 measuring	 combined	abundance	 of	 mRNAs	 with	 both	 proximal	 and	 distal	 3’-ends;	 Black:	amplification	using	primers	specific	for	the	mRNA	with	distal	3’-end.	 	
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6.2.2.	Possible	mechanisms	driving	the	change	in	3’UTR	usage	We	 next	 investigated	 possible	mechanisms	 that	may	 have	 contributed	 to	 the	statistically	 significant	 overall	 shift	 toward	 proximal	 3’UTRs	 during	 cardiac	hypertrophy.	 There	 are	 three	 possible	 processes	 that	 could	 lead	 to	 the	preferential	expression	of	the	shorter	mRNA	3’UTR	variants	in	the	cell:	1)	post-transcriptional	 degradation	 of	 longer	 3’UTR	 variants	 (e.g.	 by	 miRNAs);	 2)	alternative	 splicing	 leading	 to	 alternative	 terminal	 exon	 usage;	 3)	 different	poly(A)	 site	 usage	 within	 one	 primary	 transcript	 (e.g.	 APA	 within	 the	 same	terminal	exon)	(Elkon	et	al.,	2013).			
6.2.2.1.	Post-transcriptional	degradation	of	longer	3’UTR	variants	by	miRNAs	The	 interaction	 between	 mRNA	 and	 miRNA-guided	 RISC	 complex	 has	previously	 been	 shown	 to	 result	 in	 degradation	 of	 the	 mRNA	 (Akman	 et	 al.,	2015).	 As	 mRNA	 variants	 with	 extended	 3’UTRs	 are	 likely	 to	 harbor	 more	miRNA	target	sites	than	those	with	shorter	3’UTRs	(Hollerer	et	al.,	2014b),	an	up-regulation	 of	 certain	 miRNAs	 in	 the	 cell	 could	 result	 in	 their	 selective	degradation,	 effectively	 shifting	 the	 balance	 towards	 shorter	 mRNA	 variants.	Conversely,	it	has	also	been	observed	that	a	feedback	loop	exists	where	miRNAs	themselves	 can	 be	 degraded	when	 their	 targets	 are	 absent	 (Chatterjee	 et	 al.,	2011).	 In	 this	 instance,	 a	 shift	 in	 balance	 towards	 shorter	 3’UTRs	 would	 be	expected	to	 lead	to	a	decrease	in	affected	miRNAs.	We	used	our	miRNA	target	prediction	analysis	discussed	in	Section	6.2.1	to	assess	whether	either	of	these	relationships	 is	 present	 in	 our	 data.	 We	 found	 no	 significant	 correlation	between	 3’UTR	 shortening	 and	 relevant	 miRNA	 expression	 (Figure	 6.4),	suggesting	 that	 interdependence	 between	 miRNA	 and	 mRNA	 levels	 may	 not	play	a	major	role	in	hypertrophy-associated	APA.		
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Figure	 6.4.	 Lack	 of	 correlation	 between	 changes	 in	 mRNA	 3’-end	
preference	 between	 TAC	 and	 sham	 samples	 with	 changes	 in	 miRNA	
expression	(2d:	R2=	0.0112;	7d:	R2=	0.0030).	The	averaged	expression	change	of	 all	 mRNAs	 predicted	 by	miRmap	 [33]	 to	 be	 targets	 of	 a	 given	miRNA	 are	plotted	against	the	differential	expression	of	that	miRNA.	Here,	data	points	for	differentially	expressed	miRNAs	at	FDR<5%	are	shown	in	red.			
6.2.2.2.	Alternative	splicing		The	 change	 in	 mRNA	 3’-end	 preference	 that	 we	 observed	 could	 also	 have	resulted	from	alternative	splicing	leading	to	alternative	terminal	exon	usage.	A	previous	 study	 have	 reported	 that	 TAC-induced	 cardiac	 hypertrophy	 is	associated	with	distinct	alternative	splicing	patterns	due	to	altered	expression	of	 splicing	 factors	 (Kim	 et	 al.,	 2014).	 	 In	 this	 project,	 we	 did	 not	 perform	 an	RNA-seq	of	all	 transcripts,	 and	 thus	have	no	 information	on	 the	expression	of	alternatively	spliced	 isoforms	 in	our	cardiomyocyte	samples.	As	a	preliminary	test	into	whether	alternative	splicing	may	have	played	a	role	in	the	shortening	that	we	observed,	we	 investigated	whether	 there	 is	a	correlation	between	 the	change	 in	 3’UTR	 length	 during	 hypertrophy,	 and	 the	 number	 of	 known	alternatively	spliced	isoforms	annotated	in	Ensembl	v.81.	We	hypothesized	that	
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if	 the	 3’UTR	 shortening	 is	 in	 fact	 due	 to	 alternative	 splicing,	 then	 genes	 that	become	 shortened	 during	TAC	would	 tend	 to	 have	more	 alternatively	 spliced	variants.	We	were	not	able	to	detect	such	a	relationship	(Figure	6.5),	which	may	suggest	 that	 alternative	 splicing	 also	 do	 not	 play	 major	 roles	 in	 determining	hypertrophy-associated	APA.  
 
 
Figure	 6.5.	 Lack	 of	 correlation	 between	 changes	 in	mRNA	 3’-end	 preference	between	 TAC	 and	 sham	 samples	 (taken	 from	 Fig.	 6)	 with	 the	 propensity	 of	genes	for	alternative	splicing	(taken	from	Ensembl	v.	81)	(2d:	p-value=	0.1069;	7d:	p-value=	0.8578;	two-tailed,	two-sample	Student’s	t-test)	
 
6.2.2.3.	Alternative	cleavage	and	polyadenylation	A	third	possible	mechanism	for	the	overall	shortening	of	3’UTRs	during	TAC	is	alternative	cleavage	and	polyadenylation	(APA)	within	one	primary	 transcript	(Elkon	 et	 al.,	 2013).	 Previous	 studies	 in	 cancer	 have	 demonstrated	 that	 the	3’UTR	 shortening	 during	 the	 disease	 resulted	 from	 APA	 (Akman	 et	 al.,	 2015,	Mayr	 and	 Bartel,	 2009a).	 Thus,	 APA	 presents	 the	 most	 likely	 mechanism	 in	driving	 3’UTR	 shortening	 that	we	 observed	 during	 cardiac	 hypertrophy.	 Two	
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main	mechanisms	drive	APA:	A)	changes	in	gene	transcription,	or	B)	the	result	of	 altered	 activity/specificity	 of	 the	 3’end	 cleavage	 and	 polyadenylation	machinery	(Elkon	et	al.,	2013,	Ji	et	al.,	2011,	Pinto	et	al.,	2011).	We	investigated	both	of	these	possibilities	during	cardiac	hypertrophy.		A	 number	 of	 studies	 have	 reported	 the	 interplay	 between	 transcription	 and	APA.	One	hypothesis	proposes	a	positive	correlation	between	gene	expression	level	 and	 the	 usage	 of	 proximal	 poly(A)	 sites	 (Elkon	 et	 al.,	 2013).	 It	 was	demonstrated	that	short	3’-UTR	isoforms	are	more	abundant	in	genes	that	are	highly	expressed	compared	 to	 those	 that	 are	 lowly	expressed	 (Ji	 et	 al.,	 2011).	Furthermore,	 it	 was	 shown	 that	 enhancing	 transcription	 through	 the	 gene	promoter	 led	 to	 increased	 cleavage	 at	more	proximal	 3’UTRs	 (Ji	 et	 al.,	 2011).	Since	 the	 proximal	 cleavage	 site	 is	 encountered	 first	 by	 the	 3’end	 processing	machinery	 during	 transcription,	 it	 has	 an	 advantage	 for	 being	 used	 over	 the	distal	site	(Elkon	et	al.,	2013),	and	therefore	may	preferentially	be	chosen	when	a	rapid	increase	in	mRNA	expressions	is	required.	The	second	emerging	theory	involves	 the	 kinetic	 coupling	 between	 transcription	 elongation	 and	 3’-end	cleavage:	A	faster	rate	of	transcription	by	RNA	pol	II	may	result	in	the	skipping	of	more	proximal	3’UTR	cleavage	sites,	and	therefore	lead	to	an	increased	usage	of	distal	cleavage	sites	 (Elkon	et	al.,	2013).	This	resembles	 the	mechanism	for	alternative	 splicing,	 whereby	 a	 slow	 moving	 RNA	 Pol	 II	 may	 result	 in	 the	inclusion	of	otherwise	skipped	exons	(de	la	Mata	et	al.,	2003).	In	support	of	this	theory,	it	has	been	shown	in	D.	melanogaster	that	reduced	RNA	Pol	II	elongation	kinetics	results	in	the	increase	in	transcripts	with	more	proximal	poly(A)	sites	(Pinto	et	al.,	2011).		Interestingly	however,	we	did	not	find	a	correlation	between	changes	in	mRNA	expression	 and	 changes	 its	3’UTR	 length	during	TAC	 in	our	data	 (Figure	6.6).	This	may	suggest	that	during	hypertrophy,	the	3’UTR	changes	are	not	driven	by	changes	 in	 transcription.	 However,	 it	 is	 also	 possible	 that	 there	 exists	 a	feedback	 loop	 whereby	 the	 3’UTR	 lengths	 in	 turn	 affects	 the	 transcript	expression	 in	 the	 cell.	 Short	 3’UTRs	 are	 generally	more	 stable,	 as	 it	 lacks	 the	destabilizing	 elements	 present	 in	 longer	 3’UTRs	 and	 avoids	 other	 cellular	
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degradation	mechanisms	 that	 affect	 longer	 3’UTRs	 (Mayr	 and	 Bartel,	 2009b).		One	would	expect	that	a	shift	towards	more	proximal	3’UTR	would	be	reflected	in	an	increase	in	mRNA	expression	during	TAC.	As	we	also	did	not	observe	this	correlation	 in	 our	 data,	 it	 is	 possible	 that	 perhaps	 we	 have	 captured	 this	convoluted	 feedback	 loop	 between	 transcription	 and	 3’UTR	 lengths	 such	 that	any	 affect	 between	 transcription	 and	 3’UTR	 length	 changes	 during	 TAC	 had	effectively	cancelled	each	other	out.	
	
 
Figure	 6.6.	 Lack	 of	 correlation	 between	 changes	 in	mRNA	 3’-end	 preference	between	 TAC	 and	 sham	 samples	 (taken	 from	 Fig.	 6)	 with	 differential	 mRNA	expression	(taken	from	Fig.	5)	(2d:	R2=	0.0002;	7d:	R2=	0.0045).	Data	points	for	mRNAs	with	3’-end	preference	change	at	FDR<10%	are	shown	in	red.			This	left	altered	activity/specificity	of	the	3’-end	cleavage	and	polyadenylation	machinery	as	a	plausible	explanation	for	the	change	in	3’UTR	length.	There	are	many	 reports	 in	 the	 literature	 on	 specific	 factors	 directly	 regulating	 3’-UTR	length	 (Elkon	 et	 al.,	 2013,	 Gruber	 et	 al.,	 2014,	 Yao	 et	 al.,	 2012).	 For	 example,	during	B-cell	development,	low	CSTF2	in	early	stages	of	development	results	in	3’-UTR	cleavage	at	more	distal	sites,	while	high	CSTF2	levels	in	activated	B-cells	
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is	associated	with	shorter	3’UTRs	(Takagaki	and	Manley,	1998,	Takagaki	et	al.,	1996).	Furthermore,	co-	depletion	of	CSTF2	and	its	paralogue	CSTF2τ	 in	HeLa	cells	resulted	in	longer	3’-UTRs.	Somewhat	surprisingly,	the	opposite	effect	has	also	 been	 reported	 for	 other	 components	 of	 the	 3’-end	 cleavage	 and	polyadenylation	 machinery.	 For	 example,	 knockdown	 of	 the	 APA	 factors	CFIm25	 (also	 known	 as	 CPSF5	 and	 NUDT21)	 and	 CFIm68	 (also	 known	 as	CPSF6)	 in	 HEK293	 cells	 led	 to	 a	 global	 shortening	 of	 3’UTRs	 (Martin	 et	 al.,	2012).	Thus,	we	next	investigated	whether	there	are	changes	in	the	expression	of	factors	involved	in	3’-end	cleavage	and	polyadenylation	during	hypertrophy.	First,	we	examined	the	mRNA	levels	of	these	factors	in	our	PAT-seq	data	as	well	as	 through	 RT-qPCR.	 The	 PAT-Seq	 data	 indicated	 differential	 expression	 of	some	 complex	 subunits	 and	 regulators,	 but	 no	 coherent	 change	 of	 the	whole	machinery	with	hypertrophy	(Figure	6.7A).	We	also	confirmed	using	RT-qPCR	the	 expression	 of	 six	 APA	 factors	 that	 have	 previously	 been	 identified	 to	 be	directly	linked	to	3’UTR	length.	RT-qPCR	analyses	did	not	find	any	statistically	significant	changes	at	the	mRNA	level	(Figure	6.7B).	This	contradicted	previous	studies,	including	one	which	found	that	3’-UTR	shortening	during	human	heart	failure	is	associated	with	lowered	PABPN1	transcript	levels.		It	was	possible	that	many	of	these	factors	are	 instead	regulated	at	the	protein	level.	 To	 check	 this,	we	 conducted	 a	 preliminary	 exploration	 into	 the	 protein	levels	 of	 some	 factors	 in	 the	 APA	 machinery	 through	 Western	 Blot	 (Figure	6.7C,D).	Many	proteins	were	tested,	including	the	proteins	of	the	transcripts	we	tested	through	RT-qPCR	(such	as	PABPN1,	CPEB1,	CFIm68,	CFIm25,	CSTF2,	and	CSTF2t).	However,	some	of	the	antibodies	were	not	able	to	be	optimized	in	time	for	the	submission	of	this	thesis.	Thus,	we	also	included	other	proteins,	such	as	CPSF1,	which	is	responsible	for	recognizing	the	PAS	motif,	and	SYMPK,	a	major	structural	 protein	 of	 the	 3’-end	 cleavage	 and	 polyadenylation	machinery.	 Our	preliminary	 results	 from	 this	 experiment	 suggest	 a	 decrease	 in	 protein	 levels	for	 PABPN1	 at	 both	 2	 and	 7	 days,	 and	 CPSF1	 at	 7	 days	 only.	We	 also	 saw	 a	higher	 level	of	CFIm68	and	SYMPK	at	both	 time	points,	as	well	as	CPEB1	at	7	days.	Unfortunately,	there	were	large	variations	within	the	groups,	including	in	the	extent	of	hypertrophy	induced	by	the	TAC	surgery,	as	indicated	by	the	levels	
		 138	
of	 the	 hypertrophic	marker	 ANP	 (Figure	 6.7C,	 D);	 Since	we	 did	 not	 have	 any	protein	lysates	from	the	samples	originally	used	for	sequencing,	we	used	fresh	samples	taken	from	mice	that	underwent	an	identical	TAC	surgery,	euthanized	at	2	and	7	days.	Thus,	these	experiments	will	have	to	be	repeated	in	the	future	to	confirm	these	preliminary	observations.		 	
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Figure	 6.7.	 The	 expression	 of	 factors	 involved	 in	 3’-end	 cleavage	 and	
polyadenylation	 during	 cardiac	 hypertrophy.	 A)	 Heat	 map	 showing	 the	mRNA	expression	of	APA	factors	during	TAC	based	on	the	PAT-seq	dataset,	with	no	statistical	significance	threshold.	The	list	of	genes	are	derived	from	(Gruber	et	al.,	2014).	B)	The	mRNA	expression	of	selected	APA	factors	validated	by	RT-qPCR.	n=4-5	pairs,	mean±SEM;	blue	**p<0.01,	two-tailed,	two-sample	Student’s	t-test.	Genes	 are	 chosen	based	on	 reports	 of	 previous	 involvement	 in	APA.	C)	Representative	western	blot	of	selected	factors	involved	in	the	3’-end	cleavage	and	polyadenylation	machinery,	based	on	4	technical	replicates.	ANP	was	used	as	a	measure	for	cardiac	hypertrophy.	GAPDH	was	used	as	a	loading	control.	D)	The	 protein	 levels	 based	 on	 densitometry,	 averaged	 across	 4	 technical	replicates,	 n=3	 pairs.	 Shown	 is	 the	mean±SEM.	 Full	 names	 for	 the	 genes	 and	
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proteins	 investigated	 are	 as	 follows:	 Cleavage	 stimulation	 factor	 subunit	 2	(CSTF2),	 Cleavage	 stimulation	 factor	 subunit	 2t	 (CSTF2t),	 Cleavage	 factor	 Im	25kd	 (CFIm25),	 Cleavage	 factor	 Im	 68kd	 (CFIm68),	 Poly(A)	 binding	 protein	nuclear	 1	 (PABPN1),	 Cytoplasmic	 polyadenylation	 element	 binding	 protein	 1	(CPEB1),	 Cleavage	 and	 polyadenylation	 specific	 factor	 1	 (CPSF1),	 Symplekin	(SYMPK).		
6.3.	Discussion	In	 this	 chapter,	 we	 have	 explored	 the	 possible	 consequences	 of	 changes	 in	3’UTR	 lengths	 in	 the	 context	 of	 cardiac	 hypertrophy.	 We	 discovered	 specific	pathways	 that	 are	 enriched	 for	 genes	with	 shortened	3’UTRs,	 suggesting	 that	3’UTR	 shortening	 is	 a	 deliberate,	 regulated	process	 during	 the	progression	of	this	disease.	 Interestingly,	 the	enriched	gene	sets	 largely	referenced	processes	that	are	not	targeted	by	transcriptional	change	(described	in	Section	5.2.1).	 In	further	support	to	the	importance	of	3’UTR	shortening	during	disease,	we	found	that	 differences	 3’UTR	 lengths	 affect	 translational	 efficiency.	 The	 3’UTRs	 of	mRNAs	contain	binding	sites	for	miRNAs	and	RBPs	that	could	have	affected	this	change	in	translational	efficiency.	However,	as	our	polysome	gradient	analyses	also	suggests,	this	effect	of	3’UTR	lengths	on	translational	efficiency	may	also	be	complicated	 by	 the	 presence	 of	 alternatively	 spliced	 isoforms.	 More	 in-depth	studies	will	 need	 to	 be	 conducted	 in	 the	 future	 to	 delineate	 the	 effects	 of	 the	different	mRNA	processing	pathways.	What	could	cause	a	change	in	mRNA	3’-end	preference	during	LVH?	Alternative	terminal	exon	usage,	changes	at	the	transcriptional	level	(Elkon	et	al.,	2013,	Ji	et	al.,	2011,	Pinto	et	al.,	2011),	or	an	 interrelationship	with	mRNA	and	 targeting	miRNA	 expression	 level	 were	 all	 plausible	 causes	 (Chatterjee	 et	 al.,	 2011,	Danckwardt	et	al.,	2008).	Our	preliminary	analysis	did	not	find	any	statistically	significant	correlations	between	these	factors	and	the	changes	in	3’UTR	length.	However,	a	more	thorough	study	will	need	to	be	conducted	 in	the	 future.	 It	 is	
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possible	that	all	of	these	factors	in	fact	contribute	to	determining	global	3’UTR	lengths,	in	which	case	it	would	not	have	been	possible	to	pinpoint	an	individual	contributing	 factor	 through	our	methods	of	analysis.	 It	has	been	hypothesised	that	 altered	 activity	 of	 the	multi-subunit	 3’-end	 cleavage	 and	 polyadenylation	machinery	 is	 involved	 in	 the	preferential	 use	 of	 proximal	PAS	 in	proliferative	cells	 (Elkon	 et	 al.,	 2013).	 Our	 sequencing,	 qPCR,	 and	 Western	 blot	 data	 of	specific	 mRNA	 3’UTR	 factors	 add	 to	 this	 wealth	 of	 knowledge,	 although	 the	evidence	 for	 this	 is	 as	 yet	 inconclusive.	 While	 expression	 levels	 of	 the	 APA	machinery	 generally	 correlate	 with	 the	 cellular	 proliferative	 potential,	 their	systematic	 depletion	 by	 RNAi	 also	 caused	 3’UTR	 shortening	 (Gruber	 et	 al.,	2014).	Selective	changes	to	the	activity	of	critical	APA	components,	perhaps	by	post-translational	 modifications	 triggered	 through	 hypertrophy-associated	signaling	pathways,	remain	particularly	interesting	options	to	explore	in	future	research.	 It	 would	 be	 interesting	 to	 use	 high	 throughput	 methods	 such	 as	Sequential	 Window	 Acquisition	 of	 all	 Theoretical	 fragment	 ion	 spectra	(SWATH)	mass	spectrometry	to	generate	the	global	proteomics	changes	during	cardiac	 hypertrophy,	 and	 correlate	 these	 changes	 to	 the	 changes	 in	 3’UTR	lengths.	 Once	 a	 critical	 APA	 component	 has	 been	 identified,	 it	 would	 be	interesting	to	study	whether	the	shortening	of	3’UTR	is	a	necessary	component	for	 hypertrophic	 growth.	 For	 example,	 would	 inhibiting	 3’UTR	 shortening	prevent	 the	 cardiomyocyte	 to	 undergo	 hypertrophic	 growth?	 This	 analysis	would	 establish	 whether	 there	 is	 a	 causal	 relationship	 between	 changes	 in	mRNA	3’end	processing	and	the	development	of	cardiac	hypertrophy,	and	thus	would	unveil	critical	targets	for	therapeutic	intervention.	Furthermore,	it	would	also	 be	 interesting	 to	 investigate	 what	 would	 happen	 to	 hypertrophic	cardiomyocytes	if	the	changes	in	3’UTR	were	reverted	back	experimentally.		In	 summary,	 this	 chapter	 has	 explored	 possible	 implications	 of	 3’UTR	shortening	 in	 the	 heart,	 and	 has	 began	 to	 entangle	 the	 possible	 mechanisms	behind	 3’UTR	 regulation	 during	 disease.	 Future	 efforts	 should	 be	 directed	towards	 identifying	 the	 molecular	 players	 driving	 these	 events	 in	 both	proliferative	and	hypertrophying	cells,	as	they	may	represent	attractive	targets	
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for	 novel	 therapy	 development	 in	 a	 variety	 of	 pathologies,	 including	 cancer	(Hollerer	et	al.,	2014b)	and	cardiac	disease	(Hynes	et	al.,	2012).		 	
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Chapter	7.	
General	Discussion	 	
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7.	General	Discussion	This	 thesis	 presents	 a	 documentation	 of	 non-coding	 and	 protein	 coding	 RNA	profiles	 of	 normal,	 pre-hypertrophic,	 and	 compensated	 hypertrophic	cardiomyocytes.	 	Although	we	have	also	described	the	expression	and	changes	of	lncRNAs,	we	have	focused	more	specifically	on	the	expression	of	miRNA	and	mRNA	 3’UTR	 variants.	 Firstly,	 a	 static	 picture	 of	 all	 the	 transcript	 variants	present	 in	cardiomyocytes	was	generated,	and	then	the	data	was	analysed	 for	differences	in	both	overall	expression	as	well	as	in	processing	between	control	and	hypertrophic	samples.		
7.1.	The	 expression	of	miRNA	and	mRNA	3’UTR	processing	 variations	 in	
the	cardiomyocyte	Our	 data	 showed	 that	 the	 expression	 of	miRNA	 and	mRNA	 3’UTR	 processing	variations	 is	 very	 common	 in	 the	 heart.	 For	 example,	 almost	 all	 expressed	miRNAs	presented	some	degree	of	processing	variations	such	as	arm	bias,	non-templated	 additions,	 5’-	 and	 3’-	 isomiRs,	 and	 internal	 editing.	 Similar	 to	previous	 findings	 (Ulitsky	 et	 al.,	 2012,	 Spies	 et	 al.,	 2013),	we	 also	 found	 that	mRNAs	 have	 many	 3’UTR	 variants	 (on	 average	 2.3	 3’UTR	 per	 gene).	Interestingly,	 we	 also	 discovered	 many	 3’UTRs	 that	 were	 not	 previously	annotated.	Combined,	our	findings	suggests	that	the	miRNA-mRNA	interaction	network	in	the	cardiomyocyte	may	be	more	complicated	than	what	is	currently	known,	with	many	more	possible	interactions	from	the	same	miRNA	and	mRNA	loci	than	previously	predicted.		It	is	critical	to	include	all	expressed	miRNA	and	mRNA	 3’UTR	 variants	 when	 determining	 the	 impact	 of	 a	 miRNA	 in	 the	 cell.	Current	target	miRNA-mRNA	target	prediction	algorithms	are	mostly	based	on	the	3’	UTRs	from	cDNA	sequence	repositories	such	as	Refseq	(Pruitt	et	al.,	2005,	Majoros	and	Ohler,	2007).	This	only	 includes	annotated	3’	UTRs,	and	does	not	take	into	account	3’	UTRs	that	are	specifically	expressed	in	the	cardiomyocytes.	The	miRNA	target	predictions	are	also	based	on	the	canonical	miRNA	sequence	defined	in	miRBase.	As	such,	the	target	prediction	results	may	not	be	reflective	
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of	 the	 miRNA-mRNA	 interactions	 actually	 present	 in	 the	 cardiomyocyte.	 We	have	generated	a	database	of	predicted	miRNA:mRNA	interactions	based	on	the	different	processing	variants	expressed	in	the	heart.			
7.2.	Changes	in	mRNA	3’UTR	expressions	during	cardiac	hypertrophy	Although	 there	 have	 been	 many	 reports	 on	 miRNA	 and	 mRNA	 expression	changes	during	cardiac	hypertrophy	in	the	literature,	our	study	marks	the	first	to	 use	 enriched	 cardiomyocytes	 during	 the	 hypertrophic	 response.	 Previous	studies	have	used	either	the	LV,	or	the	whole	heart	(van	Rooij	et	al.,	2006,	Sayed	et	al.,	2007,	Tatsuguchi	et	al.,	2007,	Cheng	et	al.,	2007,	Yang	et	al.,	2012,	Hu	et	al.,	2012).	 Furthermore,	 most	 studies	 had	 been	 based	 on	 microarray	 analysis	(Sayed	et	al.,	2007,	Cheng	et	al.,	2007,	Tatsuguchi	et	al.,	2007,	van	Rooij	et	al.,	2006),	 resulting	 in	 datasets	 defined	 only	 by	 the	 probes	 represented	 on	 the	arrays.	 Since	 the	 processing	 variants	 of	 transcripts	 have	 not	 been	 fully	annotated,	many	isoforms	would	not	be	captured	by	microarray	analysis,	 thus	presenting	 a	 limitation	 to	 such	 data.	 More	 sensitive	 detection	 using	 next-generation	 sequencing	 data,	 such	 as	 the	 data	 generated	 from	 our	 study,	 is	required	 to	 fully	 appreciate	 the	 role	 of	 miRNA	 and	 3’UTR	 dynamics	 during	normal	and	diseased	states	of	the	heart.		An	important	aspect	of	our	study	is	its	focus	on	the	pre-hypertrophic	stage	(2d)	and	 comparison	 to	 compensated	 LVH	 (7d).	 Most	 previous	 gene	 expression	studies	 in	 TAC/LVH	 reported	 change	 only	 at	 one	 week	 and	 beyond.	 This	examination	 of	 pre-hypertrophic	 cardiomyocytes	 allows	 us	 to	 distinguish	between	 changes	 that	 potentially	 play	 a	 role	 in	 the	 instigation	 of	 the	 disease	from	 changes	 that	 are	 a	 downstream	 consequence	 of	 the	 disease.	We	noticed	rapid	 and	 pronounced	 changes	 in	 mRNA	 expression,	 while	 miRNA	 changes	lagged	behind	in	comparison.	Our	data	at	7d	broadly	concurs	with	prior	miRNA	expression	studies	(Sayed	et	al.,	2007,	Cheng	et	al.,	2007,	Yang	et	al.,	2012,	Hu	et	al.,	 2012).	 (Sayed	 et	 al.,	 2007))	 sampled	whole	 hearts	 at	 1d,	 7d	 and	 14d	 and	microarray	 analysis	 similarly	 detected	 more	 pronounced	 miRNA	 changes	 at	
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later	 times.	 A	 number	 of	 reasons	 may	 explain	 the	 relative	 delay	 in	 miRNA	expression	changes.	First,	miRNAs	have	been	reported	to	be	much	more	stable	than	mRNA	transcripts,	with	half-lives	>5	days	(Gantier	et	al.,	2011).	Thus,	an	observed	 down-regulation	 of	 miRNA	 would	 take	 longer	 than	 that	 of	 mRNA	transcripts.	Second,	the	expression	of	a	mature	miRNA	is	also	dependent	on	the	time	required	to	process	its	pri-	and	pre-miRNAs	(Gantier	et	al.,	2011,	Schmitt	et	al.,	2012).	However,	it	could	also	be	argued	that	the	delayed	miRNA	response	we	 observed	 is	 perhaps	 because	 the	miRNA	 transcription	 changes	 do	 indeed	occur	secondary	to	other	upstream	changes	during	the	hypertrophic	response.	Many	 miRNAs	 are	 processed	 from	 the	 introns	 of	 protein-coding	 genes	 (van	Rooij	 et	 al.,	 2009),	 and	as	 such	 the	 change	 in	 the	expression	of	 these	miRNAs	would	be	expected	to	be	dependent	on	the	change	in	these	host	genes.	Another	time-course	study	in	melanoma	cells	similarly	reported	early	changes	to	mRNA	expression,	 followed	 by	 delayed	miRNA	 changes	 (Nazarov	 et	 al.,	 2013).	 They	suggested	that	the	primary	increase	in	the	levels	of	transcription	factors	in	the	initial	mRNA	response	was	required	for	the	downstream	regulation	of	miRNAs	(Nazarov	 et	 al.,	 2013).	 The	 requirement	 for	 initial	 changes	 in	 transcription	factor	activity,	together	with	changes	in	chromatin	state	at	miRNA	loci,	has	also	been	postulated	elsewhere	 in	 the	 literature	 (Kai	and	Pasquinelli,	2010). Thus,	the	 late	 change	 in	miRNA	expression	observed	 in	our	 study	might	delimit	 the	importance	 of	 miRNAs	 for	 pre-hypertrophic	 processes,	 pointing	 to	 perhaps	early	changes	in	mRNAs	as	a	means	of	effecting	downstream	miRNA	regulation. The	 most	 distinctive	 feature	 of	 our	 study	 on	 transcriptional	 response	 to	pressure	overload	was	our	analysis	of	the	change	in	processing	variants	of	both	miRNAs	and	mRNA	3’UTRs.	Cardiac	hypertrophy	is	a	dynamic	process	involving	many	 levels	 of	 gene	 regulation.	 However,	 previous	 studies	 have	 generally	focused	only	on	one	aspect	of	gene	regulation	in	cardiac	hypertrophy.	Our	study	on	 the	 other	 hand	 makes	 a	 key	 advance	 in	 understanding	 control	 by	 both	miRNA	and	mRNA	3’UTR	expression,	and	considered	alternative	processing	of	these	 transcripts.	Most	 strikingly,	we	observed	an	early	 and	pronounced	 shift	towards	 shorter	 mRNA	 3’UTRs	 during	 LVH,	 a	 phenomenon	 more	 commonly	
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associated	with	proliferation	and	cancer	 (Hollerer	et	al.,	2014b).	 It	 is	possible	that	APA	is	regulated	during	cardiac	hypertrophy.	First,	 it	has	previously	been	shown	 that	 a	 set	 of	 proliferative	 fetal	 genes	 is	 re-expressed	 in	 hypertrophy	(Barry	et	al.,	2008,	Rajabi	et	al.,	2007,	Taegtmeyer	et	al.,	2010,	van	Rooij	et	al.,	2006).	 Furthermore,	 the	promoters	of	pre-mRNA	processing	genes	have	been	shown	to	contain	binding	sites	for	proliferation-related	transcription	factors	(Ji	and	Tian,	2009),	suggesting	a	regulatory	link	between	cell	growth	and	APA.	This	hypothesis	has	also	been	substantiated	by	another	study	which	used	genome-wide	microarrays	 to	 demonstrate	 that	 the	 3’UTRs	 expressed	 in	 hypertrophic	mice	 are	 generally	 shorter	 (Park	 et	 al.,	 2011).	Moreover,	we	 revealed	 several	gene	 functions	 relevant	 to	 hypertrophy	 as	 enriched	 among	 mRNAs	 with	shortened	3’UTRs.	This	has	not	been	described	previously	 (Park	et	 al.,	 2011).	Interestingly,	 although	 the	 enriched	 gene	 sets	 are	 highly	 relevant	 regulatory	processes	 during	 cardiac	 hypertrophy,	 these	 processes	 were	 not	 enriched	among	 genes	 affected	 by	 transcriptional	 change,	 suggesting	 that	 the	transcriptome-wide	mRNA	APA	 trends	 serve	 separate	 regulatory	 roles	during	hypertrophy	development. 	Although	 this	 study	was	 not	 primarily	 designed	 to	 address	 APA	mechanisms,	we	 sought	 to	 glean	 some	 preliminary	 insights	 from	 the	 available	 data	 by	investigating	whether	 there	 is	a	 correlation	between	mRNA	3’-end	preference	during	 hypertrophy	 and	 either	 changes	 in	 targeting	 miRNA	 expression,	 the	tendency	 for	 genes	 to	 exhibit	 alternative	 splice	 variants,	 or	 changes	 in	 the	expression	of	the	gene.	We	were	not	able	to	detect	such	a	relationship	(Section	6.2.2.),	 which	 may	 suggest	 that	 post-transcriptional	 degradation,	 alternative	splicing,	 and	 gene	 expression	 do	 not	 play	 major	 roles	 in	 determining	hypertrophy-associated	 APA.	 However,	 further	 experiments	 will	 need	 to	 be	conducted	to	confirm	this.	What	are	the	consequences	of	a	change	in	mRNA	3’-end	preference	during	LVH?	This	 issue	 is	 controversially	 discussed	 in	 the	 context	 of	 proliferative	 cells.	Studies	 reporting	 either	 pronounced	 or	 minor	 effects	 of	 APA	 on	 post-transcriptional	gene	regulation	have	been	reported	(Gruber	et	al.,	2014,	Elkon	
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et	al.,	2013).	(Park	et	al.,	2011)	noted	an	increase	in	steady-state	level	of	mRNAs	targeted	 by	 several	 miRNA	 families	 during	 TAC/LVH.	 We	 expanded	 on	 this	observation	 by	 building	 quantitative	 networks	 of	 predicted	 miRNA-target	interactions	 for	 the	 120	 most	 highly	 expressed	 miRNAs,	 based	 on	 actual	cardiomyocyte	mRNA	 3’UTRs	 as	 determined	 by	 PAT-Seq.	 Using	 this	 resource	we	 saw	 a	widespread	 shift	 towards	weakened	miRNA	 targeting	 ability,	while	providing	 broader	 and	 more	 direct	 bioinformatics	 evidence.	 Polysome	association	experiments	furthermore	served	as	proof-of-principle	that	APA	can	affect	 mRNA	 translation	 in	 cardiomyocytes.	 Cardiac	 hypertrophy	 features	increases	 in	both	efficiency	 (e.g.	by	post-translational	activation	of	 translation	initiation	 factors)	 and	 capacity	 of	 translation	 (e.g.	 induction	 of	 ribosome	biogenesis)	 to	 meet	 protein	 synthesis	 demands	 (Hannan	 et	 al.,	 2003).	 It	 is	attractive	to	speculate	that	a	global	shift	towards	shorter	mRNA	3’UTRs	as	seen	here,	 and	 the	 anticipated	 positive	 effects	 in	 terms	 of	mRNA	 utilisation,	 are	 a	third	element	in	an	overall	strategy	to	increase	cardiomyocyte	protein	synthesis	during	hypertrophy.	Consistent	with	this	hypothesis,	it	was	interesting	to	note	that	gene	sets	relating	to	protein	signaling	cascades	and	cell	structure	proteins	were	enriched	with	genes	that	are	shortened	during	cardiac	hypertrophy.	Many	studies	 have	 reported	 the	 post-translational	 activation	 of	 many	 protein	signaling	 cascades	 during	 cardiac	 hypertrophy.	 The	 shortening	 of	 3’UTR	observed	 in	 our	 PAT-seq	 data	may	 suggest	 post-transcriptional	 regulation	 to	maximize	the	production	of	proteins	involved	in	signaling	cascades	during	the	disease.	Similarly,	the	cytoskeletal	stiffness	and	cellular	contractile	dysfunctions	observed	 in	 hypertrophy	 has	 been	 widely	 attributed	 to	 an	 accumulation	 of	structural	proteins	such	as	tubulin	in	the	cytoplasm.	Again	consistent	with	our	hypothesis,	 perhaps	 the	 3’UTR	 shortening	 that	 we	 observed	 serves	 as	 yet	another	 strategy	 the	 cell	 uses	 to	 maximize	 protein	 synthesis	 during	 cellular	growth.			
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7.3.	Future	directions		There	 is	 a	 considerable	 amount	 of	 follow-up	 efforts	 that	 could	 be	 conducted	based	on	our	findings.	For	one,	we	have	only	briefly	touched	on	the	expression	of	 lncRNAs	in	the	heart	 in	this	thesis.	Further	studies	into	the	APA	of	 lncRNAs	that	we	detected	may	be	an	interesting	avenue	in	the	future.	We	also	detected	many	unannotated	transcripts	that	may	represent	novel	non-coding	or	protein	coding	transcripts.	These	would	need	to	be	validated	in	the	cell	to	confirm	their	expression	 through	 RNA-seq	 and	 PCR.	 	 It	 would	 also	 be	 interesting	 to	 study	their	biological	 functions	 in	 the	cardiomycoytes,	 for	example	what	happens	 to	the	cell	if	these	novel	transcripts	were	knocked	down.		The	prevalent	expression	of	miRNA	and	mRNA	3’UTR	processing	variants	in	the	normal	 and	 hypertrophic	 cardiomyocytes	 poses	 a	 myriad	 of	 interesting	questions	 regarding	 the	 biological	 relevance	 of	miRNA	 processing	 and	mRNA	APA	 in	 the	 heart.	 Although	 we	 did	 not	 observe	 substantial	 changes	 in	 the	proportions	 of	 miRNA	 processing	 variants	 during	 cardiac	 hypertrophy,	 their	sheer	 prevalence	 in	 the	 cardiomyocyte	 poses	 interesting	 questions	 regarding	their	 functions.	 For	 example,	 what	 are	 the	 purposes	 of	 isomiRs	 with	overlapping	 targets?	 isomiRs	 with	 unique	 targeting	 properties	 have	 more	obvious	 roles	 in	 miRNA-mediated	 regulation.	 However,	 many	 isomiRs,	especially	 those	 with	 the	 same	 seed	 sequences	 (i.e.	 mostly	 3’	 end	 variants),	would	be	expected	to	have	mostly	overlapping	targets	to	the	canonical	miRNA.	Given	that	3’	isomiRs	are	developmentally	regulated	(Fernandez-Valverde	et	al.,	2010),	 it	 seems	 unlikely	 that	 these	 variants	 do	 not	 have	 significant	 biological	roles.	As	presented	in	this	thesis,	variation	in	3’	end	processing	is	a	widespread	phenomenon	 in	 the	 heart.	 Thus,	 it	 would	 be	 interesting	 to	 establish	whether	these	 isomiRs	 act	 through	 different	 mechanisms	 in	 the	 context	 of	cardiomyocytes,	for	example	through	mRNA	deadenylation	versus	translational	repression,	 and	whether	 they	 are	 sorted	 into	 different	AGO	proteins.	Do	 they	regulate	mRNA	expression	through	different	mechanisms?		It	 remains	 to	 be	 explored	 whether	 the	 changes	 in	 mRNA	 3’UTR	 play	 a	pathological	 role	 in	 the	 development	 cardiac	 hypertrophy,	 or	 if	 it	 is	merely	 a	
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response	to	stress.	Our	data	could	underlie	future	studies	to	generate	a	systems	level	 interaction	map	of	miRNA	and	their	 targets	 in	health	and	during	cardiac	hypertrophy.	 It	 would	 be	 interesting	 to	 validate	 the	 potential	 miRNA-mRNA	3’UTR	 interactions	 reported	 in	 this	 thesis,	 and	 study	 whether	 hypertrophy	could	 be	 induced	 if	 HL-1	 cardiomyocytes	 were	 manipulated	 to	 contain	 the	specific	miRNA	and	mRNA	variants	observed	in	hypertrophic	hearts	 identified	in	 this	 thesis.	 	 To	 investigate	 this,	 the	 endogenous	3’UTRs	of	 selected	mRNAs	could	 be	 manipulated	 with	 2’-	 O-methoxy	 ethyl/phosphorothioate	 (2’	 MOE)	modified	antisense	oligonucleotides,	for	example.	These	oligonucleotides	could	be	 designed	 to	 hybridize	 to	 certain	 poly(A)	 sites,	 thus	 inhibiting	 APA	 at	 the	chosen	 sites.	Using	 this	 technique,	 the	healthy	HL-1	 cells	 could	be	 “forced”	 to	produce	the	3’UTRs	variants	observed	 in	the	hypertrophic	hearts	 identified	 in	Chapter	 6.	 If	 signs	 of	 cellular	 hypertrophy	 were	 detected	 following	 this	treatment,	this	would	suggest	a	causal	relationship	between	changes	in	mRNA	3’end	processing	and	the	development	of	cardiac	hypertrophy.	Following	from	this,	it	would	also	be	interesting	to	analyze	whether	reverting	the	hypertrophic-specific	3’UTR	variants	 to	 those	expressed	 in	 the	normal	 cell	 could	 revert	 the	pathologies	of	hypertrophic	cardiomyocyte,	or	protect	normal	cardiomyocytes	from	becoming	 hypertrophic.	 These	 experiments	would	 unveil	 critical	 targets	for	 therapeutic	 intervention.	 Thus,	 the	 results	 of	 these	 experiments	 could	potentially	have	direct	clinical	relevance.				
7.3.1.	The	outlook	for	miRNA-based	therapy	for	CVD Current	treatments	for	CVD	primarily	aim	only	to	alleviate	the	symptoms	of	the	disease	and	slow	down	disease	progression	(Tijsen	et	al.,	2016).	Currently,	no	drugs	are	available	to	tackle	the	underlying	cause	of	the	disease.	As	a	result,	the	prevalence	and	costs	associated	with	CVD	continue	to	 increase. Since	a	causal	link	between	miRNAs	changes	and	various	CVDs	has	been	established,	miRNAs	have	emerged	as	an	appealing	therapeutic	target.		The	 expression	 of	 miRNAs	 could	 be	 therapeutically	 manipulated	 through	 2	
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approaches:	miRNA	mimics	 (also	known	as	miRNA	 replacement	 therapy)	 and	miRNA	antagonists	(Dangwal	and	Thum,	2014,	Christopher	et	al.,	2016,	Wiggins	et	 al.,	 2010).	miRNA	mimics	 are	 used	 to	 increase	 the	 amount	 of	miRNAs;	 for	example,	 to	 restore	 miRNAs	 that	 are	 usually	 expressed	 in	 high	 amounts	 in	healthy	cells	but	lost	during	disease.	miRNA	antagonists,	on	the	other	hand,	aim	to	 reduce	 the	 amount	 of	 miRNAs.	 miRNA	 antagonists	 are	 complementary	sequences	to	the	target	miRNA,	which	therefore	binds	to	the	target	miRNA	and	inhibits	 its	activity.	A	candidate	for	miRNA-based	therapy	for	CVD	is	currently	in	 pre-clinical	 development.	 MGN-9103	 is	 a	 candidate	 drug	 designed	 as	 an	antagonist	against	miRNA-208a-3p	for	treatment	against	chronic	heart	 failure.	It	 has	 previously	 been	 shown	 that	 miR-208a-/-	 mice	 do	 not	 develop	 fibrosis,	cardiac	 hypertrophy,	 and	 heart	 failure	 following	 induced	 stress	 to	 the	 heart	(Callis	 et	 al.,	 2009,	 van	 Rooij	 et	 al.,	 2009).	 Furthermore,	 it	 has	 also	 been	demonstrated	that	lowering	the	levels	and/or	activity	of	miR-208a	in	the	heart	could	be	used	as	a	treatment	for	heart	disease	(Montgomery	et	al.,	2011).	MGN-9013	is	designed	to	target	only	the	-3p	arm	of	miRNA-208a,	previously	known	as	the	“canonical”	arm.	Interestingly,	in	our	data,	59.3%	of	the	miR-208a	hairpin	is	actually	derived	from	the	“non-canonical”	-5p	arm.	It	would	be	important	to	confirm	 whether	 the	 proportions	 of	 miR-208	 strands	 are	 expressed	 in	equivalent	proportions	in	the	human	heart.	The	involvement	of	miR-208a	in	the	heart	 was	 originally	 determined	 by	 knocking	 out	 the	 miR-208	 hairpin.	Therefore,	based	on	our	data,	to	achieve	the	same	protective	effects	achieved	in	the	knockout	mouse	model,	 it	may	be	more	effective	 to	 target	both	strands	of	miR-208	in	therapeutic	use.		Therefore,	our	data	highlights	 the	 importance	of	addressing	 the	complexity	of	miRNA	and	mRNA	processing	variance	in	understanding	their	involvements	in	disease	pathology.	By	having	a	more	detailed	knowledge	of	the	specific	miRNA	and	 mRNA	 3’UTR	 isoforms	 regulating	 cardiac	 hypertrophy	 a	 more	 precise	miRNA-based	therapeutics	could	be	developed.			
		 153	
	
7.4.	Concluding	remarks	 The	development	of	miRNA-based	therapeutics	has	been	laid	on	the	framework	of	a	poor	understanding	of	miRNA	and	mRNA	3	‘UTR	expression	and	functions	in	the	heart.	Research	into	the	mechanism	and	broader	role	of	APA	is	still	in	its	infancy.	 Our	 APA	 data	 allow	 us	 to	 ‘rewire’	 interaction	 networks	 around	 key	cardiac	 post-transcriptional	 regulators,	 based	 on	 extant	 mRNA	 3’UTRs.	 By	studying	 the	 cardiac-specific	 miRNA-mRNA	 interactions	 in	 more	 detail,	 this	thesis	has	more	thoroughly	unraveled	the	complexity	that	underlies	the	miRNA-mediated	 regulatory	 network,	 thereby	 improving	 our	 understanding	 of	 RNA-level	control	in	the	heart.	The	results	reported	in	this	thesis	may	therefore	be	of	importance	 for	 the	 future	 development	 of	 more	 specific	 miRNA-based	interventions	 for	 cardiac	 diseases.	 Future	 efforts	 should	 be	 directed	 towards	exploring	whether	 3’-end	 processing	 could	 itself	 serve	 as	 a	 novel	 therapeutic	target,	 and	 identifying	 the	 molecular	 players	 driving	 these	 events	 in	 both	proliferative	and	hypertrophic	cell.	These	may	represent	attractive	 targets	 for	novel	 therapy	 development	 in	 a	 variety	 of	 pathologies,	 including	 cancer	(Hollerer	et	al.,	2014b)	and	cardiac	disease	(Hynes	et	al.,	2012).		 	
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